1	The	DT	O	the	det	3	SENT_1	[p1l714t81r752b103],
2	NEW	NNP	O	NEW	nn	3	SENT_1	[p1l764t83r844b103],
3	ENGLAND	NNP	O	ENGLAND	_	0	SENT_1	[p1l858t83r1033b103],
4	JOURNAL	NNP	O	JOURNAL	nn	5	SENT_1	[p1l1047t83r1213b110],
5	afMEDICINE	NNP	O	afMEDICINE	dep	3	SENT_1	[p1l1227t81r1443b109],

1	|	NN	O	|	nn	3	SENT_2	[p1l235t185r238b387],
2	E	NN	O	e	nn	3	SENT_2	[p1l901t265r929b297],
3	D	NN	O	d	_	0	SENT_2	[p1l939t265r974b297],
4	I	PRP	O	I	dep	3	SENT_2	[p1l984t265r1001b297],
5	TO	TO	O	to	infmod	4	SENT_2	[p1l1009t265r1082b297],
6	RIAL	NNP	O	RIAL	nn	7	SENT_2	[p1l1092t265r1227b297],
7	S	NN	O	s	dobj	5	SENT_2	[p1l1235t265r1257b297],

1	$	$	MONEY	$	_	0	SENT_3	[p1l1039t416r1065b439],
2	3	CD	MONEY	3	num	1	SENT_3	[p1l1039t416r1065b439],
3	"	``	O	"	punct	5	SENT_3	[p1l1094t416r1119b438],
4	5	CD	NUMBER	5	num	5	SENT_3	[p1l1094t416r1119b438],
5	“	NN	O	“	dep	1	SENT_3	[p1l1012t429r1066b476],
6	=	JJ	O	=	amod	5	SENT_3	[p1l1012t429r1066b476],
7	<	JJR	O	<	dep	6	SENT_3	[p1l1012t429r1066b476],
8	4	CD	PERCENT	4	number	9	SENT_3	[p1l1110t428r1148b482],
9	%	NN	PERCENT	%	amod	5	SENT_3	[p1l1110t428r1148b482],
10	,	,	O	,	_	0	SENT_3	[p1l1110t428r1148b482],
11	E1323	NN	O	e1323	nn	13	SENT_3	[p1l1012t477r1062b509],
12	\	CD	NUMBER	\	num	13	SENT_3	[p1l1072t473r1104b506],
13	\	NN	O	\	appos	5	SENT_3	[p1l1072t473r1104b506],
14	5	CD	PERCENT	5	num	18	SENT_3	[p1l1128t483r1148b503],
15	06.1925	CD	PERCENT	06.1925	number	16	SENT_3	[p1l1021t507r1093b541],
16	5	CD	PERCENT	5	dep	17	SENT_3	[p1l1117t504r1140b529],
17	%	NN	PERCENT	%	dep	18	SENT_3	[p1l1117t504r1140b529],
18	mmo	NN	O	mmo	dep	13	SENT_3	[p1l1054t526r1113b549],
19	\	IN	O	\	amod	18	SENT_3	[p1l1054t526r1113b549],

1	Targeting	NN	O	targeting	nn	2	SENT_4	[p1l451t637r699b699],
2	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_4	[p1l719t639r865b684],
3	in	IN	O	in	_	0	SENT_4	[p1l884t637r928b683],
4	Non	NNP	O	Non	prep_in	2	SENT_4	[p1l953t636r1358b684],
5	.	.	O	.	_	0	SENT_4	[p1l953t636r1358b684],

1	—	NN	O	—	_	0	SENT_5	[p1l953t636r1358b684],
2	.	.	O	.	_	0	SENT_5	[p1l953t636r1358b684],

1	SmaI	NN	O	smaus	_	0	SENT_6	[p1l953t636r1358b684],
2	|	SYM	O	|	dep	1	SENT_6	[p1l953t636r1358b684],
3	-	:	O	-	_	0	SENT_6	[p1l953t636r1358b684],
4	Cell	NN	O	cell	dep	1	SENT_6	[p1l953t636r1358b684],
5	Lung	NN	O	lung	nn	6	SENT_6	[p1l1382t640r1511b699],
6	Cancer	NN	O	cancer	dep	4	SENT_6	[p1l1528t639r1710b684],

1	James	NNP	PERSON	James	nn	3	SENT_7	[p1l851t718r958b755],
2	H.	NNP	PERSON	H.	nn	3	SENT_7	[p1l975t718r1010b746],
3	Doroshow	NNP	PERSON	Doroshow	_	0	SENT_7	[p1l1027t715r1206b751],
4	,	,	O	,	_	0	SENT_7	[p1l1027t715r1206b751],
5	M.D.	NNP	O	M.D.	appos	3	SENT_7	[p1l1223t718r1303b746],

1	The	DT	O	the	det	2	SENT_8	[p1l7t905r169b983],
2	development	NN	O	development	nsubj	36	SENT_8	[p1l207t905r757b1005],
3	of	IN	O	of	_	0	SENT_8	[p1l790t904r890b984],
4	small	JJ	O	small	amod	7	SENT_8	[p1l911t905r1561b984],
5	—	NN	O	—	nn	7	SENT_8	[p1l911t905r1561b984],
6	molecule	NN	O	molecule	nn	7	SENT_8	[p1l911t905r1561b984],
7	inhibitors	NNS	O	inhibitor	prep_of	2	SENT_8	[p1l1598t905r2012b984],
8	of	IN	O	of	_	0	SENT_8	[p1l2053t904r2153b984],
9	the	DT	O	the	det	35	SENT_8	[p1l11t1034r139b1112],
10	epidermal	JJ	O	epidermal	amod	35	SENT_8	[p1l163t1034r588b1134],
11	growth	NN	O	growth	nn	16	SENT_8	[p1l610t1034r913b1135],
12	factor	NN	O	factor	nn	16	SENT_8	[p1l935t1033r1181b1113],
13	receptor	NN	O	receptor	nn	16	SENT_8	[p1l1200t1051r1552b1134],
14	(	CD	NUMBER	(	num	16	SENT_8	[p1l1576t1040r1911b1130],
15	EGFR	NN	ORGANIZATION	egfr	nn	16	SENT_8	[p1l1576t1040r1911b1130],
16	)	NN	O	)	tmod	10	SENT_8	[p1l1576t1040r1911b1130],
17	,	,	O	,	_	0	SENT_8	[p1l1576t1040r1911b1130],
18	such	JJ	O	such	_	0	SENT_8	[p1l1940t1034r2135b1113],
19	as	IN	O	as	_	0	SENT_8	[p1l10t1188r95b1240],
20	erlotinib	NN	O	erlotinib	prep_such_as	16	SENT_8	[p1l126t1162r493b1241],
21	and	CC	O	and	_	0	SENT_8	[p1l522t1162r680b1241],
22	gefitinib	NN	O	gefitinib	conj_and	20	SENT_8	[p1l708t1161r1096b1263],
23	,	,	O	,	_	0	SENT_8	[p1l708t1161r1096b1263],
24	for	IN	O	for	_	0	SENT_8	[p1l1131t1161r1256b1241],
25	the	DT	O	the	det	26	SENT_8	[p1l1282t1162r1412b1240],
26	treatment	NN	O	treatment	prep_for	20	SENT_8	[p1l1442t1179r1865b1241],
27	of	IN	O	of	_	0	SENT_8	[p1l1888t1161r1990b1241],
28	advanced	JJ	O	advanced	amod	30	SENT_8	[p1l1999t1162r2132b1241, p1l6t1290r299b1369],
29	non	JJ	O	non	amod	30	SENT_8	[p1l356t1290r988b1369],
30	—	NN	O	—	prep_of	26	SENT_8	[p1l356t1290r988b1369],
31	small	JJ	O	small	amod	35	SENT_8	[p1l356t1290r988b1369],
32	—	NN	O	—	nn	35	SENT_8	[p1l356t1290r988b1369],
33	cell	NN	O	cell	nn	35	SENT_8	[p1l356t1290r988b1369],
34	lung	NN	O	lung	nn	35	SENT_8	[p1l1043t1290r1238b1391],
35	cancer	NN	O	cancer	prep_of	7	SENT_8	[p1l1292t1316r1567b1368],
36	illustrates	VBZ	O	illustrate	_	0	SENT_8	[p1l1621t1290r2033b1369],
37	a	DT	O	a	det	38	SENT_8	[p1l2092t1316r2136b1368],
38	pattern	NN	O	pattern	dobj	36	SENT_8	[p1l9t1434r312b1517],
39	of	IN	O	of	_	0	SENT_8	[p1l334t1416r434b1496],
40	initial	JJ	O	initial	amod	43	SENT_8	[p1l436t1417r679b1495],
41	overly	RB	O	overly	advmod	42	SENT_8	[p1l701t1417r951b1517],
42	enthusiastic	JJ	O	enthusiastic	amod	43	SENT_8	[p1l968t1417r1476b1496],
43	interest	NN	O	interest	prep_of	38	SENT_8	[p1l1496t1418r1836b1513],
44	,	,	O	,	_	0	SENT_8	[p1l1496t1418r1836b1513],
45	subsequent	JJ	O	subsequent	amod	47	SENT_8	[p1l1864t1417r2133b1497, p1l11t1562r255b1645],
46	critical	JJ	O	critical	amod	47	SENT_8	[p1l308t1546r591b1624],
47	disappointment	NN	O	disappointment	conj_and	38	SENT_8	[p1l647t1546r1344b1645],
48	,	,	O	,	_	0	SENT_8	[p1l647t1546r1344b1645],
49	and	CC	O	and	_	0	SENT_8	[p1l1406t1546r1561b1624],
50	eventual	JJ	O	eventual	amod	52	SENT_8	[p1l1618t1546r1966b1625],
51	renewed	VBN	O	renew	amod	52	SENT_8	[p1l2022t1572r2133b1624, p1l10t1673r284b1753],
52	appreciation	NN	O	appreciation	conj_and	38	SENT_8	[p1l307t1674r836b1773],
53	of	IN	O	of	_	0	SENT_8	[p1l860t1672r961b1752],
54	the	DT	O	the	det	58	SENT_8	[p1l967t1673r1096b1751],
55	clinical	JJ	O	clinical	amod	58	SENT_8	[p1l1121t1673r1421b1751],
56	and	CC	O	and	_	0	SENT_8	[p1l1444t1673r1600b1752],
57	mechanistic	JJ	O	mechanistic	conj_and	55	SENT_8	[p1l1624t1673r2135b1751],
58	complexities	NNS	O	complexity	prep_of	52	SENT_8	[p1l11t1802r537b1902],
59	surrounding	VBG	O	surround	dep	36	SENT_8	[p1l562t1802r1088b1903],
60	the	DT	O	the	det	61	SENT_8	[p1l1105t1802r1233b1880],
61	introduction	NN	O	introduction	dobj	59	SENT_8	[p1l1254t1802r1779b1881],
62	of	IN	O	of	_	0	SENT_8	[p1l1799t1801r1900b1881],
63	a	DT	O	a	det	65	SENT_8	[p1l1901t1828r1945b1880],
64	new	JJ	O	new	amod	65	SENT_8	[p1l1964t1828r2139b1881],
65	therapy	NN	O	therapy	prep_of	61	SENT_8	[p1l11t1930r328b2030],
66	for	IN	O	for	_	0	SENT_8	[p1l350t1929r474b2009],
67	cancer	NN	O	cancer	prep_for	65	SENT_8	[p1l499t1956r790b2009],
68	.	.	O	.	_	0	SENT_8	[p1l499t1956r790b2009],

1	Such	PDT	O	such	predet	3	SENT_9	[p1l826t1930r1028b2009],
2	a	DT	O	a	det	3	SENT_9	[p1l1056t1956r1100b2008],
3	pattern	NN	O	pattern	nsubj	7	SENT_9	[p1l1124t1947r1427b2030],
4	has	VBZ	O	have	aux	7	SENT_9	[p1l1455t1930r1596b2008],
5	been	VBN	O	be	cop	7	SENT_9	[p1l1626t1930r1825b2009],
6	regrettably	RB	O	regrettably	advmod	7	SENT_9	[p1l1853t1947r2133b2031, p1l11t2058r217b2158],
7	common	JJ	O	common	_	0	SENT_9	[p1l255t2084r635b2137],
8	in	IN	O	in	_	0	SENT_9	[p1l677t2059r757b2136],
9	the	DT	O	the	det	10	SENT_9	[p1l800t2058r929b2136],
10	history	NN	O	history	prep_in	7	SENT_9	[p1l972t2058r1265b2158],
11	of	IN	O	of	_	0	SENT_9	[p1l1304t2057r1405b2137],
12	oncologic	JJ	O	oncologic	amod	13	SENT_9	[p1l1429t2058r1845b2159],
13	therapeutics	NNS	O	therapeutics	prep_of	10	SENT_9	[p1l1887t2058r2133b2136, p1l9t2187r333b2285],
14	.	.	O	.	_	0	SENT_9	[p1l1887t2058r2133b2136, p1l9t2187r333b2285],

1	The	DT	O	the	det	3	SENT_10	[p1l136t2313r298b2391],
2	initial	JJ	O	initial	amod	3	SENT_10	[p1l318t2313r561b2391],
3	safety	NN	O	safety	nsubj	11	SENT_10	[p1l583t2312r824b2413],
4	and	CC	O	and	_	0	SENT_10	[p1l841t2313r996b2392],
5	efﬁcacy	NN	O	efﬁcacy	nn	6	SENT_10	[p1l1017t2312r1336b2413],
6	studies	NNS	O	study	conj_and	3	SENT_10	[p1l1354t2313r1647b2393],
7	of	IN	O	of	_	0	SENT_10	[p1l1671t2312r1772b2392],
8	erlotinib	NN	O	erlotinib	prep_of	3	SENT_10	[p1l1775t2313r2133b2392],
9	and	CC	O	and	_	0	SENT_10	[p1l10t2442r167b2521],
10	geﬁtinib	NN	O	geﬁtinib	prep_of	3	SENT_10	[p1l195t2441r559b2543],
11	evoked	VBD	O	evoke	_	0	SENT_10	[p1l589t2442r887b2521],
12	a	DT	O	a	det	14	SENT_10	[p1l915t2468r960b2520],
13	remarkable	JJ	O	remarkable	amod	14	SENT_10	[p1l986t2442r1476b2521],
14	degree	NN	O	degree	dobj	11	SENT_10	[p1l1505t2442r1789b2543],
15	of	IN	O	of	_	0	SENT_10	[p1l1819t2441r1920b2521],
16	optimism	NN	O	optimism	prep_of	14	SENT_10	[p1l1931t2443r2132b2542, p1l10t2571r250b2648],
17	that	WDT	O	that	nsubjpass	19	SENT_10	[p1l270t2570r436b2648],
18	was	VBD	O	be	auxpass	19	SENT_10	[p1l447t2596r607b2649],
19	based	VBN	O	base	rcmod	14	SENT_10	[p1l631t2570r870b2649],
20	on	IN	O	on	_	0	SENT_10	[p1l892t2596r997b2649],
21	prolonged	JJ	O	prolonged	amod	22	SENT_10	[p1l1017t2570r1452b2671],
22	remissions	NNS	O	remission	prep_on	19	SENT_10	[p1l1473t2571r1930b2649],
23	and	CC	O	and	_	0	SENT_10	[p1l1953t2570r2130b2666],
24	,	,	O	,	_	0	SENT_10	[p1l1953t2570r2130b2666],
25	in	IN	O	in	dep	22	SENT_10	[p1l10t2699r91b2775],
26	some	DT	O	some	det	27	SENT_10	[p1l115t2724r339b2776],
27	cases	NNS	O	case	pobj	25	SENT_10	[p1l363t2724r606b2793],
28	,	,	O	,	_	0	SENT_10	[p1l363t2724r606b2793],
29	dramatic	JJ	O	dramatic	amod	30	SENT_10	[p1l635t2698r1008b2776],
30	improvements	NNS	O	improvement	conj_and	22	SENT_10	[p1l1029t2699r1639b2797],
31	in	IN	O	in	_	0	SENT_10	[p1l1664t2699r1745b2775],
32	the	DT	O	the	det	33	SENT_10	[p1l1768t2698r1897b2776],
33	quality	NN	O	quality	prep_in	30	SENT_10	[p1l1920t2698r2133b2797, p1l10t2826r112b2925],
34	of	IN	O	of	_	0	SENT_10	[p1l136t2824r237b2904],
35	life	NN	O	life	prep_of	33	SENT_10	[p1l246t2824r376b2903],
36	in	IN	O	in	_	0	SENT_10	[p1l404t2826r485b2903],
37	small	JJ	O	small	amod	38	SENT_10	[p1l515t2825r743b2903],
38	numbers	NNS	O	number	prep_in	19	SENT_10	[p1l771t2825r1145b2905],
39	of	IN	O	of	_	0	SENT_10	[p1l1176t2824r1277b2904],
40	patients	NNS	O	patient	prep_of	38	SENT_10	[p1l1285t2826r1620b2925],
41	whose	WP$	O	whose	poss	42	SENT_10	[p1l1646t2825r1920b2905],
42	condition	NN	O	condition	nsubj	46	SENT_10	[p1l1949t2851r2133b2904, p1l11t2954r259b3033],
43	was	VBD	O	be	aux	46	SENT_10	[p1l287t2980r447b3033],
44	no	RB	O	no	advmod	45	SENT_10	[p1l482t2980r587b3033],
45	longer	RB	O	longer	advmod	46	SENT_10	[p1l619t2954r896b3055],
46	responding	VBG	O	respond	rcmod	40	SENT_10	[p1l924t2954r1412b3055],
47	to	TO	O	to	_	0	SENT_10	[p1l1441t2971r1520b3033],
48	standard	JJ	O	standard	amod	51	SENT_10	[p1l1554t2954r1926b3033],
49	che	NN	O	che	nn	51	SENT_10	[p1l1958t2954r2133b3032],
50	—	NN	O	—	nn	51	SENT_10	[p1l1958t2954r2133b3032],
51	motherapy	NN	O	motherapy	prep_to	46	SENT_10	[p1l10t3076r602b3180],
52	.1	CD	NUMBER	.1	num	53	SENT_10	[p1l10t3076r602b3180],
53	’	NN	O	’	dobj	46	SENT_10	[p1l10t3076r602b3180],
54	2	CD	NUMBER	2	nsubj	75	SENT_10	[p1l10t3076r602b3180],
55	Furthermore	RB	O	furthermore	advmod	54	SENT_10	[p1l647t3081r1221b3176],
56	,	,	O	,	_	0	SENT_10	[p1l647t3081r1221b3176],
57	clinical	JJ	O	clinical	amod	58	SENT_10	[p1l1274t3081r1582b3159],
58	beneﬁt	NN	O	beneﬁt	nsubjpass	60	SENT_10	[p1l1629t3080r1931b3159],
59	was	VBD	O	be	auxpass	60	SENT_10	[p1l1968t3107r2131b3160],
60	achieved	VBN	O	achieve	parataxis	75	SENT_10	[p1l10t3209r380b3288],
61	by	IN	O	by	_	0	SENT_10	[p1l417t3209r515b3308],
62	treatments	NNS	O	treatment	agent	60	SENT_10	[p1l547t3225r1007b3287],
63	that	WDT	O	that	nsubj	64	SENT_10	[p1l1046t3209r1216b3287],
64	appeared	VBD	O	appear	rcmod	62	SENT_10	[p1l1246t3209r1640b3308],
65	to	TO	O	to	aux	66	SENT_10	[p1l1677t3226r1757b3287],
66	control	VB	O	control	xcomp	64	SENT_10	[p1l1795t3209r2128b3304],
67	,	,	O	,	_	0	SENT_10	[p1l1795t3209r2128b3304],
68	with	IN	O	with	_	0	SENT_10	[p1l6t3336r198b3416],
69	acceptable	JJ	O	acceptable	amod	70	SENT_10	[p1l239t3336r694b3436],
70	levels	NNS	O	level	prep_with	64	SENT_10	[p1l735t3336r967b3416],
71	of	IN	O	of	_	0	SENT_10	[p1l1012t3335r1114b3415],
72	toxic	JJ	O	toxic	amod	73	SENT_10	[p1l1137t3337r1343b3415],
73	effects	NNS	O	effect	prep_of	70	SENT_10	[p1l1385t3335r1687b3432],
74	,	,	O	,	_	0	SENT_10	[p1l1385t3335r1687b3432],
75	advanced	VBD	O	advance	rcmod	53	SENT_10	[p1l1734t3336r2134b3416],
76	non	JJ	O	non	amod	82	SENT_10	[p1l10t3465r646b3544],
77	—	JJ	O	—	amod	78	SENT_10	[p1l10t3465r646b3544],
78	small	JJ	O	small	amod	82	SENT_10	[p1l10t3465r646b3544],
79	—	NN	O	—	nn	82	SENT_10	[p1l10t3465r646b3544],
80	cell	NN	O	cell	nn	82	SENT_10	[p1l10t3465r646b3544],
81	lung	NN	O	lung	nn	82	SENT_10	[p1l670t3465r864b3566],
82	cancer	NN	O	cancer	dobj	75	SENT_10	[p1l887t3491r1162b3544],
83	through	IN	O	through	_	0	SENT_10	[p1l1185t3465r1526b3566],
84	a	DT	O	a	det	87	SENT_10	[p1l1551t3491r1595b3543],
85	speciﬁc	JJ	O	speciﬁc	amod	87	SENT_10	[p1l1620t3464r1939b3565],
86	molecular	JJ	O	molecular	amod	87	SENT_10	[p1l1963t3491r2133b3544, p1l10t3592r291b3671],
87	mechanism	NN	O	mechanism	prep_through	82	SENT_10	[p1l313t3592r825b3670],
88	.	.	O	.	_	0	SENT_10	[p1l313t3592r825b3670],

1	However	RB	O	however	advmod	19	SENT_11	[p1l854t3599r1242b3687],
2	,	,	O	,	_	0	SENT_11	[p1l854t3599r1242b3687],
3	when	WRB	O	when	advmod	10	SENT_11	[p1l1268t3592r1500b3671],
4	in	IN	O	in	_	0	SENT_11	[p1l1524t3593r1605b3669],
5	randomized	VBN	O	randomize	prepc_in	10	SENT_11	[p1l1629t3592r2135b3670],
6	clinical	JJ	O	clinical	amod	8	SENT_11	[p1l11t3720r312b3798],
7	trials	NNS	O	trial	nn	8	SENT_11	[p1l336t3720r543b3798],
8	EGFRinhibitors	NNS	O	egfrinhibitor	nsubjpass	10	SENT_11	[p1l568t3720r1254b3803],
9	were	VBD	O	be	auxpass	10	SENT_11	[p1l1276t3746r1478b3799],
10	combined	VBN	O	combine	advcl	19	SENT_11	[p1l1503t3720r1926b3799],
11	with	IN	O	with	_	0	SENT_11	[p1l1945t3720r2135b3799],
12	cytotoxic	JJ	O	cytotoxic	amod	13	SENT_11	[p2l11t37r385b136],
13	chemotherapy	NN	O	chemotherapy	prep_with	10	SENT_11	[p2l406t36r1024b136],
14	,	,	O	,	_	0	SENT_11	[p2l406t36r1024b136],
15	no	DT	O	no	det	16	SENT_11	[p2l1051t62r1156b115],
16	advantage	NN	O	advantage	nsubj	19	SENT_11	[p2l1177t36r1604b137],
17	was	VBD	O	be	cop	19	SENT_11	[p2l1621t62r1781b115],
18	demon	NN	O	demon	nn	19	SENT_11	[p2l1805t36r2133b115],
19	—	NN	O	—	dep	25	SENT_11	[p2l1805t36r2133b115],
20	strated	VBD	O	strate	rcmod	19	SENT_11	[p2l12t164r297b242],
21	over	IN	O	over	_	0	SENT_11	[p2l327t190r504b243],
22	standard	JJ	O	standard	amod	23	SENT_11	[p2l532t164r903b242],
23	chemotherapy	NN	O	chemotherapy	prep_over	20	SENT_11	[p2l933t164r1540b263],
24	alone	RB	O	alone	advmod	25	SENT_11	[p2l1563t164r1792b242],
25	—	VBD	O	—	_	0	SENT_11	[p2l1817t209r1925b217],
26	a	DT	O	a	det	27	SENT_11	[p2l1950t190r1994b241],
27	result	NN	O	result	dobj	25	SENT_11	[p2l2021t190r2133b242, p2l12t292r165b371],
28	that	IN	O	that	nsubj	29	SENT_11	[p2l180t292r344b370],
29	provoked	VBN	O	provoke	rcmod	27	SENT_11	[p2l358t292r747b392],
30	substantial	JJ	O	substantial	amod	31	SENT_11	[p2l769t292r1222b371],
31	consternation	NN	O	consternation	dobj	29	SENT_11	[p2l1243t293r1815b371],
32	regarding	VBG	O	regard	_	0	SENT_11	[p2l1835t292r2134b393, p2l10t421r147b521],
33	the	DT	O	the	det	35	SENT_11	[p2l166t420r294b499],
34	potential	JJ	O	potential	amod	35	SENT_11	[p2l315t420r691b520],
35	value	NN	O	value	prep_regarding	31	SENT_11	[p2l709t420r927b499],
36	of	IN	O	of	_	0	SENT_11	[p2l950t419r1051b499],
37	this	DT	O	this	det	39	SENT_11	[p2l1056t420r1208b498],
38	new	JJ	O	new	amod	39	SENT_11	[p2l1233t446r1409b499],
39	class	NN	O	class	prep_of	35	SENT_11	[p2l1428t420r1627b498],
40	of	IN	O	of	_	0	SENT_11	[p2l1652t419r1753b499],
41	agents	NNS	O	agent	prep_of	39	SENT_11	[p2l1756t437r2029b521],
42	in	IN	O	in	_	0	SENT_11	[p2l2053t421r2135b498],
43	the	DT	O	the	det	44	SENT_11	[p2l11t548r139b626],
44	treatment	NN	O	treatment	prep_in	41	SENT_11	[p2l183t565r597b626],
45	of	IN	O	of	_	0	SENT_11	[p2l635t547r735b627],
46	non	JJ	O	non	amod	52	SENT_11	[p2l759t548r1391b627],
47	—	JJ	O	—	amod	52	SENT_11	[p2l759t548r1391b627],
48	small	JJ	O	small	amod	52	SENT_11	[p2l759t548r1391b627],
49	—	NN	O	—	nn	52	SENT_11	[p2l759t548r1391b627],
50	cell	NN	O	cell	nn	52	SENT_11	[p2l759t548r1391b627],
51	lung	NN	O	lung	nn	52	SENT_11	[p2l1431t548r1626b649],
52	cancer	NN	O	cancer	prep_of	44	SENT_11	[p2l1665t574r1940b626],
53	and	CC	O	and	_	0	SENT_11	[p2l1979t548r2135b627],
54	doubts	NNS	O	doubt	conj_and	29	SENT_11	[p2l11t676r298b755],
55	about	IN	O	about	_	0	SENT_11	[p2l330t676r574b755],
56	the	DT	O	the	det	57	SENT_11	[p2l601t676r730b754],
57	clarity	NN	O	clarity	prep_about	54	SENT_11	[p2l762t676r1019b776],
58	of	IN	O	of	_	0	SENT_11	[p2l1046t675r1147b755],
59	our	PRP$	O	we	poss	60	SENT_11	[p2l1160t702r1304b755],
60	knowledge	NN	O	knowledge	prep_of	57	SENT_11	[p2l1332t676r1795b777],
61	of	IN	O	of	_	0	SENT_11	[p2l1827t675r1927b755],
62	their	PRP$	O	they	poss	64	SENT_11	[p2l1940t676r2137b754],
63	presumed	JJ	O	presumed	amod	64	SENT_11	[p2l9t803r432b902],
64	mechanism	NN	O	mechanism	prep_of	60	SENT_11	[p2l456t803r950b881],
65	of	IN	O	of	_	0	SENT_11	[p2l976t802r1077b881],
66	action	NN	O	action	nn	67	SENT_11	[p2l1083t798r1474b881],
67	.3	NN	NUMBER	.3	prep_of	64	SENT_11	[p2l1083t798r1474b881],
68	’	CD	NUMBER	’	num	67	SENT_11	[p2l1083t798r1474b881],
69	4	CD	NUMBER	4	nsubj	25	SENT_11	[p2l1083t798r1474b881],

1	In	IN	O	in	_	0	SENT_12	[p2l138t938r225b1008],
2	2004	CD	DATE	2004	prep_in	49	SENT_12	[p2l253t936r484b1026],
3	,	,	O	,	_	0	SENT_12	[p2l253t936r484b1026],
4	the	DT	O	the	det	6	SENT_12	[p2l518t930r647b1008],
5	public	JJ	O	public	amod	6	SENT_12	[p2l674t930r939b1030],
6	presentation	NN	O	presentation	nsubj	49	SENT_12	[p2l964t931r1500b1030],
7	of	IN	O	of	_	0	SENT_12	[p2l1529t929r1629b1009],
8	clinical	JJ	O	clinical	amod	11	SENT_12	[p2l1639t930r1940b1008],
9	trial	NN	O	trial	nn	11	SENT_12	[p2l1969t930r2135b1008],
10	BR	NN	O	br	nn	11	SENT_12	[p2l9t1064r263b1142],
11	.21	NN	NUMBER	.21	prep_of	6	SENT_12	[p2l9t1064r263b1142],
12	conducted	VBN	O	conduct	partmod	11	SENT_12	[p2l286t1058r717b1138],
13	by	IN	O	by	_	0	SENT_12	[p2l739t1058r835b1158],
14	the	DT	O	the	det	17	SENT_12	[p2l851t1058r979b1136],
15	National	NNP	ORGANIZATION	National	nn	17	SENT_12	[p2l998t1058r1358b1137],
16	Cancer	NNP	ORGANIZATION	Cancer	nn	17	SENT_12	[p2l1379t1064r1670b1137],
17	Institute	NNP	ORGANIZATION	Institute	agent	12	SENT_12	[p2l1687t1059r2033b1138],
18	of	IN	ORGANIZATION	of	_	0	SENT_12	[p2l2054t1057r2154b1137],
19	Canada	NNP	ORGANIZATION	Canada	prep_of	17	SENT_12	[p2l10t1187r326b1266],
20	(	CD	ORGANIZATION	(	num	19	SENT_12	[p2l358t1194r461b1278],
21	N	NN	ORGANIZATION	n	prep	12	SENT_12	[p2l358t1194r461b1278],
22	CIC	NNP	ORGANIZATION	CIC	dep	21	SENT_12	[p2l464t1193r651b1278],
23	)	CD	NUMBER	)	num	22	SENT_12	[p2l464t1193r651b1278],
24	showing	VBG	O	show	xcomp	12	SENT_12	[p2l687t1187r1052b1288],
25	a	DT	O	a	det	30	SENT_12	[p2l1078t1213r1122b1265],
26	two	CD	NUMBER	two	num	30	SENT_12	[p2l1150t1187r1625b1266],
27	—	CD	NUMBER	—	num	30	SENT_12	[p2l1150t1187r1625b1266],
28	month	NN	NUMBER	month	nn	30	SENT_12	[p2l1150t1187r1625b1266],
29	survival	NN	O	survival	nn	30	SENT_12	[p2l1656t1187r1974b1266],
30	advantage	NN	O	advantage	tmod	24	SENT_12	[p2l2002t1187r2133b1266, p2l6t1332r334b1416],
31	with	IN	O	with	_	0	SENT_12	[p2l358t1315r548b1394],
32	erlotinib	NN	O	erlotinib	prep_with	24	SENT_12	[p2l577t1315r961b1411],
33	,	,	O	,	_	0	SENT_12	[p2l577t1315r961b1411],
34	as	RB	O	as	advmod	36	SENT_12	[p2l994t1341r1078b1393],
35	is	VBZ	O	be	auxpass	36	SENT_12	[p2l1109t1316r1174b1393],
36	reported	VBN	O	report	ccomp	12	SENT_12	[p2l1205t1315r1564b1415],
37	in	IN	O	in	_	0	SENT_12	[p2l1592t1316r1673b1393],
38	full	JJ	O	full	advmod	48	SENT_12	[p2l1702t1314r1842b1394],
39	in	IN	O	in	_	0	SENT_12	[p2l1870t1316r1950b1393],
40	this	DT	O	this	det	41	SENT_12	[p2l1980t1315r2132b1393],
41	issue	NN	O	issue	prep_in	38	SENT_12	[p2l10t1444r220b1521],
42	of	IN	O	of	_	0	SENT_12	[p2l249t1441r349b1521],
43	the	DT	O	the	det	44	SENT_12	[p2l358t1436r918b1543],
44	]	NN	O	]	prep_of	41	SENT_12	[p2l358t1436r918b1543],
45	ournal	JJ	O	ournal	amod	44	SENT_12	[p2l358t1436r918b1543],
46	,5	CD	NUMBER	,5	number	47	SENT_12	[p2l358t1436r918b1543],
47	’	CD	NUMBER	’	dep	45	SENT_12	[p2l358t1436r918b1543],
48	6	CD	NUMBER	6	prep_in	36	SENT_12	[p2l358t1436r918b1543],
49	had	VBD	O	have	_	0	SENT_12	[p2l945t1442r1100b1521],
50	a	DT	O	a	det	52	SENT_12	[p2l1127t1468r1171b1520],
51	positive	JJ	O	positive	amod	52	SENT_12	[p2l1195t1444r1521b1542],
52	reception	NN	O	reception	dobj	49	SENT_12	[p2l1549t1444r1945b1542],
53	that	WDT	O	that	nsubjpass	56	SENT_12	[p2l1973t1442r2140b1520],
54	was	VBD	O	be	auxpass	56	SENT_12	[p2l6t1596r165b1650],
55	particularly	RB	O	particularly	advmod	56	SENT_12	[p2l187t1570r661b1670],
56	warranted	VBN	O	warrant	rcmod	52	SENT_12	[p2l673t1570r1098b1650],
57	because	IN	O	because	mark	64	SENT_12	[p2l1119t1570r1446b1650],
58	many	JJ	O	many	nsubj	64	SENT_12	[p2l1468t1596r1699b1670],
59	of	IN	O	of	_	0	SENT_12	[p2l1716t1569r1816b1649],
60	the	DT	O	the	det	61	SENT_12	[p2l1819t1570r1947b1648],
61	participants	NNS	O	participant	prep_of	58	SENT_12	[p2l1967t1596r2134b1670, p2l11t1700r366b1798],
62	had	VBD	O	have	aux	64	SENT_12	[p2l389t1699r543b1777],
63	previously	RB	DATE	previously	advmod	64	SENT_12	[p2l561t1699r991b1798],
64	received	VBN	O	receive	advcl	56	SENT_12	[p2l1007t1699r1344b1778],
65	two	CD	NUMBER	two	num	67	SENT_12	[p2l1365t1715r1516b1778],
66	chemotherapy	NN	O	chemotherapy	nn	67	SENT_12	[p2l1539t1699r2140b1798],
67	regimens	NNS	O	regimen	dobj	64	SENT_12	[p2l10t1828r428b1928],
68	.	.	O	.	_	0	SENT_12	[p2l10t1828r428b1928],

1	As	IN	O	as	_	0	SENT_13	[p2l456t1835r560b1905],
2	a	DT	O	a	det	3	SENT_13	[p2l587t1853r632b1905],
3	group	NN	O	group	prep_as	10	SENT_13	[p2l655t1853r931b1928],
4	,	,	O	,	_	0	SENT_13	[p2l655t1853r931b1928],
5	such	JJ	O	such	amod	6	SENT_13	[p2l963t1827r1158b1906],
6	patients	NNS	O	patient	nsubj	10	SENT_13	[p2l1182t1828r1517b1927],
7	are	VBP	O	be	cop	10	SENT_13	[p2l1544t1853r1669b1905],
8	unlikely	JJ	O	unlikely	amod	10	SENT_13	[p2l1695t1827r2033b1927],
9	to	TO	O	to	dep	10	SENT_13	[p2l2054t1844r2133b1906],
10	beneﬁt	JJ	O	beneﬁt	_	0	SENT_13	[p2l11t1953r300b2033],
11	from	IN	O	from	_	0	SENT_13	[p2l314t1953r518b2033],
12	further	JJ	O	further	amod	14	SENT_13	[p2l537t1953r826b2034],
13	cytotoxic	JJ	O	cytotoxic	amod	14	SENT_13	[p2l843t1955r1207b2054],
14	approaches	NNS	O	approach	prep_from	10	SENT_13	[p2l1225t1954r1722b2054],
15	.	.	O	.	_	0	SENT_13	[p2l1225t1954r1722b2054],

1	At	IN	O	at	_	0	SENT_14	[p2l1744t1962r1842b2032],
2	almost	RB	O	almost	advmod	5	SENT_14	[p2l1855t1954r2141b2033],
3	the	DT	O	the	det	5	SENT_14	[p2l11t2082r140b2159],
4	same	JJ	O	same	amod	5	SENT_14	[p2l166t2108r383b2159],
5	moment	NN	O	moment	prep_at	12	SENT_14	[p2l408t2098r790b2177],
6	,	,	O	,	_	0	SENT_14	[p2l408t2098r790b2177],
7	interest	NN	O	interest	nsubjpass	12	SENT_14	[p2l819t2083r1140b2159],
8	in	IN	O	in	_	0	SENT_14	[p2l1159t2083r1241b2159],
9	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_14	[p2l1264t2088r1522b2165],
10	inhibitors	NNS	O	inhibitor	prep_in	7	SENT_14	[p2l1536t2082r1949b2160],
11	was	VBD	O	be	auxpass	12	SENT_14	[p2l1972t2108r2133b2161],
12	heightened	VBN	O	heighten	ccomp	47	SENT_14	[p2l10t2210r485b2311],
13	by	IN	O	by	_	0	SENT_14	[p2l518t2210r615b2310],
14	reports	NNS	O	report	agent	12	SENT_14	[p2l643t2227r943b2310],
15	linking	VBG	O	link	partmod	14	SENT_14	[p2l976t2210r1282b2311],
16	mutations	NNS	O	mutation	dobj	15	SENT_14	[p2l1312t2211r1743b2289],
17	in	IN	O	in	_	0	SENT_14	[p2l1777t2211r1858b2288],
18	exons	NNS	O	exon	prep_in	16	SENT_14	[p2l1892t2236r2133b2289],
19	18	CD	NUMBER	18	num	18	SENT_14	[p2l14t2344r109b2417],
20	through	IN	O	through	_	0	SENT_14	[p2l142t2338r484b2439],
21	21	CD	NUMBER	21	prep_through	18	SENT_14	[p2l513t2344r614b2416],
22	of	IN	O	of	_	0	SENT_14	[p2l646t2337r746b2417],
23	the	DT	O	the	det	25	SENT_14	[p2l758t2338r886b2416],
24	EGFR	NN	ORGANIZATION	egfr	nn	25	SENT_14	[p2l915t2345r1128b2418],
25	gene	NN	O	gene	prep_of	16	SENT_14	[p2l1150t2364r1349b2439],
26	to	TO	O	to	_	0	SENT_14	[p2l1380t2355r1459b2417],
27	the	DT	O	the	det	28	SENT_14	[p2l1491t2338r1620b2416],
28	responsiveness	NN	O	responsiveness	prep_to	15	SENT_14	[p2l1650t2339r2133b2438, p2l10t2492r193b2544],
29	of	IN	O	of	_	0	SENT_14	[p2l229t2465r329b2545],
30	non	JJ	O	non	amod	36	SENT_14	[p2l343t2466r975b2545],
31	—	JJ	O	—	amod	36	SENT_14	[p2l343t2466r975b2545],
32	small	JJ	O	small	amod	36	SENT_14	[p2l343t2466r975b2545],
33	—	NN	O	—	nn	36	SENT_14	[p2l343t2466r975b2545],
34	cell	NN	O	cell	nn	36	SENT_14	[p2l343t2466r975b2545],
35	lung	NN	O	lung	nn	36	SENT_14	[p2l1006t2466r1200b2567],
36	cancer	NN	O	cancer	prep_of	28	SENT_14	[p2l1229t2492r1504b2544],
37	to	TO	O	to	aux	38	SENT_14	[p2l1533t2483r1613b2545],
38	geﬁtinib	VB	O	geﬁtinib	xcomp	15	SENT_14	[p2l1646t2461r2133b2567],
39	.7	CD	NUMBER	.7	number	40	SENT_14	[p2l1646t2461r2133b2567],
40	’	CD	NUMBER	’	num	41	SENT_14	[p2l1646t2461r2133b2567],
41	8	CD	NUMBER	8	dobj	38	SENT_14	[p2l1646t2461r2133b2567],
42	Taken	VBN	O	take	partmod	41	SENT_14	[p2l7t2594r263b2673],
43	together	RB	O	together	advmod	42	SENT_14	[p2l295t2594r666b2695],
44	,	,	O	,	_	0	SENT_14	[p2l295t2594r666b2695],
45	these	DT	O	these	det	46	SENT_14	[p2l704t2594r922b2673],
46	ﬁndings	NNS	O	ﬁndings	nsubj	47	SENT_14	[p2l954t2593r1303b2695],
47	rekindled	VBD	O	rekindle	_	0	SENT_14	[p2l1336t2594r1739b2673],
48	substantial	JJ	O	substantial	amod	49	SENT_14	[p2l1771t2594r2134b2673, p2l11t2722r138b2800],
49	enthusiasm	NN	O	enthusiasm	dobj	47	SENT_14	[p2l158t2722r641b2801],
50	for	IN	O	for	_	0	SENT_14	[p2l663t2721r784b2801],
51	the	DT	O	the	det	52	SENT_14	[p2l802t2722r930b2800],
52	use	NN	O	use	prep_for	47	SENT_14	[p2l951t2748r1089b2801],
53	of	IN	O	of	_	0	SENT_14	[p2l1110t2721r1210b2801],
54	EGFR	NN	ORGANIZATION	egfr	nn	55	SENT_14	[p2l1211t2728r1468b2805],
55	inhibitors	NNS	O	inhibitor	prep_of	52	SENT_14	[p2l1478t2722r1884b2801],
56	in	IN	O	in	_	0	SENT_14	[p2l1906t2723r1987b2799],
57	the	DT	O	the	det	58	SENT_14	[p2l2008t2722r2136b2800],
58	treatment	NN	O	treatment	prep_in	47	SENT_14	[p2l11t2867r421b2929],
59	of	IN	O	of	_	0	SENT_14	[p2l440t2849r540b2929],
60	non	JJ	O	non	amod	66	SENT_14	[p2l545t2850r1170b2929],
61	—	JJ	O	—	amod	66	SENT_14	[p2l545t2850r1170b2929],
62	small	JJ	O	small	amod	66	SENT_14	[p2l545t2850r1170b2929],
63	—	NN	O	—	nn	66	SENT_14	[p2l545t2850r1170b2929],
64	cell	NN	O	cell	nn	66	SENT_14	[p2l545t2850r1170b2929],
65	lung	NN	O	lung	nn	66	SENT_14	[p2l1192t2850r1384b2951],
66	cancer	NN	O	cancer	prep_of	58	SENT_14	[p2l1405t2876r1693b2929],
67	.	.	O	.	_	0	SENT_14	[p2l1405t2876r1693b2929],

1	The	DT	O	the	det	2	SENT_15	[p2l1718t2850r1878b2928],
2	result	NN	O	result	nsubj	6	SENT_15	[p2l1902t2850r2140b2929],
3	has	VBZ	O	have	aux	6	SENT_15	[p2l10t2978r148b3056],
4	been	VBN	O	be	cop	6	SENT_15	[p2l171t2978r366b3057],
5	a	DT	O	a	det	6	SENT_15	[p2l386t3004r431b3056],
6	ﬂurry	NN	O	ﬂurry	_	0	SENT_15	[p2l448t2977r675b3078],
7	of	IN	O	of	_	0	SENT_15	[p2l691t2977r790b3057],
8	investigative	JJ	O	investigative	amod	9	SENT_15	[p2l791t2979r1296b3079],
9	activity	NN	O	activity	prep_of	6	SENT_15	[p2l1316t2979r1602b3078],
10	to	TO	O	to	aux	11	SENT_15	[p2l1618t2995r1696b3057],
11	determine	VB	O	determine	infmod	6	SENT_15	[p2l1718t2978r2136b3057],
12	the	DT	O	the	det	13	SENT_15	[p2l11t3105r140b3183],
13	role	NN	O	role	dobj	11	SENT_15	[p2l168t3105r329b3184],
14	of	IN	O	of	_	0	SENT_15	[p2l358t3104r459b3184],
15	these	DT	O	these	det	16	SENT_15	[p2l469t3105r687b3183],
16	mutations	NNS	O	mutation	prep_of	13	SENT_15	[p2l716t3106r1172b3201],
17	,	,	O	,	_	0	SENT_15	[p2l716t3106r1172b3201],
18	and	CC	O	and	_	0	SENT_15	[p2l1205t3105r1361b3184],
19	potentially	RB	O	potentially	advmod	20	SENT_15	[p2l1388t3105r1838b3205],
20	that	DT	O	that	conj_and	13	SENT_15	[p2l1863t3105r2029b3183],
21	of	IN	O	of	_	0	SENT_15	[p2l2053t3104r2153b3184],
22	other	JJ	O	other	amod	23	SENT_15	[p2l11t3234r235b3313],
23	alterations	NNS	O	alteration	prep_of	20	SENT_15	[p2l270t3234r715b3313],
24	in	IN	O	in	_	0	SENT_15	[p2l755t3235r836b3312],
25	EGFR	NN	ORGANIZATION	egfr	nn	27	SENT_15	[p2l874t3240r1133b3317],
26	signaling	NN	O	signaling	nn	27	SENT_15	[p2l1163t3234r1557b3335],
27	pathways	NNS	O	pathway	prep_in	11	SENT_15	[p2l1592t3234r2010b3334],
28	,	,	O	,	_	0	SENT_15	[p2l1592t3234r2010b3334],
29	in	IN	O	in	_	0	SENT_15	[p2l2054t3235r2135b3312],
30	selecting	NN	O	selecting	nn	31	SENT_15	[p2l12t3362r388b3463],
31	patients	NNS	O	patient	prep_in	11	SENT_15	[p2l417t3363r752b3462],
32	who	WP	O	who	nsubj	34	SENT_15	[p2l784t3362r967b3441],
33	might	MD	O	might	aux	34	SENT_15	[p2l1003t3362r1261b3463],
34	benefit	VB	O	benefit	rcmod	31	SENT_15	[p2l1291t3361r1588b3441],
35	from	IN	O	from	_	0	SENT_15	[p2l1617t3361r1824b3441],
36	EGFRinhibitor	NN	O	egfrinhibitor	nn	37	SENT_15	[p2l1857t3368r2134b3445, p2l10t3490r385b3568],
37	therapy	NN	O	therapy	prep_from	34	SENT_15	[p2l408t3486r782b3589],
38	.9	CD	NUMBER	.9	num	37	SENT_15	[p2l408t3486r782b3589],

1	The	DT	O	the	det	3	SENT_16	[p2l136t3617r298b3695],
2	two	CD	NUMBER	two	num	3	SENT_16	[p2l330t3634r481b3697],
3	reports	NNS	O	report	nsubj	48	SENT_16	[p2l514t3634r813b3717],
4	from	IN	O	from	_	0	SENT_16	[p2l846t3616r1054b3696],
5	the	DT	O	the	det	7	SENT_16	[p2l1086t3617r1215b3695],
6	N	NN	O	n	nn	7	SENT_16	[p2l1244t3625r1319b3697],
7	CIC	NN	ORGANIZATION	cic	prep_from	3	SENT_16	[p2l1322t3623r1478b3696],
8	in	IN	O	in	_	0	SENT_16	[p2l1511t3618r1592b3695],
9	this	DT	O	this	det	10	SENT_16	[p2l1624t3617r1776b3695],
10	issue	NN	O	issue	prep_in	7	SENT_16	[p2l1810t3618r2020b3697],
11	of	IN	O	of	_	0	SENT_16	[p2l2053t3616r2153b3696],
12	thejoumal	JJ	O	thejoumal	prep_of	10	SENT_16	[p3l11t24r448b125],
13	,	,	O	,	_	0	SENT_16	[p3l11t24r448b125],
14	by	IN	O	by	_	0	SENT_16	[p3l474t24r570b124],
15	Shepherd	NNP	PERSON	Shepherd	prep_by	3	SENT_16	[p3l589t24r984b124],
16	and	CC	O	and	_	0	SENT_16	[p3l1005t24r1158b103],
17	colleagues5	NN	O	colleagues5	prep_by	3	SENT_16	[p3l1180t20r1650b125],
18	on	IN	O	on	_	0	SENT_16	[p3l1675t50r1781b103],
19	the	DT	O	the	det	21	SENT_16	[p3l1802t24r1930b102],
20	clinical	JJ	O	clinical	amod	21	SENT_16	[p3l1952t24r2134b102, p3l10t151r151b229],
21	results	NNS	O	result	prep_on	17	SENT_16	[p3l174t151r451b230],
22	and	CC	O	and	_	0	SENT_16	[p3l477t151r632b230],
23	by	IN	O	by	_	0	SENT_16	[p3l656t151r753b251],
24	Tsao	NNP	PERSON	Tsao	prep_by	3	SENT_16	[p3l770t158r967b230],
25	and	CC	O	and	_	0	SENT_16	[p3l993t151r1148b230],
26	colleagues6	NN	O	colleagues6	conj_and	15	SENT_16	[p3l1173t145r1654b252],
27	on	IN	O	on	_	0	SENT_16	[p3l1679t177r1785b230],
28	the	DT	O	the	det	30	SENT_16	[p3l1810t151r1939b229],
29	molecular	JJ	O	molecular	amod	30	SENT_16	[p3l1963t177r2133b230, p3l10t280r294b359],
30	results	NNS	O	result	prep_on	26	SENT_16	[p3l318t280r596b359],
31	of	IN	O	of	_	0	SENT_16	[p3l625t279r725b359],
32	a	DT	O	a	det	34	SENT_16	[p3l733t306r778b358],
33	randomized	JJ	O	randomized	amod	34	SENT_16	[p3l802t280r1313b359],
34	trial	NN	O	trial	prep_of	30	SENT_16	[p3l1341t280r1507b358],
35	comparing	VBG	O	compare	partmod	34	SENT_16	[p3l1535t281r1998b381],
36	erlotinib	NN	O	erlotinib	dobj	35	SENT_16	[p3l2023t306r2134b358, p3l9t408r286b487],
37	with	IN	O	with	_	0	SENT_16	[p3l306t408r495b487],
38	placebo	NN	O	placebo	prep_with	35	SENT_16	[p3l517t408r843b508],
39	in	IN	O	in	_	0	SENT_16	[p3l866t409r948b486],
40	non	JJ	O	non	amod	46	SENT_16	[p3l971t408r1602b487],
41	—	JJ	O	—	amod	46	SENT_16	[p3l971t408r1602b487],
42	small	JJ	O	small	amod	46	SENT_16	[p3l971t408r1602b487],
43	—	NN	O	—	nn	46	SENT_16	[p3l971t408r1602b487],
44	cell	NN	O	cell	nn	46	SENT_16	[p3l971t408r1602b487],
45	lung	NN	O	lung	nn	46	SENT_16	[p3l1624t408r1818b509],
46	cancer	NN	O	cancer	prep_in	38	SENT_16	[p3l1838t434r2130b504],
47	,	,	O	,	_	0	SENT_16	[p3l1838t434r2130b504],
48	provide	VBP	O	provide	_	0	SENT_16	[p3l9t536r325b636],
49	data	NNS	O	datum	dobj	48	SENT_16	[p3l353t536r532b615],
50	that	WDT	O	that	nsubj	51	SENT_16	[p3l558t536r725b614],
51	have	VBP	O	have	rcmod	49	SENT_16	[p3l747t536r935b615],
52	a	DT	O	a	det	54	SENT_16	[p3l962t562r1006b614],
53	substantial	JJ	O	substantial	amod	54	SENT_16	[p3l1033t536r1496b615],
54	bearing	NN	O	bearing	dobj	51	SENT_16	[p3l1524t536r1847b637],
55	on	IN	O	on	_	0	SENT_16	[p3l1872t562r1978b615],
56	the	DT	O	the	det	57	SENT_16	[p3l2006t536r2134b615],
57	treatment	NN	O	treatment	prep_on	54	SENT_16	[p3l11t681r425b742],
58	of	IN	O	of	_	0	SENT_16	[p3l460t663r560b743],
59	patients	NNS	O	patient	prep_of	57	SENT_16	[p3l579t665r913b764],
60	with	IN	O	with	_	0	SENT_16	[p3l950t664r1140b743],
61	advanced	JJ	O	advanced	amod	63	SENT_16	[p3l1178t664r1570b743],
62	lung	NN	O	lung	nn	63	SENT_16	[p3l1607t664r1801b765],
63	cancer	NN	O	cancer	prep_with	59	SENT_16	[p3l1838t690r2129b743],
64	.	.	O	.	_	0	SENT_16	[p3l1838t690r2129b743],

1	From	IN	O	from	_	0	SENT_17	[p3l9t798r237b869],
2	these	DT	O	these	det	3	SENT_17	[p3l265t791r484b868],
3	studies	NNS	O	study	prep_from	10	SENT_17	[p3l513t791r832b886],
4	,	,	O	,	_	0	SENT_17	[p3l513t791r832b886],
5	critical	JJ	O	critical	amod	6	SENT_17	[p3l865t791r1149b868],
6	lessons	NNS	O	lesson	nsubjpass	10	SENT_17	[p3l1175t791r1485b869],
7	can	MD	O	can	aux	10	SENT_17	[p3l1514t817r1659b868],
8	also	RB	O	also	advmod	10	SENT_17	[p3l1685t791r1852b869],
9	be	VB	O	be	auxpass	10	SENT_17	[p3l1882t791r1977b869],
10	derived	VBN	O	derive	_	0	SENT_17	[p3l2005t791r2134b869, p3l10t919r215b998],
11	on	IN	O	on	_	0	SENT_17	[p3l247t945r353b998],
12	how	WRB	O	how	advmod	27	SENT_17	[p3l385t919r569b998],
13	anticancer	JJ	O	anticancer	amod	14	SENT_17	[p3l596t920r1036b998],
14	agents	NNS	O	agent	nsubjpass	27	SENT_17	[p3l1064t936r1337b1020],
15	that	WDT	O	that	nsubjpass	18	SENT_17	[p3l1371t919r1538b997],
16	have	VBP	O	have	aux	18	SENT_17	[p3l1564t919r1753b998],
17	been	VBN	O	be	auxpass	18	SENT_17	[p3l1785t919r1984b998],
18	selected	VBN	O	select	rcmod	14	SENT_17	[p3l2017t945r2133b997, p3l10t1046r254b1125],
19	to	TO	O	to	aux	20	SENT_17	[p3l278t1063r356b1125],
20	affect	VB	O	affect	xcomp	18	SENT_17	[p3l380t1045r614b1124],
21	a	DT	O	a	det	24	SENT_17	[p3l632t1072r676b1124],
22	specific	JJ	O	specific	amod	24	SENT_17	[p3l700t1045r1015b1146],
23	molecular	JJ	O	molecular	amod	24	SENT_17	[p3l1037t1046r1459b1126],
24	pathway	NN	O	pathway	dobj	20	SENT_17	[p3l1478t1046r1831b1146],
25	should	MD	O	should	aux	27	SENT_17	[p3l1851t1046r2135b1126],
26	be	VB	O	be	auxpass	27	SENT_17	[p3l11t1175r107b1253],
27	developed	VBN	O	develop	prepc_on	10	SENT_17	[p3l132t1175r580b1274],
28	.	.	O	.	_	0	SENT_17	[p3l132t1175r580b1274],

1	The	DT	O	the	det	4	SENT_18	[p3l136t1302r298b1380],
2	N	NN	O	n	nn	4	SENT_18	[p3l319t1310r394b1381],
3	CIC	NN	ORGANIZATION	cic	nn	4	SENT_18	[p3l397t1308r553b1381],
4	trial	NN	O	trial	nsubj	7	SENT_18	[p3l580t1302r746b1380],
5	is	VBZ	O	be	cop	7	SENT_18	[p3l768t1303r833b1380],
6	the	DT	O	the	det	7	SENT_18	[p3l860t1302r989b1380],
7	first	JJ	ORDINAL	first	_	0	SENT_18	[p3l1013t1301r1186b1380],
8	randomized	VBN	O	randomize	partmod	7	SENT_18	[p3l1205t1302r1716b1381],
9	study	NN	O	study	dobj	8	SENT_18	[p3l1741t1302r1967b1402],
10	of	IN	O	of	_	0	SENT_18	[p3l1987t1301r2087b1381],
11	a	DT	O	a	det	14	SENT_18	[p3l2092t1328r2136b1380],
12	tyrosine	NN	O	tyrosine	nn	14	SENT_18	[p3l11t1432r346b1530],
13	kinase	NN	O	kinase	nn	14	SENT_18	[p3l379t1431r650b1510],
14	inhibitor	NN	O	inhibitor	prep_of	9	SENT_18	[p3l683t1431r1059b1509],
15	to	TO	O	to	aux	16	SENT_18	[p3l1090t1448r1169b1509],
16	demonstrate	VB	O	demonstrate	xcomp	8	SENT_18	[p3l1205t1431r1736b1509],
17	substantial	JJ	O	substantial	amod	18	SENT_18	[p3l1771t1431r2134b1510, p3l11t1558r140b1636],
18	benefit	NN	O	benefit	dobj	16	SENT_18	[p3l186t1557r482b1637],
19	in	IN	O	in	_	0	SENT_18	[p3l523t1559r605b1636],
20	terms	NNS	O	term	prep_in	16	SENT_18	[p3l651t1575r889b1636],
21	of	IN	O	of	_	0	SENT_18	[p3l938t1557r1038b1637],
22	both	DT	O	both	det	23	SENT_18	[p3l1066t1558r1259b1637],
23	relief	NN	O	relief	prep_of	20	SENT_18	[p3l1306t1557r1538b1636],
24	of	IN	O	of	_	0	SENT_18	[p3l1566t1557r1667b1637],
25	symptoms	NNS	O	symptom	prep_of	23	SENT_18	[p3l1696t1575r2133b1658],
26	(	JJ	O	(	amod	27	SENT_18	[p3l15t1687r330b1788],
27	cough	NN	O	cough	dep	23	SENT_18	[p3l15t1687r330b1788],
28	,	,	O	,	_	0	SENT_18	[p3l15t1687r330b1788],
29	dyspnea	NN	O	dyspnea	conj_and	27	SENT_18	[p3l370t1687r736b1787],
30	,	,	O	,	_	0	SENT_18	[p3l370t1687r736b1787],
31	and	CC	O	and	_	0	SENT_18	[p3l775t1687r931b1766],
32	pain	NN	O	pain	nn	33	SENT_18	[p3l964t1688r1178b1787],
33	)	NN	O	)	conj_and	27	SENT_18	[p3l964t1688r1178b1787],
34	and	CC	O	and	_	0	SENT_18	[p3l1217t1687r1373b1766],
35	median	NN	O	median	conj_and	27	SENT_18	[p3l1407t1687r1724b1766],
36	and	CC	O	and	_	0	SENT_18	[p3l1757t1687r1913b1766],
37	oneyear	JJ	O	oneyear	amod	38	SENT_18	[p3l1948t1713r2134b1766, p3l6t1841r184b1915],
38	survival	NN	O	survival	prep_of	20	SENT_18	[p3l219t1815r544b1894],
39	in	IN	O	in	_	0	SENT_18	[p3l579t1816r662b1893],
40	non	JJ	O	non	amod	46	SENT_18	[p3l697t1815r1343b1894],
41	—	JJ	O	—	amod	46	SENT_18	[p3l697t1815r1343b1894],
42	small	JJ	O	small	amod	46	SENT_18	[p3l697t1815r1343b1894],
43	—	NN	O	—	nn	46	SENT_18	[p3l697t1815r1343b1894],
44	cell	NN	O	cell	nn	46	SENT_18	[p3l697t1815r1343b1894],
45	lung	NN	O	lung	nn	46	SENT_18	[p3l1377t1815r1575b1916],
46	cancer	NN	O	cancer	prep_in	38	SENT_18	[p3l1608t1841r1905b1894],
47	.	.	O	.	_	0	SENT_18	[p3l1608t1841r1905b1894],

1	This	DT	O	this	det	2	SENT_19	[p3l1944t1815r2131b1893],
2	outcome	NN	O	outcome	nsubjpass	21	SENT_19	[p3l11t1960r383b2022],
3	was	VBD	O	be	auxpass	4	SENT_19	[p3l408t1969r569b2022],
4	achieved	VBN	O	achieve	_	0	SENT_19	[p3l598t1943r961b2022],
5	with	IN	O	with	_	0	SENT_19	[p3l984t1943r1174b2022],
6	mild	JJ	O	mild	amod	8	SENT_19	[p3l1201t1943r1394b2022],
7	toxic	JJ	O	toxic	amod	8	SENT_19	[p3l1422t1944r1623b2022],
8	effects	NNS	O	effect	prep_with	4	SENT_19	[p3l1651t1942r1921b2021],
9	with	IN	O	with	_	0	SENT_19	[p3l1945t1943r2135b2022],
10	the	DT	O	the	det	11	SENT_19	[p3l11t2071r139b2149],
11	use	NN	O	use	prep_with	4	SENT_19	[p3l176t2097r316b2150],
12	of	IN	O	of	_	0	SENT_19	[p3l353t2070r454b2150],
13	an	DT	O	a	det	19	SENT_19	[p3l471t2097r571b2149],
14	oral	JJ	O	oral	amod	19	SENT_19	[p3l609t2071r770b2150],
15	antineoplastic	JJ	O	antineoplastic	amod	19	SENT_19	[p3l806t2071r1402b2171],
16	agent	NN	O	agent	nn	19	SENT_19	[p3l1437t2088r1674b2172],
17	(	NN	O	(	nn	19	SENT_19	[p3l1710t2071r2130b2162],
18	erlotinib	NN	O	erlotinib	nn	19	SENT_19	[p3l1710t2071r2130b2162],
19	)	NN	O	)	prep_of	11	SENT_19	[p3l1710t2071r2130b2162],
20	and	CC	O	and	_	0	SENT_19	[p3l10t2198r165b2277],
21	led	VBD	O	lead	conj_and	4	SENT_19	[p3l206t2198r331b2277],
22	to	TO	O	to	_	0	SENT_19	[p3l373t2215r452b2277],
23	its	PRP$	O	its	poss	24	SENT_19	[p3l494t2199r590b2276],
24	approval	NN	O	approval	prep_to	21	SENT_19	[p3l633t2198r998b2298],
25	for	IN	O	for	_	0	SENT_19	[p3l1039t2197r1162b2277],
26	use	NN	O	use	prep_for	24	SENT_19	[p3l1201t2224r1340b2278],
27	in	IN	O	in	_	0	SENT_19	[p3l1381t2199r1462b2276],
28	non	JJ	O	non	amod	34	SENT_19	[p3l1504t2198r2135b2277],
29	—	JJ	O	—	amod	34	SENT_19	[p3l1504t2198r2135b2277],
30	small	JJ	O	small	amod	34	SENT_19	[p3l1504t2198r2135b2277],
31	—	NN	O	—	nn	34	SENT_19	[p3l1504t2198r2135b2277],
32	cell	NN	O	cell	nn	34	SENT_19	[p3l1504t2198r2135b2277],
33	lung	NN	O	lung	nn	34	SENT_19	[p3l9t2327r203b2428],
34	cancer	NN	O	cancer	prep_in	26	SENT_19	[p3l231t2353r506b2405],
35	by	IN	O	by	_	0	SENT_19	[p3l535t2327r631b2427],
36	the	DT	O	the	det	40	SENT_19	[p3l657t2327r787b2405],
37	Food	NNP	ORGANIZATION	Food	nn	40	SENT_19	[p3l816t2327r1030b2406],
38	and	CC	ORGANIZATION	and	_	0	SENT_19	[p3l1060t2327r1215b2406],
39	Drug	NNP	ORGANIZATION	Drug	conj_and	37	SENT_19	[p3l1244t2333r1463b2428],
40	Administration	NNP	ORGANIZATION	Administration	prep_by	21	SENT_19	[p3l1486t2327r2135b2406],
41	in	IN	O	in	_	0	SENT_19	[p3l10t2457r91b2534],
42	November	NNP	DATE	November	prep_in	21	SENT_19	[p3l127t2456r572b2535],
43	2004	CD	DATE	2004	num	42	SENT_19	[p3l607t2462r837b2535],
44	.	.	O	.	_	0	SENT_19	[p3l607t2462r837b2535],

1	Patient	NN	O	patient	nn	2	SENT_20	[p3l880t2457r1176b2534],
2	characteristics	NNS	O	characteristic	nsubj	24	SENT_20	[p3l1210t2456r1814b2535],
3	that	WDT	O	that	dobj	18	SENT_20	[p3l1855t2456r2022b2534],
4	in	IN	O	in	_	0	SENT_20	[p3l2054t2457r2135b2534],
5	phase	NN	O	phase	prep_in	18	SENT_20	[p3l9t2584r255b2684],
6	2	CD	NUMBER	2	num	7	SENT_20	[p3l284t2590r331b2662],
7	studies	NNS	O	study	nsubjpass	18	SENT_20	[p3l363t2584r656b2663],
8	of	IN	O	of	_	0	SENT_20	[p3l688t2583r788b2663],
9	non	JJ	O	non	amod	15	SENT_20	[p3l799t2584r1431b2663],
10	—	JJ	O	—	amod	15	SENT_20	[p3l799t2584r1431b2663],
11	small	JJ	O	small	amod	15	SENT_20	[p3l799t2584r1431b2663],
12	—	NN	O	—	nn	15	SENT_20	[p3l799t2584r1431b2663],
13	cell	NN	O	cell	nn	15	SENT_20	[p3l799t2584r1431b2663],
14	lung	NN	O	lung	nn	15	SENT_20	[p3l1459t2584r1653b2685],
15	cancer	NN	O	cancer	prep_of	7	SENT_20	[p3l1679t2610r1954b2662],
16	had	VBD	O	have	aux	18	SENT_20	[p3l1980t2584r2135b2663],
17	been	VBN	O	be	auxpass	18	SENT_20	[p3l11t2712r210b2790],
18	associated	VBN	O	associate	rcmod	2	SENT_20	[p3l246t2712r683b2790],
19	With	IN	O	with	_	0	SENT_20	[p3l715t2712r904b2791],
20	responsiveness	NN	O	responsiveness	prep_with	18	SENT_20	[p3l941t2713r1579b2811],
21	to	TO	O	to	_	0	SENT_20	[p3l1619t2729r1698b2790],
22	EGFR	NN	ORGANIZATION	egfr	nn	23	SENT_20	[p3l1735t2718r1994b2795],
23	inhibitors	NNS	O	inhibitor	prep_to	18	SENT_20	[p3l2020t2713r2134b2789, p3l10t2840r338b2919],
24	—	VBP	O	—	_	0	SENT_20	[p3l362t2885r469b2893],
25	histologic	JJ	O	histologic	amod	26	SENT_20	[p3l490t2840r910b2941],
26	features	NNS	O	feature	dobj	24	SENT_20	[p3l935t2839r1267b2919],
27	of	IN	O	of	_	0	SENT_20	[p3l1295t2839r1395b2919],
28	adenocarcinoma	NN	O	adenocarcinoma	prep_of	26	SENT_20	[p3l1401t2840r2129b2936],
29	,	,	O	,	_	0	SENT_20	[p3l1401t2840r2129b2936],
30	female	JJ	O	female	amod	31	SENT_20	[p3l10t2967r293b3047],
31	sex	NN	O	sex	conj_and	28	SENT_20	[p3l328t2994r482b3064],
32	,	,	O	,	_	0	SENT_20	[p3l328t2994r482b3064],
33	no	DT	O	no	det	34	SENT_20	[p3l522t2994r628b3047],
34	history	NN	O	history	conj_and	28	SENT_20	[p3l664t2968r958b3068],
35	of	IN	O	of	_	0	SENT_20	[p3l989t2967r1089b3047],
36	smoking	NN	O	smoking	prep_of	34	SENT_20	[p3l1106t2968r1502b3069],
37	,	,	O	,	_	0	SENT_20	[p3l1106t2968r1502b3069],
38	and	CC	O	and	_	0	SENT_20	[p3l1541t2968r1697b3047],
39	Asian	JJ	MISC	asian	amod	40	SENT_20	[p3l1727t2969r1966b3046],
40	anzoo	NN	O	anzoo	conj_and	28	SENT_20	[p3l2001t2994r2134b3046, p3l149t3144r206b3165],

1	N	NN	O	n	nn	2	SENT_21	[p3l919t3146r933b3161],
2	ENGLJ	NN	O	englj	nsubj	3	SENT_21	[p3l948t3145r1032b3167],
3	MED	VBD	O	med	_	0	SENT_21	[p3l1047t3146r1100b3161],
4	35	CD	NUMBER	35	number	5	SENT_21	[p3l1112t3145r1137b3167],
5	:2	CD	NUMBER	:2	num	7	SENT_21	[p3l1156t3145r1176b3165],
6	WWW.NEjM.ORG	NN	O	www.nejm.org	nn	7	SENT_21	[p3l1211t3145r1422b3167],
7	JULY14	NN	O	july14	dobj	3	SENT_21	[p3l1456t3145r1563b3167],
8	,	,	O	,	_	0	SENT_21	[p3l1456t3145r1563b3167],
9	2005	CD	DATE	2005	appos	7	SENT_21	[p3l1576t3145r1639b3167],

1	The	DT	O	the	det	4	SENT_22	[p3l936t3178r987b3202],
2	New	NNP	O	New	nn	4	SENT_22	[p3l996t3179r1058b3202],
3	Englan	NNP	O	Englan	nn	4	SENT_22	[p3l1067t3178r1161b3209],
4	ournal	NN	O	ournal	_	0	SENT_22	[p3l1201t3178r1284b3202],
5	of	IN	O	of	_	0	SENT_22	[p3l1294t3178r1323b3202],
6	Medicine	NN	MISC	medicine	prep_of	4	SENT_22	[p3l1330t3178r1455b3202],

1	Downloaded	VBN	O	download	_	0	SENT_23	[p3l378t3219r548b3242],
2	from	IN	O	from	_	0	SENT_23	[p3l557t3219r621b3242],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_23	[p3l630t3219r748b3249],
4	at	IN	O	at	_	0	SENT_23	[p3l759t3223r782b3242],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_23	[p3l790t3219r973b3242],
6	on	IN	O	on	_	0	SENT_23	[p3l982t3226r1015b3242],
7	January	NNP	DATE	January	prep_on	1	SENT_23	[p3l1023t3219r1126b3249],
8	5	CD	DATE	5	num	7	SENT_23	[p3l1136t3219r1159b3246],
9	,	,	DATE	,	_	0	SENT_23	[p3l1136t3219r1159b3246],
10	2014	CD	DATE	2014	num	7	SENT_23	[p3l1170t3219r1242b3242],
11	.	.	O	.	_	0	SENT_23	[p3l1170t3219r1242b3242],

1	For	IN	O	for	_	0	SENT_24	[p3l1252t3219r1299b3242],
2	personal	JJ	O	personal	amod	3	SENT_24	[p3l1307t3219r1419b3249],
3	use	NN	O	use	pobj	1	SENT_24	[p3l1428t3226r1472b3242],
4	only	RB	O	only	advmod	3	SENT_24	[p3l1482t3219r1546b3249],
5	.	.	O	.	_	0	SENT_24	[p3l1482t3219r1546b3249],

1	No	DT	O	no	det	3	SENT_25	[p3l1557t3219r1597b3242],
2	other	JJ	O	other	amod	3	SENT_25	[p3l1607t3219r1675b3242],
3	uses	NNS	O	use	_	0	SENT_25	[p3l1683t3226r1739b3242],
4	without	IN	O	without	_	0	SENT_25	[p3l1749t3219r1850b3242],
5	permission	NN	O	permission	prep_without	3	SENT_25	[p3l1859t3219r2011b3249],
6	.	.	O	.	_	0	SENT_25	[p3l1859t3219r2011b3249],

1	Copyright	NN	O	copyright	_	0	SENT_26	[p3l728t3260r863b3291],
2	©	CD	NUMBER	©	num	6	SENT_26	[p3l872t3260r896b3284],
3	2005	CD	DATE	2005	num	6	SENT_26	[p3l906t3260r970b3284],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_26	[p3l980t3260r1171b3284],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_26	[p3l1181t3260r1289b3284],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_26	[p3l1300t3260r1405b3291],
7	.	.	O	.	_	0	SENT_26	[p3l1300t3260r1405b3291],

1	All	DT	O	all	det	2	SENT_27	[p3l1416t3260r1457b3284],
2	rights	NNS	O	rights	nsubj	3	SENT_27	[p3l1466t3260r1541b3291],
3	reserved	VBN	O	reserve	_	0	SENT_27	[p3l1551t3260r1670b3284],
4	.	.	O	.	_	0	SENT_27	[p3l1551t3260r1670b3284],

1	EDITORIALS	NNS	O	editorial	_	0	SENT_28	[p3l979t3366r1181b3385],

1	cestry	NN	O	cestry	nsubj	3	SENT_29	[p3l11t3596r256b3680],
2	—	CD	NUMBER	—	num	1	SENT_29	[p3l282t3624r390b3632],
3	correlated	VBD	O	correlate	_	0	SENT_29	[p3l421t3580r843b3658],
4	signiﬁcantly	RB	O	signiﬁcantly	advmod	3	SENT_29	[p3l879t3579r1400b3680],
5	with	IN	O	with	_	0	SENT_29	[p3l1426t3580r1616b3659],
6	responsiveness	NN	O	responsiveness	prep_with	3	SENT_29	[p3l1650t3580r2133b3680, p3l11t3734r194b3787],
7	to	TO	O	to	aux	8	SENT_29	[p3l221t3725r300b3787],
8	erlotinib	VB	O	erlotinib	xcomp	3	SENT_29	[p3l327t3709r686b3787],
9	in	IN	O	in	_	0	SENT_29	[p3l711t3709r793b3786],
10	this	DT	O	this	det	11	SENT_29	[p3l818t3709r971b3787],
11	trial	NN	O	trial	prep_in	8	SENT_29	[p3l998t3709r1187b3787],
12	.	.	O	.	_	0	SENT_29	[p3l998t3709r1187b3787],

1	In	IN	O	in	_	0	SENT_30	[p4l138t40r225b110],
2	the	DT	O	the	det	4	SENT_30	[p4l248t33r377b111],
3	accompanying	VBG	O	accompany	amod	4	SENT_30	[p4l400t33r1021b133],
4	study	NN	O	study	prep_in	40	SENT_30	[p4l1042t33r1267b133],
5	of	IN	O	of	_	0	SENT_30	[p4l1287t32r1387b111],
6	potential	JJ	O	potential	amod	8	SENT_30	[p4l1391t33r1767b133],
7	molecular	JJ	O	molecular	amod	8	SENT_30	[p4l1789t32r2133b112, p4l9t160r121b238],
8	correlates	NNS	O	correlate	prep_of	4	SENT_30	[p4l156t160r564b238],
9	of	IN	O	of	_	0	SENT_30	[p4l605t159r705b238],
10	sensitivity	NN	O	sensitivity	prep_of	8	SENT_30	[p4l726t161r1146b260],
11	to	TO	O	to	aux	12	SENT_30	[p4l1179t176r1258b238],
12	erlotinib	VB	O	erlotinib	infmod	4	SENT_30	[p4l1298t153r1727b255],
13	,6	CD	NUMBER	,6	num	15	SENT_30	[p4l1298t153r1727b255],
14	paraffinembedded	JJ	O	paraffinembedded	amod	15	SENT_30	[p4l1764t159r2132b260, p4l11t288r452b367],
15	biopsy	NN	O	biopsy	dobj	12	SENT_30	[p4l490t289r768b389],
16	and	CC	O	and	_	0	SENT_30	[p4l801t288r958b367],
17	surgical	JJ	O	surgical	amod	20	SENT_30	[p4l996t288r1751b389],
18	—	NN	O	—	nn	20	SENT_30	[p4l996t288r1751b389],
19	resection	NN	O	resection	nn	20	SENT_30	[p4l996t288r1751b389],
20	samples	NNS	O	sample	dobj	12	SENT_30	[p4l1790t289r2132b389],
21	of	IN	O	of	_	0	SENT_30	[p4l11t416r112b495],
22	non	JJ	O	non	amod	25	SENT_30	[p4l116t416r748b495],
23	—	JJ	O	—	amod	25	SENT_30	[p4l116t416r748b495],
24	small	JJ	O	small	amod	25	SENT_30	[p4l116t416r748b495],
25	—	NN	O	—	prep_of	20	SENT_30	[p4l116t416r748b495],
26	cell	NN	O	cell	nn	28	SENT_30	[p4l116t416r748b495],
27	lung	NN	O	lung	nn	28	SENT_30	[p4l769t416r963b517],
28	cancer	NN	O	cancer	nsubj	40	SENT_30	[p4l983t442r1275b512],
29	,	,	O	,	_	0	SENT_30	[p4l983t442r1275b512],
30	adequate	JJ	O	adequate	amod	28	SENT_30	[p4l1303t417r1681b517],
31	for	IN	O	for	_	0	SENT_30	[p4l1704t416r1827b495],
32	at	IN	O	at	quantmod	34	SENT_30	[p4l1846t433r1926b495],
33	least	JJS	O	least	mwe	32	SENT_30	[p4l1943t417r2139b495],
34	one	CD	NUMBER	one	num	35	SENT_30	[p4l11t570r163b623],
35	analysis	NN	O	analysis	prep_for	30	SENT_30	[p4l197t545r527b645],
36	of	IN	O	of	_	0	SENT_30	[p4l565t544r665b623],
37	EGFR	NN	ORGANIZATION	egfr	prep_of	35	SENT_30	[p4l680t550r952b640],
38	,	,	O	,	_	0	SENT_30	[p4l680t550r952b640],
39	were	VBD	O	be	cop	40	SENT_30	[p4l987t571r1189b624],
40	available	JJ	O	available	_	0	SENT_30	[p4l1223t544r1587b624],
41	from	IN	O	from	_	0	SENT_30	[p4l1622t544r1829b623],
42	328	CD	NUMBER	328	prep_from	40	SENT_30	[p4l1864t550r2015b623],
43	of	IN	O	of	_	0	SENT_30	[p4l2052t544r2152b623],
44	the	DT	O	the	det	46	SENT_30	[p4l11t672r139b751],
45	731	CD	NUMBER	731	num	46	SENT_30	[p4l160t678r312b751],
46	patients	NNS	O	patient	prep_of	42	SENT_30	[p4l331t673r662b773],
47	enrolled	VBD	O	enrol	partmod	46	SENT_30	[p4l685t672r1051b751],
48	.	.	O	.	_	0	SENT_30	[p4l685t672r1051b751],

1	Response	NN	O	response	nsubjpass	14	SENT_31	[p4l1075t679r1480b773],
2	to	TO	O	to	_	0	SENT_31	[p4l1501t689r1579b751],
3	erlotinib	NN	O	erlotinib	prep_to	1	SENT_31	[p4l1602t672r1956b751],
4	was	VBD	O	be	auxpass	6	SENT_31	[p4l1973t699r2133b752],
5	signiﬁcantly	RB	O	signiﬁcantly	advmod	6	SENT_31	[p4l12t800r527b901],
6	associated	VBN	O	associate	_	0	SENT_31	[p4l542t801r975b879],
7	with	IN	O	with	_	0	SENT_31	[p4l991t800r1178b880],
8	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_31	[p4l1199t806r1456b884],
9	positivity	NN	O	positivity	prep_with	6	SENT_31	[p4l1466t801r1847b901],
10	on	IN	O	on	_	0	SENT_31	[p4l1864t826r1970b879],
11	immunohistochemical	JJ	O	immunohistochemical	amod	12	SENT_31	[p4l1991t801r2134b878, p4l11t928r858b1008],
12	analysis	NN	O	analysis	prep_on	9	SENT_31	[p4l897t929r1227b1029],
13	and	CC	O	and	_	0	SENT_31	[p4l1269t928r1425b1007],
14	increased	VBD	O	increase	conj_and	6	SENT_31	[p4l1464t928r1866b1007],
15	numbers	NNS	O	number	dobj	14	SENT_31	[p4l1905t954r2133b1008, p4l11t1056r185b1135],
16	of	IN	O	of	_	0	SENT_31	[p4l216t1056r317b1135],
17	copies	NNS	O	copy	prep_of	15	SENT_31	[p4l327t1057r591b1157],
18	of	IN	O	of	_	0	SENT_31	[p4l622t1056r723b1135],
19	the	DT	O	the	det	21	SENT_31	[p4l733t1057r862b1135],
20	EGFR	NN	ORGANIZATION	egfr	nn	21	SENT_31	[p4l888t1063r1101b1136],
21	gene	NN	O	gene	prep_of	17	SENT_31	[p4l1121t1082r1344b1157],
22	.	.	O	.	_	0	SENT_31	[p4l1121t1082r1344b1157],

1	Although	IN	O	although	mark	9	SENT_32	[p4l1374t1056r1774b1157],
2	twice	RB	O	twice	quantmod	4	SENT_32	[p4l1803t1057r2020b1136],
3	as	RB	O	as	quantmod	4	SENT_32	[p4l2048t1083r2132b1135],
4	many	JJ	O	many	num	5	SENT_32	[p4l11t1210r241b1285],
5	patients	NNS	O	patient	nsubj	9	SENT_32	[p4l263t1185r590b1285],
6	with	IN	O	with	_	0	SENT_32	[p4l615t1185r801b1264],
7	EGFR	NN	ORGANIZATION	egfr	nn	8	SENT_32	[p4l827t1191r1039b1264],
8	mutations	NNS	O	mutation	prep_with	5	SENT_32	[p4l1062t1185r1483b1264],
9	had	VBD	O	have	advcl	29	SENT_32	[p4l1513t1184r1666b1263],
10	a	DT	O	a	det	11	SENT_32	[p4l1693t1211r1737b1263],
11	response	NN	O	response	dobj	9	SENT_32	[p4l1764t1210r2134b1285],
12	to	TO	O	to	_	0	SENT_32	[p4l11t1329r88b1391],
13	treatment	NN	O	treatment	prep_to	9	SENT_32	[p4l118t1329r550b1408],
14	,	,	O	,	_	0	SENT_32	[p4l118t1329r550b1408],
15	as	IN	O	as	advmod	9	SENT_32	[p4l583t1339r667b1391],
16	compared	VBN	O	compare	_	0	SENT_32	[p4l697t1313r1120b1413],
17	with	IN	O	with	prepc_compared_with	9	SENT_32	[p4l1143t1313r1332b1392],
18	patients	NNS	O	patient	pobj	9	SENT_32	[p4l1358t1313r1692b1413],
19	whose	WP$	O	whose	poss	20	SENT_32	[p4l1717t1313r1991b1392],
20	tumors	NNS	O	tumor	nsubj	21	SENT_32	[p4l2019t1329r2133b1392, p4l11t1465r225b1518],
21	lacked	VBD	O	lack	rcmod	18	SENT_32	[p4l248t1439r519b1519],
22	mutations	NNS	O	mutation	dobj	21	SENT_32	[p4l540t1440r995b1534],
23	,	,	O	,	_	0	SENT_32	[p4l540t1440r995b1534],
24	this	DT	O	this	det	25	SENT_32	[p4l1023t1440r1175b1517],
25	difference	NN	O	difference	nsubj	29	SENT_32	[p4l1199t1439r1620b1518],
26	was	VBD	O	be	cop	29	SENT_32	[p4l1637t1466r1798b1519],
27	not	RB	O	not	neg	29	SENT_32	[p4l1821t1456r1965b1518],
28	statistically	RB	O	statistically	advmod	29	SENT_32	[p4l1983t1456r2133b1517, p4l11t1568r371b1668],
29	signiﬁcant	JJ	O	signiﬁcant	_	0	SENT_32	[p4l406t1567r887b1668],
30	.	.	O	.	_	0	SENT_32	[p4l406t1567r887b1668],

1	In	IN	O	in	_	0	SENT_33	[p4l928t1575r1016b1645],
2	the	DT	O	the	det	4	SENT_33	[p4l1054t1567r1185b1646],
3	univariate	JJ	O	univariate	amod	4	SENT_33	[p4l1223t1568r1647b1647],
4	analysis	NN	O	analysis	prep_in	10	SENT_33	[p4l1684t1567r2048b1668],
5	,	,	O	,	_	0	SENT_33	[p4l1684t1567r2048b1668],
6	a	DT	O	a	det	8	SENT_33	[p4l2090t1594r2135b1646],
7	survival	NN	O	survival	nn	8	SENT_33	[p4l12t1696r337b1775],
8	advantage	NN	O	advantage	nsubjpass	10	SENT_33	[p4l376t1695r802b1796],
9	was	VBD	O	be	auxpass	10	SENT_33	[p4l835t1722r996b1775],
10	associated	VBN	O	associate	_	0	SENT_33	[p4l1036t1696r1473b1774],
11	with	IN	O	with	_	0	SENT_33	[p4l1507t1695r1696b1775],
12	increased	VBN	O	increase	amod	13	SENT_33	[p4l1733t1695r2134b1774],
13	numbers	NNS	O	number	prep_with	10	SENT_33	[p4l11t1823r385b1903],
14	of	IN	O	of	_	0	SENT_33	[p4l412t1823r513b1902],
15	gene	NN	O	gene	nn	16	SENT_33	[p4l519t1849r718b1924],
16	copies	NNS	O	copy	prep_of	13	SENT_33	[p4l743t1824r1008b1924],
17	or	CC	O	or	_	0	SENT_33	[p4l1035t1849r1124b1902],
18	EGFR	NN	ORGANIZATION	egfr	nn	19	SENT_33	[p4l1145t1829r1404b1907],
19	expression	NN	O	expression	conj_or	13	SENT_33	[p4l1419t1824r1872b1924],
20	in	IN	O	in	_	0	SENT_33	[p4l1896t1824r1977b1901],
21	pa	NN	O	pa	nn	23	SENT_33	[p4l2001t1850r2133b1924],
22	—	NN	O	—	nn	23	SENT_33	[p4l2001t1850r2133b1924],
23	tients	NNS	O	tient	prep_in	19	SENT_33	[p4l11t1951r241b2028],
24	treated	VBN	O	treat	partmod	23	SENT_33	[p4l270t1950r558b2029],
25	with	IN	O	with	_	0	SENT_33	[p4l580t1950r769b2030],
26	erlotinib	NN	O	erlotinib	prep_with	24	SENT_33	[p4l796t1951r1181b2045],
27	;	:	O	;	_	0	SENT_33	[p4l796t1951r1181b2045],
28	however	RB	O	however	advmod	34	SENT_33	[p4l1212t1951r1583b2045],
29	,	,	O	,	_	0	SENT_33	[p4l1212t1951r1583b2045],
30	this	DT	O	this	det	31	SENT_33	[p4l1615t1951r1768b2028],
31	association	NN	O	association	nsubjpass	34	SENT_33	[p4l1796t1951r2133b2029, p4l11t2079r176b2157],
32	was	VBD	O	be	auxpass	34	SENT_33	[p4l197t2105r358b2158],
33	not	RB	O	not	neg	34	SENT_33	[p4l385t2095r528b2157],
34	found	VBN	O	find	parataxis	10	SENT_33	[p4l549t2078r799b2158],
35	in	IN	O	in	_	0	SENT_33	[p4l823t2079r905b2156],
36	the	DT	O	the	det	38	SENT_33	[p4l930t2078r1059b2157],
37	multivariate	JJ	O	multivariate	amod	38	SENT_33	[p4l1084t2079r1587b2158],
38	analyses	NNS	O	analysis	prep_in	34	SENT_33	[p4l1611t2079r1986b2179],
39	.	.	O	.	_	0	SENT_33	[p4l1611t2079r1986b2179],

1	The	DT	O	the	det	2	SENT_34	[p4l136t2207r296b2285],
2	importance	NN	O	importance	nsubjpass	7	SENT_34	[p4l318t2207r800b2307],
3	of	IN	O	of	_	0	SENT_34	[p4l823t2206r923b2285],
4	these	DT	O	these	det	5	SENT_34	[p4l928t2207r1144b2285],
5	results	NNS	O	result	prep_of	2	SENT_34	[p4l1165t2206r1439b2286],
6	is	VBZ	O	be	auxpass	7	SENT_34	[p4l1463t2207r1527b2285],
7	heightened	VBN	O	heighten	_	0	SENT_34	[p4l1551t2206r2021b2307],
8	by	IN	O	by	_	0	SENT_34	[p4l2043t2207r2139b2307],
9	the	DT	O	the	det	10	SENT_34	[p4l11t2334r139b2413],
10	fact	NN	O	fact	agent	7	SENT_34	[p4l160t2334r315b2413],
11	that	IN	O	that	complm	15	SENT_34	[p4l332t2335r497b2413],
12	molecular	JJ	O	molecular	amod	13	SENT_34	[p4l514t2334r936b2414],
13	correlations	NNS	O	correlation	nsubjpass	15	SENT_34	[p4l955t2334r1450b2413],
14	were	VBD	O	be	auxpass	15	SENT_34	[p4l1470t2361r1670b2414],
15	performed	VBN	O	perform	dep	10	SENT_34	[p4l1690t2334r2135b2435],
16	in	IN	O	in	_	0	SENT_34	[p4l9t2463r91b2540],
17	the	DT	O	the	det	18	SENT_34	[p4l115t2463r244b2541],
18	context	NN	O	context	prep_in	15	SENT_34	[p4l269t2479r581b2541],
19	of	IN	O	of	_	0	SENT_34	[p4l600t2462r701b2541],
20	a	DT	O	a	prep_of	18	SENT_34	[p4l706t2489r750b2541],
21	randomized	VBN	O	randomize	partmod	20	SENT_34	[p4l773t2462r1307b2558],
22	,	,	O	,	_	0	SENT_34	[p4l773t2462r1307b2558],
23	placebo	NN	O	placebo	nn	24	SENT_34	[p4l1335t2462r2134b2563],
24	—	NN	O	—	appos	10	SENT_34	[p4l1335t2462r2134b2563],
25	controlled	JJ	O	controlled	amod	26	SENT_34	[p4l1335t2462r2134b2563],
26	study	NN	O	study	dep	24	SENT_34	[p4l12t2591r246b2691],
27	.	.	O	.	_	0	SENT_34	[p4l12t2591r246b2691],

1	The	DT	O	the	det	2	SENT_35	[p4l271t2591r431b2669],
2	observation	NN	O	observation	nsubj	44	SENT_35	[p4l455t2590r941b2670],
3	that	IN	O	that	complm	29	SENT_35	[p4l964t2590r1129b2669],
4	the	DT	O	the	det	6	SENT_35	[p4l1147t2591r1275b2669],
5	clinical	JJ	O	clinical	amod	6	SENT_35	[p4l1299t2590r1596b2669],
6	beneﬁt	NN	O	beneﬁt	nsubj	29	SENT_35	[p4l1619t2590r1912b2669],
7	from	IN	O	from	_	0	SENT_35	[p4l1929t2590r2135b2669],
8	treatment	NN	O	treatment	prep_from	6	SENT_35	[p4l11t2735r421b2797],
9	with	IN	O	with	_	0	SENT_35	[p4l433t2719r620b2798],
10	erlotinib	NN	O	erlotinib	prep_with	8	SENT_35	[p4l643t2719r996b2797],
11	found	VBN	O	find	partmod	10	SENT_35	[p4l1019t2718r1267b2798],
12	in	IN	O	in	_	0	SENT_35	[p4l1288t2719r1369b2796],
13	all	DT	O	all	det	14	SENT_35	[p4l1390t2718r1488b2797],
14	subgroups	NNS	O	subgroup	prep_in	11	SENT_35	[p4l1510t2719r1951b2819],
15	that	WDT	O	that	nsubj	16	SENT_35	[p4l1975t2719r2140b2797],
16	underwent	VBD	O	undergo	rcmod	14	SENT_35	[p4l11t2847r469b2926],
17	the	DT	O	the	det	19	SENT_35	[p4l488t2847r617b2925],
18	EGFR	NN	ORGANIZATION	egfr	nn	19	SENT_35	[p4l639t2852r898b2930],
19	analysis	NN	O	analysis	nsubj	21	SENT_35	[p4l910t2847r1240b2947],
20	was	VBD	O	be	cop	21	SENT_35	[p4l1262t2873r1422b2926],
21	similar	JJ	O	similar	ccomp	16	SENT_35	[p4l1449t2846r1745b2925],
22	to	TO	O	to	_	0	SENT_35	[p4l1765t2863r1844b2925],
23	that	DT	O	that	prep_to	21	SENT_35	[p4l1869t2846r2036b2925],
24	in	IN	O	in	_	0	SENT_35	[p4l2054t2847r2134b2924],
25	the	DT	O	the	det	28	SENT_35	[p4l11t2975r140b3053],
26	entire	JJ	O	entire	amod	28	SENT_35	[p4l163t2975r403b3053],
27	study	NN	O	study	nn	28	SENT_35	[p4l428t2974r653b3075],
28	population	NN	O	population	prep_in	23	SENT_35	[p4l670t2975r1134b3075],
29	suggests	VBZ	O	suggest	dep	2	SENT_35	[p4l1159t2991r1520b3075],
30	that	IN	O	that	complm	40	SENT_35	[p4l1546t2974r1712b3053],
31	the	DT	O	the	det	32	SENT_35	[p4l1730t2975r1859b3053],
32	distribution	NN	O	distribution	nsubj	40	SENT_35	[p4l1883t2975r2133b3053, p4l11t3102r287b3182],
33	of	IN	O	of	_	0	SENT_35	[p4l309t3102r410b3181],
34	tumor	NN	O	tumor	nn	35	SENT_35	[p4l413t3119r675b3182],
35	samples	NNS	O	sample	prep_of	32	SENT_35	[p4l696t3103r1038b3203],
36	within	IN	O	within	_	0	SENT_35	[p4l1058t3102r1332b3182],
37	the	DT	O	the	det	38	SENT_35	[p4l1355t3103r1483b3181],
38	subgroups	NNS	O	subgroup	prep_within	35	SENT_35	[p4l1507t3102r1952b3203],
39	was	VBD	O	be	cop	40	SENT_35	[p4l1971t3129r2133b3182],
40	representative	NN	O	representative	ccomp	29	SENT_35	[p4l11t3231r603b3331],
41	of	IN	O	of	_	0	SENT_35	[p4l634t3230r735b3309],
42	all	DT	O	all	det	43	SENT_35	[p4l746t3230r844b3309],
43	patients	NNS	O	patient	prep_of	40	SENT_35	[p4l872t3231r1207b3331],
44	entered	VBD	O	enter	_	0	SENT_35	[p4l1240t3231r1554b3309],
45	into	IN	O	into	_	0	SENT_35	[p4l1583t3231r1748b3309],
46	the	DT	O	the	det	47	SENT_35	[p4l1780t3230r1909b3309],
47	trial	NN	O	trial	prep_into	44	SENT_35	[p4l1939t3231r2129b3309],
48	.	.	O	.	_	0	SENT_35	[p4l1939t3231r2129b3309],

1	In	IN	O	in	dep	7	SENT_36	[p4l9t3366r96b3436],
2	support	NN	O	support	pobj	1	SENT_36	[p4l127t3375r459b3459],
3	of	IN	O	of	_	0	SENT_36	[p4l484t3358r585b3437],
4	the	DT	O	the	det	5	SENT_36	[p4l596t3359r725b3437],
5	N	NN	O	n	prep_of	2	SENT_36	[p4l753t3366r828b3438],
6	CIC	NN	ORGANIZATION	cic	nn	7	SENT_36	[p4l831t3364r986b3437],
7	findings	NNS	O	finding	_	0	SENT_36	[p4l1018t3358r1394b3459],
8	,	,	O	,	_	0	SENT_36	[p4l1018t3358r1394b3459],
9	the	DT	O	the	det	10	SENT_36	[p4l1429t3358r1558b3437],
10	role	NN	O	role	appos	7	SENT_36	[p4l1588t3359r1748b3437],
11	of	IN	O	of	_	0	SENT_36	[p4l1779t3358r1880b3437],
12	an	DT	O	a	det	13	SENT_36	[p4l1890t3384r1990b3437],
13	increase	NN	O	increase	prep_of	10	SENT_36	[p4l2019t3359r2133b3436, p4l11t3513r270b3565],
14	in	IN	O	in	_	0	SENT_36	[p4l292t3487r373b3564],
15	the	DT	O	the	det	16	SENT_36	[p4l396t3486r525b3565],
16	numbers	NNS	O	number	prep_in	13	SENT_36	[p4l548t3487r923b3566],
17	of	IN	O	of	_	0	SENT_36	[p4l948t3486r1048b3565],
18	copies	NNS	O	copy	prep_of	16	SENT_36	[p4l1053t3487r1318b3587],
19	of	IN	O	of	_	0	SENT_36	[p4l1344t3486r1444b3565],
20	the	DT	O	the	det	22	SENT_36	[p4l1449t3487r1578b3565],
21	EGFR	NN	ORGANIZATION	egfr	nn	22	SENT_36	[p4l1599t3493r1811b3566],
22	gene	NN	O	gene	prep_of	18	SENT_36	[p4l1827t3512r2026b3587],
23	as	IN	O	as	_	0	SENT_36	[p4l2047t3513r2132b3565],
24	a	DT	O	a	det	26	SENT_36	[p4l9t3641r54b3693],
25	potential	JJ	O	potential	amod	26	SENT_36	[p4l73t3615r448b3715],
26	marker	NN	O	marker	prep_as	22	SENT_36	[p4l470t3615r776b3694],
27	of	IN	O	of	_	0	SENT_36	[p4l795t3614r896b3693],
28	sensitivity	NN	O	sensitivity	prep_of	26	SENT_36	[p4l900t3615r1319b3715],
29	to	TO	O	to	_	0	SENT_36	[p4l1337t3631r1416b3693],
30	geﬁtinib	NN	O	geﬁtinib	prep_to	28	SENT_36	[p4l1438t3614r1793b3715],
31	in	IN	O	in	_	0	SENT_36	[p4l1815t3615r1897b3692],
32	nonsmall	JJ	O	nonsmall	amod	34	SENT_36	[p4l1917t3640r2138b3693, p5l12t20r420b99],
33	—	NN	O	—	nn	34	SENT_36	[p4l1917t3640r2138b3693, p5l12t20r420b99],
34	cell	NN	O	cell	prep_in	7	SENT_36	[p4l1917t3640r2138b3693, p5l12t20r420b99],

1	lung	NN	O	lung	nn	2	SENT_37	[p5l461t21r655b121],
2	cancer	NN	O	cancer	nsubjpass	6	SENT_37	[p5l693t46r968b99],
3	has	VBZ	O	have	aux	6	SENT_37	[p5l1008t21r1149b99],
4	recently	RB	DATE	recently	advmod	6	SENT_37	[p5l1192t20r1525b121],
5	been	VBN	O	be	auxpass	6	SENT_37	[p5l1564t21r1763b99],
6	demonstrated	VBN	O	demonstrate	_	0	SENT_37	[p5l1805t21r2133b99, p5l12t149r297b227],
7	by	IN	O	by	_	0	SENT_37	[p5l323t149r420b249],
8	others	NNS	O	other	agent	6	SENT_37	[p5l440t143r815b227],
9	.	.	O	.	_	0	SENT_37	[p5l440t143r815b227],

1	”	NN	O	”	_	0	SENT_38	[p5l440t143r815b227],

1	These	DT	O	these	det	2	SENT_39	[p5l136t277r386b355],
2	results	NNS	O	result	nsubj	6	SENT_39	[p5l417t277r719b372],
3	,	,	O	,	_	0	SENT_39	[p5l417t277r719b372],
4	however	RB	O	however	advmod	2	SENT_39	[p5l755t277r1127b372],
5	,	,	O	,	_	0	SENT_39	[p5l755t277r1127b372],
6	raise	VB	O	raise	_	0	SENT_39	[p5l1162t277r1359b355],
7	critical	JJ	O	critical	amod	9	SENT_39	[p5l1390t277r1674b355],
8	new	JJ	O	new	amod	9	SENT_39	[p5l1703t302r1879b356],
9	questions	NNS	O	question	dobj	6	SENT_39	[p5l1906t303r2133b377, p5l11t405r222b483],
10	with	IN	O	with	_	0	SENT_39	[p5l257t405r449b484],
11	regard	NN	O	regard	_	0	SENT_39	[p5l486t405r764b505],
12	to	TO	O	to	_	0	SENT_39	[p5l801t421r882b483],
13	the	DT	O	the	det	14	SENT_39	[p5l920t405r1052b483],
14	mechanism	NN	O	mechanism	prep_with_regard_to	6	SENT_39	[p5l1089t405r1591b483],
15	of	IN	O	of	_	0	SENT_39	[p5l1629t404r1730b483],
16	action	NN	O	action	prep_of	14	SENT_39	[p5l1748t405r2013b483],
17	of	IN	O	of	_	0	SENT_39	[p5l2050t404r2152b483],
18	erlotinib	NN	O	erlotinib	prep_of	16	SENT_39	[p5l11t533r378b611],
19	in	IN	O	in	_	0	SENT_39	[p5l423t533r505b610],
20	non	JJ	O	non	amod	26	SENT_39	[p5l550t532r1195b611],
21	—	JJ	O	—	amod	22	SENT_39	[p5l550t532r1195b611],
22	small	JJ	O	small	amod	26	SENT_39	[p5l550t532r1195b611],
23	—	NN	O	—	nn	26	SENT_39	[p5l550t532r1195b611],
24	cell	NN	O	cell	nn	26	SENT_39	[p5l550t532r1195b611],
25	lung	NN	O	lung	nn	26	SENT_39	[p5l1239t533r1436b633],
26	cancer	NN	O	cancer	prep_in	6	SENT_39	[p5l1478t558r1758b611],
27	and	CC	O	and	_	0	SENT_39	[p5l1799t533r1957b611],
28	the	DT	O	the	det	30	SENT_39	[p5l2002t533r2133b611],
29	methodologic	JJ	O	methodologic	amod	30	SENT_39	[p5l11t660r595b761],
30	requirements	NNS	O	requirement	conj_and	26	SENT_39	[p5l616t661r1173b761],
31	for	IN	O	for	_	0	SENT_39	[p5l1196t660r1319b739],
32	molecular	JJ	O	molecular	amod	34	SENT_39	[p5l1337t661r1758b740],
33	pharmacodynamic	JJ	O	pharmacodynamic	amod	34	SENT_39	[p5l1775t661r2133b761, p5l11t788r461b889],
34	studies	NNS	O	study	prep_for	30	SENT_39	[p5l483t788r771b868],
35	in	IN	O	in	_	0	SENT_39	[p5l794t789r874b866],
36	the	DT	DATE	the	det	37	SENT_39	[p5l896t789r1023b867],
37	future	NN	DATE	future	prep_in	34	SENT_39	[p5l1044t788r1315b868],
38	.	.	O	.	_	0	SENT_39	[p5l1044t788r1315b868],

1	Although	IN	O	although	mark	17	SENT_40	[p5l1338t789r1733b889],
2	increases	NNS	O	increase	nsubjpass	17	SENT_40	[p5l1753t789r2133b867],
3	in	IN	O	in	_	0	SENT_40	[p5l9t917r91b994],
4	the	DT	O	the	det	5	SENT_40	[p5l122t916r251b995],
5	number	NN	O	number	prep_in	2	SENT_40	[p5l282t917r618b996],
6	of	IN	O	of	_	0	SENT_40	[p5l646t916r746b995],
7	gene	NN	O	gene	nn	8	SENT_40	[p5l759t942r957b1017],
8	copies	NNS	O	copy	prep_of	5	SENT_40	[p5l989t917r1279b1017],
9	,	,	O	,	_	0	SENT_40	[p5l989t917r1279b1017],
10	protein	NN	O	protein	nn	11	SENT_40	[p5l1314t917r1621b1017],
11	expression	NN	O	expression	prep_of	5	SENT_40	[p5l1652t917r2129b1017],
12	,	,	O	,	_	0	SENT_40	[p5l1652t917r2129b1017],
13	and	CC	O	and	_	0	SENT_40	[p5l10t1044r167b1123],
14	EGFR	NN	ORGANIZATION	egfr	nn	15	SENT_40	[p5l212t1051r428b1124],
15	mutations	NNS	O	mutation	prep_of	5	SENT_40	[p5l468t1045r907b1124],
16	were	VBD	O	be	auxpass	17	SENT_40	[p5l951t1071r1156b1124],
17	associated	VBN	O	associate	_	0	SENT_40	[p5l1202t1044r1649b1123],
18	with	IN	O	with	_	0	SENT_40	[p5l1690t1044r1883b1124],
19	a	DT	O	a	det	20	SENT_40	[p5l1929t1071r1973b1123],
20	response	NN	O	response	prep_with	17	SENT_40	[p5l2018t1071r2132b1123, p5l12t1198r336b1273],
21	,	,	O	,	_	0	SENT_40	[p5l2018t1071r2132b1123, p5l12t1198r336b1273],

1	objective	JJ	O	objective	amod	2	SENT_41	[p5l376t1172r742b1273],
2	responses	NNS	O	response	nsubjpass	7	SENT_41	[p5l776t1198r1196b1273],
3	to	TO	O	to	_	0	SENT_41	[p5l1231t1189r1310b1251],
4	erlotinib	NN	O	erlotinib	prep_to	2	SENT_41	[p5l1344t1172r1702b1251],
5	were	VBD	O	be	auxpass	7	SENT_41	[p5l1732t1199r1934b1252],
6	also	RB	O	also	advmod	7	SENT_41	[p5l1966t1173r2133b1251],
7	found	VBN	O	find	_	0	SENT_41	[p5l11t1300r261b1380],
8	in	IN	O	in	_	0	SENT_41	[p5l282t1301r363b1378],
9	the	DT	O	the	det	10	SENT_41	[p5l385t1300r513b1379],
10	absence	NN	O	absence	prep_in	7	SENT_41	[p5l534t1301r870b1379],
11	of	IN	O	of	_	0	SENT_41	[p5l893t1300r993b1379],
12	these	DT	O	these	det	13	SENT_41	[p5l996t1301r1215b1379],
13	features	NNS	O	feature	prep_of	10	SENT_41	[p5l1236t1300r1594b1380],
14	.	.	O	.	_	0	SENT_41	[p5l1236t1300r1594b1380],

1	This	DT	O	this	dep	111	SENT_42	[p5l1618t1301r1803b1379],
2	ﬁnding	NN	O	ﬁnding	dep	111	SENT_42	[p5l1826t1300r2138b1401],
3	suggests	VBZ	O	suggest	dep	111	SENT_42	[p5l12t1445r374b1529],
4	that	IN	O	that	dep	111	SENT_42	[p5l402t1428r568b1507],
5	erlotinib	NN	O	erlotinib	dep	111	SENT_42	[p5l589t1429r947b1507],
6	may	MD	O	may	dep	111	SENT_42	[p5l973t1455r1150b1529],
7	affect	VB	O	affect	dep	111	SENT_42	[p5l1170t1428r1425b1524],
8	,	,	O	,	_	0	SENT_42	[p5l1170t1428r1425b1524],
9	or	CC	O	or	dep	111	SENT_42	[p5l1456t1454r1545b1507],
10	be	VB	O	be	dep	111	SENT_42	[p5l1568t1428r1663b1507],
11	dependent	JJ	O	dependent	dep	111	SENT_42	[p5l1689t1429r2139b1529],
12	for	IN	O	for	dep	111	SENT_42	[p5l11t1556r134b1635],
13	its	PRP$	O	its	dep	111	SENT_42	[p5l174t1557r270b1635],
14	activity	NN	O	activity	dep	111	SENT_42	[p5l316t1557r612b1657],
15	on	IN	O	on	dep	111	SENT_42	[p5l653t1582r783b1652],
16	,	,	O	,	_	0	SENT_42	[p5l653t1582r783b1652],
17	additional	JJ	O	additional	dep	111	SENT_42	[p5l832t1556r1260b1635],
18	signaling	NN	O	signaling	dep	111	SENT_42	[p5l1306t1557r1700b1657],
19	pathways	NNS	O	pathway	dep	111	SENT_42	[p5l1740t1557r2133b1657],
20	that	WDT	O	that	dep	111	SENT_42	[p5l11t1685r177b1763],
21	were	VBD	O	be	dep	111	SENT_42	[p5l199t1711r401b1764],
22	not	RB	O	not	dep	111	SENT_42	[p5l432t1701r576b1763],
23	assessed	VBN	O	assess	dep	111	SENT_42	[p5l601t1685r965b1763],
24	in	IN	O	in	dep	111	SENT_42	[p5l995t1685r1076b1762],
25	the	DT	O	the	dep	111	SENT_42	[p5l1108t1684r1237b1763],
26	N	NN	O	n	dep	111	SENT_42	[p5l1266t1692r1341b1764],
27	CIC	NN	ORGANIZATION	cic	dep	111	SENT_42	[p5l1344t1690r1500b1763],
28	study	NN	O	study	dep	111	SENT_42	[p5l1535t1685r1760b1785],
29	(	CD	NUMBER	(	dep	111	SENT_42	[p5l1792t1685r2018b1776],
30	such	JJ	O	such	dep	111	SENT_42	[p5l1792t1685r2018b1776],
31	as	IN	O	as	dep	111	SENT_42	[p5l2048t1711r2132b1763],
32	Akt	NN	O	akt	dep	111	SENT_42	[p5l7t1813r159b1892],
33	phosphorylation	NN	O	phosphorylation	dep	111	SENT_42	[p5l179t1813r881b1913],
34	or	CC	O	or	dep	111	SENT_42	[p5l908t1838r998b1891],
35	erbB	NN	O	erbb	dep	111	SENT_42	[p5l1022t1813r1300b1891],
36	—	CD	NUMBER	—	dep	111	SENT_42	[p5l1022t1813r1300b1891],
37	3	CD	NUMBER	3	dep	111	SENT_42	[p5l1022t1813r1300b1891],
38	status	NN	O	status	dep	111	SENT_42	[p5l1331t1820r1608b1904],
39	)	NN	O	)	dep	111	SENT_42	[p5l1331t1820r1608b1904],
40	and	CC	O	and	dep	111	SENT_42	[p5l1638t1812r1795b1891],
41	that	DT	O	that	dep	111	SENT_42	[p5l1821t1813r1987b1891],
42	are	VBP	O	be	dep	111	SENT_42	[p5l2009t1839r2134b1891],
43	essential	JJ	O	essential	dep	111	SENT_42	[p5l11t1941r376b2019],
44	for	IN	O	for	dep	111	SENT_42	[p5l428t1940r551b2019],
45	tumor	NN	O	tumor	dep	111	SENT_42	[p5l601t1941r1043b2020],
46	—	NN	O	—	dep	111	SENT_42	[p5l601t1941r1043b2020],
47	cell	NN	O	cell	dep	111	SENT_42	[p5l601t1941r1043b2020],
48	proliferation	NN	O	proliferation	dep	111	SENT_42	[p5l1093t1935r1841b2041],
49	.1	CD	NUMBER	.1	dep	111	SENT_42	[p5l1093t1935r1841b2041],
50	°	CD	NUMBER	°	dep	111	SENT_42	[p5l1093t1935r1841b2041],
51	’“	NN	O	’“	dep	111	SENT_42	[p5l1093t1935r1841b2041],
52	Thus	RB	O	thus	dep	111	SENT_42	[p5l1891t1941r2128b2036],
53	,	,	O	,	_	0	SENT_42	[p5l1891t1941r2128b2036],
54	further	JJ	O	further	dep	111	SENT_42	[p5l11t2068r305b2148],
55	investigation	NN	O	investigation	dep	111	SENT_42	[p5l324t2069r869b2169],
56	to	TO	O	to	dep	111	SENT_42	[p5l891t2085r970b2147],
57	determine	VB	O	determine	dep	111	SENT_42	[p5l995t2069r1422b2147],
58	the	DT	O	the	dep	111	SENT_42	[p5l1445t2069r1574b2147],
59	mechanisms	NNS	O	mechanism	dep	111	SENT_42	[p5l1597t2069r2132b2147],
60	by	IN	O	by	dep	111	SENT_42	[p5l11t2196r108b2297],
61	which	WDT	O	which	dep	111	SENT_42	[p5l139t2196r399b2276],
62	erlotinib	NN	O	erlotinib	dep	111	SENT_42	[p5l440t2197r799b2275],
63	alters	VBZ	O	alter	dep	111	SENT_42	[p5l840t2197r1066b2275],
64	the	DT	O	the	dep	111	SENT_42	[p5l1109t2196r1238b2275],
65	full	JJ	O	full	dep	111	SENT_42	[p5l1279t2196r1418b2276],
66	range	NN	O	range	dep	111	SENT_42	[p5l1458t2222r1694b2297],
67	of	IN	O	of	dep	111	SENT_42	[p5l1736t2196r1836b2275],
68	EGFRrelated	JJ	O	egfrrelated	dep	111	SENT_42	[p5l1856t2202r2133b2280, p5l11t2324r296b2403],
69	signaling	NN	O	signaling	dep	111	SENT_42	[p5l323t2325r718b2425],
70	pathways	NNS	O	pathway	dep	111	SENT_42	[p5l738t2325r1131b2425],
71	is	VBZ	O	be	dep	111	SENT_42	[p5l1158t2325r1222b2403],
72	essential	JJ	O	essential	dep	111	SENT_42	[p5l1251t2325r1616b2403],
73	and	CC	O	and	dep	111	SENT_42	[p5l1641t2325r1796b2403],
74	is	VBZ	O	be	dep	111	SENT_42	[p5l1821t2325r1886b2403],
75	likely	JJ	O	likely	dep	111	SENT_42	[p5l1912t2324r2139b2425],
76	to	TO	O	to	dep	111	SENT_42	[p5l11t2469r88b2531],
77	lead	VB	O	lead	dep	111	SENT_42	[p5l109t2453r278b2531],
78	to	TO	O	to	dep	111	SENT_42	[p5l298t2469r376b2531],
79	the	DT	O	the	dep	111	SENT_42	[p5l397t2452r524b2531],
80	discovery	NN	O	discovery	dep	111	SENT_42	[p5l545t2452r929b2553],
81	of	IN	O	of	dep	111	SENT_42	[p5l946t2452r1044b2531],
82	a	DT	O	a	dep	111	SENT_42	[p5l1045t2479r1089b2531],
83	panel	NN	O	panel	dep	111	SENT_42	[p5l1106t2453r1333b2553],
84	of	IN	O	of	dep	111	SENT_42	[p5l1353t2452r1453b2531],
85	molecular	JJ	O	molecular	dep	111	SENT_42	[p5l1454t2452r1871b2532],
86	mark	NN	O	mark	dep	111	SENT_42	[p5l1887t2453r2134b2532],
87	—	NN	O	—	dep	111	SENT_42	[p5l1887t2453r2134b2532],
88	ers	NNPS	O	ers	dep	111	SENT_42	[p5l11t2607r128b2659],
89	that	WDT	O	that	dep	111	SENT_42	[p5l154t2581r319b2659],
90	will	MD	O	will	dep	111	SENT_42	[p5l336t2580r492b2660],
91	eventually	RB	O	eventually	dep	111	SENT_42	[p5l519t2581r941b2681],
92	be	VB	O	be	dep	111	SENT_42	[p5l963t2580r1058b2659],
93	used	VBN	O	use	dep	111	SENT_42	[p5l1084t2580r1279b2660],
94	to	TO	O	to	dep	111	SENT_42	[p5l1305t2597r1384b2659],
95	predict	VB	O	predict	dep	111	SENT_42	[p5l1410t2581r1710b2681],
96	the	DT	O	the	dep	111	SENT_42	[p5l1731t2581r1859b2659],
97	therapeutic	JJ	O	therapeutic	dep	111	SENT_42	[p5l1886t2581r2133b2659, p5l9t2709r267b2809],
98	activity	NN	O	activity	dep	111	SENT_42	[p5l297t2709r593b2809],
99	of	IN	O	of	dep	111	SENT_42	[p5l620t2708r721b2787],
100	this	DT	O	this	dep	111	SENT_42	[p5l735t2709r886b2787],
101	class	NN	O	class	dep	111	SENT_42	[p5l921t2709r1120b2787],
102	of	IN	O	of	dep	111	SENT_42	[p5l1154t2708r1254b2787],
103	drugs	NNS	O	drug	dep	111	SENT_42	[p5l1268t2708r1505b2809],
104	in	IN	O	in	dep	111	SENT_42	[p5l1538t2709r1619b2786],
105	non	JJ	O	non	dep	111	SENT_42	[p5l1651t2709r2134b2787],
106	—	JJ	O	—	dep	111	SENT_42	[p5l1651t2709r2134b2787],
107	small	JJ	O	small	dep	111	SENT_42	[p5l1651t2709r2134b2787],
108	—	NN	O	—	dep	111	SENT_42	[p5l1651t2709r2134b2787],
109	cell	NN	O	cell	dep	111	SENT_42	[p5l11t2836r153b2915],
110	lung	NN	O	lung	dep	111	SENT_42	[p5l176t2837r370b2937],
111	cancer	NN	O	cancer	_	0	SENT_42	[p5l393t2862r684b2915],
112	.	.	O	.	_	0	SENT_42	[p5l393t2862r684b2915],

1	Perhaps	RB	O	perhaps	advmod	5	SENT_43	[p5l138t2965r473b3065],
2	of	IN	O	of	_	0	SENT_43	[p5l512t2964r613b3043],
3	greatest	JJS	O	greatest	amod	4	SENT_43	[p5l629t2981r966b3065],
4	importance	NN	O	importance	prep_of	5	SENT_43	[p5l996t2965r1483b3065],
5	is	VBZ	O	be	_	0	SENT_43	[p5l1518t2965r1584b3043],
6	the	DT	O	the	det	7	SENT_43	[p5l1621t2965r1750b3043],
7	fact	NN	O	fact	nsubj	5	SENT_43	[p5l1786t2964r1943b3043],
8	that	IN	O	that	complm	27	SENT_43	[p5l1973t2965r2140b3043],
9	samples	NNS	O	sample	nsubj	27	SENT_43	[p5l12t3092r354b3193],
10	of	IN	O	of	_	0	SENT_43	[p5l387t3092r487b3171],
11	tumor	NN	O	tumor	nn	12	SENT_43	[p5l498t3109r761b3172],
12	tissues	NNS	O	tissue	prep_of	9	SENT_43	[p5l788t3093r1070b3172],
13	from	IN	O	from	_	0	SENT_43	[p5l1101t3092r1309b3171],
14	fewer	JJR	O	fewer	quantmod	16	SENT_43	[p5l1338t3092r1572b3172],
15	than	IN	O	than	quantmod	16	SENT_43	[p5l1598t3093r1786b3171],
16	half	PDT	O	half	num	18	SENT_43	[p5l1816t3092r1994b3171],
17	the	DT	O	the	det	18	SENT_43	[p5l2006t3093r2135b3171],
18	patients	NNS	O	patient	prep_from	12	SENT_43	[p5l9t3221r344b3321],
19	who	WP	O	who	nsubj	20	SENT_43	[p5l363t3220r546b3300],
20	participated	VBD	O	participate	rcmod	18	SENT_43	[p5l567t3221r1072b3321],
21	in	IN	O	in	_	0	SENT_43	[p5l1092t3221r1174b3298],
22	the	DT	O	the	det	25	SENT_43	[p5l1195t3220r1324b3299],
23	N	NN	O	n	nn	25	SENT_43	[p5l1344t3228r1419b3299],
24	CIC	NN	ORGANIZATION	cic	nn	25	SENT_43	[p5l1421t3226r1577b3299],
25	trial	NN	O	trial	prep_in	20	SENT_43	[p5l1601t3221r1767b3299],
26	were	VBD	O	be	cop	27	SENT_43	[p5l1784t3247r1985b3300],
27	usable	JJ	O	usable	ccomp	7	SENT_43	[p5l2007t3247r2134b3300, p5l10t3349r178b3427],
28	for	IN	O	for	_	0	SENT_43	[p5l198t3348r320b3427],
29	EGFR	NN	ORGANIZATION	egfr	nn	30	SENT_43	[p5l335t3354r591b3432],
30	analysis	NN	O	analysis	prep_for	27	SENT_43	[p5l600t3349r948b3449],
31	.	.	O	.	_	0	SENT_43	[p5l600t3349r948b3449],

1	In	IN	O	in	_	0	SENT_44	[p5l972t3356r1058b3426],
2	particular	JJ	O	particular	prep_in	22	SENT_44	[p5l1077t3349r1493b3449],
3	,	,	O	,	_	0	SENT_44	[p5l1077t3349r1493b3449],
4	the	DT	O	the	det	6	SENT_44	[p5l1519t3348r1646b3427],
5	small	JJ	O	small	amod	6	SENT_44	[p5l1668t3348r1891b3427],
6	number	NN	O	number	nsubj	22	SENT_44	[p5l1910t3374r2135b3428, p5l11t3476r147b3555],
7	of	IN	O	of	_	0	SENT_44	[p5l164t3476r264b3555],
8	samples	NNS	O	sample	prep_of	6	SENT_44	[p5l268t3477r607b3577],
9	that	WDT	O	that	nsubjpass	12	SENT_44	[p5l630t3477r795b3555],
10	could	MD	O	could	aux	12	SENT_44	[p5l811t3476r1041b3556],
11	be	VB	O	be	auxpass	12	SENT_44	[p5l1061t3477r1157b3555],
12	examined	VBN	O	examine	rcmod	8	SENT_44	[p5l1178t3476r1583b3555],
13	for	IN	O	for	_	0	SENT_44	[p5l1603t3476r1725b3555],
14	EGFR	NN	ORGANIZATION	egfr	nn	15	SENT_44	[p5l1740t3483r1950b3556],
15	mutations	NNS	O	mutation	prep_for	12	SENT_44	[p5l1964t3503r2134b3556, p5l11t3605r294b3683],
16	or	CC	O	or	_	0	SENT_44	[p5l317t3630r405b3683],
17	number	NN	O	number	prep_for	12	SENT_44	[p5l422t3604r754b3684],
18	of	IN	O	of	_	0	SENT_44	[p5l772t3604r872b3683],
19	gene	NN	O	gene	nn	20	SENT_44	[p5l874t3630r1070b3705],
20	copies	NNS	O	copy	prep_of	15	SENT_44	[p5l1091t3605r1352b3705],
21	clearly	RB	O	clearly	advmod	22	SENT_44	[p5l1375t3604r1642b3705],
22	reduced	VBD	O	reduce	_	0	SENT_44	[p5l1658t3605r1988b3684],
23	the	DT	O	the	det	24	SENT_44	[p5l2008t3605r2136b3683],
24	strength	NN	O	strength	dobj	22	SENT_44	[p6l12t21r364b121],
25	of	IN	O	of	_	0	SENT_44	[p6l390t20r490b99],
26	the	DT	O	the	det	27	SENT_44	[p6l497t20r627b99],
27	conclusions	NNS	O	conclusion	prep_of	24	SENT_44	[p6l653t21r1157b100],
28	it	PRP	O	it	nsubj	30	SENT_44	[p6l1183t21r1243b99],
29	was	VBD	O	be	cop	30	SENT_44	[p6l1259t47r1419b100],
30	possible	JJ	O	possible	rcmod	27	SENT_44	[p6l1446t20r1796b121],
31	to	TO	O	to	aux	32	SENT_44	[p6l1822t37r1901b99],
32	draw	VB	O	draw	xcomp	30	SENT_44	[p6l1928t21r2139b100],
33	from	IN	O	from	_	0	SENT_44	[p6l11t148r218b227],
34	this	DT	O	this	det	35	SENT_44	[p6l243t149r396b227],
35	study	NN	O	study	prep_from	32	SENT_44	[p6l425t149r662b249],
36	.	.	O	.	_	0	SENT_44	[p6l425t149r662b249],

1	Furthermore	RB	O	furthermore	advmod	9	SENT_45	[p6l691t149r1254b244],
2	,	,	O	,	_	0	SENT_45	[p6l691t149r1254b244],
3	the	DT	O	the	det	4	SENT_45	[p6l1285t149r1414b227],
4	tissues	NNS	O	tissue	nsubjpass	9	SENT_45	[p6l1440t149r1723b228],
5	that	WDT	O	that	nsubj	7	SENT_45	[p6l1750t149r1917b227],
6	were	VBD	O	be	cop	7	SENT_45	[p6l1933t175r2135b228],
7	available	JJ	O	available	rcmod	4	SENT_45	[p6l10t277r383b356],
8	were	VBD	O	be	auxpass	9	SENT_45	[p6l423t303r628b356],
9	taken	VBN	O	take	_	0	SENT_45	[p6l673t276r910b356],
10	from	IN	O	from	_	0	SENT_45	[p6l954t276r1165b355],
11	either	CC	O	either	preconj	14	SENT_45	[p6l1211t277r1459b355],
12	initial	JJ	O	initial	amod	14	SENT_45	[p6l1500t277r1749b355],
13	surgical	JJ	O	surgical	amod	14	SENT_45	[p6l1795t277r2135b377],
14	specimens	NNS	O	specimen	prep_from	9	SENT_45	[p6l12t405r464b505],
15	or	CC	O	or	_	0	SENT_45	[p6l510t430r600b483],
16	initial	JJ	O	initial	amod	19	SENT_45	[p6l638t405r881b483],
17	or	CC	O	or	_	0	SENT_45	[p6l923t430r1011b483],
18	subsequent	JJ	O	subsequent	conj_or	16	SENT_45	[p6l1052t404r1539b505],
19	biopsies	NNS	O	biopsy	prep_from	9	SENT_45	[p6l1576t404r1922b505],
20	per	IN	O	per	_	0	SENT_45	[p6l1964t431r2134b505],
21	—	NN	O	—	prep_per	9	SENT_45	[p6l1964t431r2134b505],
22	formed	VBN	O	form	partmod	21	SENT_45	[p6l11t532r320b611],
23	before	IN	O	before	_	0	SENT_45	[p6l353t532r620b611],
24	the	DT	O	the	det	25	SENT_45	[p6l655t533r783b611],
25	initiation	NN	O	initiation	prep_before	22	SENT_45	[p6l816t533r1202b611],
26	of	IN	O	of	_	0	SENT_45	[p6l1237t532r1337b611],
27	therapy	NN	O	therapy	prep_of	25	SENT_45	[p6l1353t533r1681b633],
28	.	.	O	.	_	0	SENT_45	[p6l1353t533r1681b633],

1	In	IN	O	in	_	0	SENT_46	[p6l1719t540r1806b610],
2	the	DT	O	the	det	3	SENT_46	[p6l1840t532r1969b611],
3	absence	NN	O	absence	prep_in	37	SENT_46	[p6l2003t532r2134b611, p6l12t686r243b739],
4	of	IN	O	of	_	0	SENT_46	[p6l281t660r381b739],
5	a	DT	O	a	det	7	SENT_46	[p6l398t687r442b739],
6	standardized	JJ	O	standardized	amod	7	SENT_46	[p6l478t660r1025b739],
7	approach	NN	O	approach	prep_of	3	SENT_46	[p6l1061t660r1457b761],
8	to	TO	O	to	_	0	SENT_46	[p6l1493t677r1572b739],
9	ensuring	VBG	O	ensure	prepc_to	7	SENT_46	[p6l1611t661r1987b761],
10	tumor	NN	O	tumor	nn	11	SENT_46	[p6l2020t677r2134b740, p6l11t814r188b867],
11	acquisition	NN	O	acquisition	dobj	9	SENT_46	[p6l208t789r677b889],
12	at	IN	O	at	_	0	SENT_46	[p6l700t805r779b867],
13	entry	NN	O	entry	prep_at	9	SENT_46	[p6l799t805r1012b889],
14	into	IN	O	into	_	0	SENT_46	[p6l1031t789r1197b867],
15	the	DT	O	the	det	16	SENT_46	[p6l1223t789r1352b867],
16	study	NN	O	study	prep_into	9	SENT_46	[p6l1378t789r1615b889],
17	,	,	O	,	_	0	SENT_46	[p6l1378t789r1615b889],
18	the	DT	O	the	det	19	SENT_46	[p6l1645t788r1774b867],
19	effect	NN	O	effect	nsubjpass	37	SENT_46	[p6l1799t788r2033b867],
20	of	IN	O	of	_	0	SENT_46	[p6l2053t788r2154b867],
21	tumor	NN	O	tumor	nn	22	SENT_46	[p6l11t933r274b996],
22	size	NN	O	size	prep_of	19	SENT_46	[p6l307t917r465b995],
23	and	CC	O	and	_	0	SENT_46	[p6l500t916r655b995],
24	time	NN	O	time	prep_of	19	SENT_46	[p6l691t917r877b995],
25	from	IN	O	from	_	0	SENT_46	[p6l912t916r1119b995],
26	diagnosis	NN	O	diagnosis	prep_from	22	SENT_46	[p6l1154t917r1558b1017],
27	to	TO	O	to	_	0	SENT_46	[p6l1595t933r1674b995],
28	first	JJ	ORDINAL	first	amod	29	SENT_46	[p6l1710t916r1883b995],
29	treatment	NN	O	treatment	prep_to	26	SENT_46	[p6l1914t933r2134b995, p6l11t1061r233b1123],
30	on	IN	O	on	_	0	SENT_46	[p6l250t1070r356b1123],
31	measures	NNS	O	measure	prep_on	29	SENT_46	[p6l377t1071r776b1124],
32	of	IN	O	of	_	0	SENT_46	[p6l800t1044r900b1123],
33	EGFR	NN	ORGANIZATION	egfr	prep_of	31	SENT_46	[p6l902t1050r1161b1128],
34	could	MD	O	could	aux	37	SENT_46	[p6l1173t1044r1405b1124],
35	not	RB	O	not	neg	37	SENT_46	[p6l1426t1061r1569b1123],
36	be	VB	O	be	auxpass	37	SENT_46	[p6l1586t1045r1681b1123],
37	controlled	VBN	O	control	_	0	SENT_46	[p6l1704t1044r2135b1123],
38	for	IN	O	for	prep	37	SENT_46	[p6l11t1173r134b1252],
39	in	IN	O	in	pcomp	38	SENT_46	[p6l155t1174r236b1251],
40	the	DT	O	the	det	41	SENT_46	[p6l261t1174r391b1252],
41	trial	NN	O	trial	pobj	39	SENT_46	[p6l416t1173r606b1252],
42	.	.	O	.	_	0	SENT_46	[p6l416t1173r606b1252],

1	With	IN	O	with	_	0	SENT_47	[p6l136t1301r346b1380],
2	the	DT	O	the	det	3	SENT_47	[p6l384t1302r512b1380],
3	development	NN	O	development	prep_with	18	SENT_47	[p6l550t1301r1100b1402],
4	of	IN	O	of	_	0	SENT_47	[p6l1133t1301r1233b1380],
5	trastuzumab	NN	O	trastuzumab	nn	6	SENT_47	[p6l1253t1302r1784b1381],
6	therapy	NN	O	therapy	prep_of	3	SENT_47	[p6l1822t1302r2140b1402],
7	for	IN	O	for	_	0	SENT_47	[p6l11t1428r134b1507],
8	breast	NN	O	breast	nn	9	SENT_47	[p6l162t1429r422b1507],
9	cancer	NN	O	cancer	prep_for	6	SENT_47	[p6l449t1454r724b1507],
10	as	IN	O	as	_	0	SENT_47	[p6l751t1455r836b1507],
11	a	DT	O	a	det	12	SENT_47	[p6l868t1455r913b1507],
12	model	NN	O	model	prep_as	9	SENT_47	[p6l942t1423r1318b1524],
13	,	,	O	,	_	0	SENT_47	[p6l942t1423r1318b1524],
14	”	CD	NUMBER	”	appos	12	SENT_47	[p6l942t1423r1318b1524],
15	it	PRP	O	it	nsubj	18	SENT_47	[p6l1349t1430r1408b1507],
16	is	VBZ	O	be	cop	18	SENT_47	[p6l1434t1430r1499b1507],
17	now	RB	DATE	now	advmod	18	SENT_47	[p6l1532t1454r1716b1508],
18	clear	JJ	O	clear	_	0	SENT_47	[p6l1744t1429r1945b1507],
19	that	IN	O	that	complm	25	SENT_47	[p6l1973t1429r2140b1507],
20	predictive	JJ	O	predictive	amod	22	SENT_47	[p6l9t1557r420b1658],
21	molecular	JJ	O	molecular	amod	22	SENT_47	[p6l444t1557r870b1637],
22	assays	NNS	O	assay	nsubjpass	25	SENT_47	[p6l891t1584r1151b1658],
23	must	MD	O	must	aux	25	SENT_47	[p6l1177t1574r1394b1637],
24	be	VB	O	be	auxpass	25	SENT_47	[p6l1413t1558r1508b1636],
25	devised	VBN	O	devise	ccomp	18	SENT_47	[p6l1533t1557r1844b1637],
26	before	IN	O	before	_	0	SENT_47	[p6l1869t1557r2135b1636],
27	the	DT	O	the	det	28	SENT_47	[p6l11t1686r140b1764],
28	initiation	NN	O	initiation	prep_before	25	SENT_47	[p6l163t1686r549b1764],
29	of	IN	O	of	_	0	SENT_47	[p6l573t1685r673b1764],
30	clinical	JJ	O	clinical	amod	31	SENT_47	[p6l679t1686r979b1764],
31	trials	NNS	O	trial	prep_of	28	SENT_47	[p6l1003t1686r1210b1764],
32	for	IN	O	for	_	0	SENT_47	[p6l1235t1685r1358b1764],
33	new	JJ	O	new	prep_for	25	SENT_47	[p6l1378t1711r1553b1765],
34	targeted	VBN	O	target	partmod	33	SENT_47	[p6l1573t1686r1919b1786],
35	anticancer	JJ	O	anticancer	amod	36	SENT_47	[p6l1941t1686r2134b1764, p6l11t1839r286b1892],
36	agents	NNS	O	agent	dobj	34	SENT_47	[p6l324t1830r597b1914],
37	if	IN	O	if	mark	45	SENT_47	[p6l639t1813r714b1891],
38	the	DT	O	the	det	39	SENT_47	[p6l737t1814r867b1892],
39	speciﬁcity	NN	O	speciﬁcity	nsubj	45	SENT_47	[p6l909t1813r1333b1914],
40	and	CC	O	and	_	0	SENT_47	[p6l1369t1813r1525b1892],
41	usefulness	NN	O	usefulness	conj_and	39	SENT_47	[p6l1565t1813r2009b1893],
42	of	IN	O	of	_	0	SENT_47	[p6l2053t1813r2153b1892],
43	these	DT	O	these	det	44	SENT_47	[p6l11t1942r229b2020],
44	drugs	NNS	O	drug	prep_of	39	SENT_47	[p6l256t1942r493b2042],
45	are	VBP	O	be	advcl	34	SENT_47	[p6l519t1968r645b2020],
46	to	TO	O	to	aux	49	SENT_47	[p6l671t1958r750b2020],
47	be	VB	O	be	auxpass	49	SENT_47	[p6l777t1942r872b2020],
48	meaningfully	RB	O	meaningfully	advmod	49	SENT_47	[p6l897t1941r1461b2042],
49	evaluated	VBN	O	evaluate	xcomp	45	SENT_47	[p6l1482t1942r1875b2021],
50	in	IN	O	in	_	0	SENT_47	[p6l1899t1942r1980b2019],
51	the	DT	O	the	det	52	SENT_47	[p6l2006t1942r2135b2020],
52	population	NN	O	population	prep_in	49	SENT_47	[p6l9t2070r473b2170],
53	of	IN	O	of	_	0	SENT_47	[p6l507t2069r607b2148],
54	patients	NNS	O	patient	prep_of	52	SENT_47	[p6l621t2070r956b2170],
55	most	RBS	O	most	advmod	56	SENT_47	[p6l990t2086r1207b2148],
56	likely	JJ	O	likely	amod	54	SENT_47	[p6l1234t2069r1460b2170],
57	to	TO	O	to	aux	58	SENT_47	[p6l1489t2086r1568b2148],
58	beneﬁt	JJ	O	beneﬁt	xcomp	56	SENT_47	[p6l1603t2069r1900b2148],
59	from	IN	O	from	_	0	SENT_47	[p6l1928t2069r2135b2148],
60	the	DT	O	the	det	61	SENT_47	[p6l11t2198r139b2276],
61	treatment	NN	O	treatment	prep_from	58	SENT_47	[p6l163t2214r592b2276],
62	.	.	O	.	_	0	SENT_47	[p6l163t2214r592b2276],

1	Furthermore	RB	O	furthermore	advmod	15	SENT_48	[p6l619t2197r1175b2293],
2	,	,	O	,	_	0	SENT_48	[p6l619t2197r1175b2293],
3	the	DT	O	the	det	4	SENT_48	[p6l1205t2197r1332b2276],
4	designs	NNS	O	design	nsubj	15	SENT_48	[p6l1358t2198r1674b2298],
5	of	IN	O	of	_	0	SENT_48	[p6l1700t2197r1801b2276],
6	modern	JJ	O	modern	amod	7	SENT_48	[p6l1805t2198r2136b2276],
7	phase	NN	O	phase	prep_of	4	SENT_48	[p6l9t2326r255b2426],
8	2	CD	NUMBER	2	dep	7	SENT_48	[p6l277t2331r324b2403],
9	and	CC	O	and	_	0	SENT_48	[p6l346t2325r502b2404],
10	phase	NN	O	phase	prep_of	4	SENT_48	[p6l522t2326r768b2426],
11	3	CD	NUMBER	3	num	13	SENT_48	[p6l790t2331r834b2404],
12	clinical	JJ	O	clinical	amod	13	SENT_48	[p6l860t2325r1161b2404],
13	trials	NNS	O	trial	dep	10	SENT_48	[p6l1182t2326r1389b2404],
14	must	MD	O	must	aux	15	SENT_48	[p6l1412t2342r1629b2405],
15	incorporate	VB	O	incorporate	_	0	SENT_48	[p6l1645t2326r2135b2426],
16	speciﬁc	JJ	O	speciﬁc	amod	18	SENT_48	[p6l12t2453r321b2554],
17	molecular	JJ	O	molecular	amod	18	SENT_48	[p6l341t2454r756b2533],
18	assays	NNS	O	assay	dobj	15	SENT_48	[p6l772t2480r1027b2554],
19	to	TO	O	to	aux	20	SENT_48	[p6l1050t2470r1127b2532],
20	maximize	VB	O	maximize	xcomp	15	SENT_48	[p6l1149t2454r1553b2532],
21	the	DT	O	the	det	22	SENT_48	[p6l1573t2454r1700b2532],
22	likelihood	NN	O	likelihood	dobj	20	SENT_48	[p6l1719t2453r2136b2533],
23	of	IN	O	of	_	0	SENT_48	[p6l11t2581r112b2660],
24	deﬁnitive	JJ	O	deﬁnitive	amod	26	SENT_48	[p6l122t2581r511b2661],
25	clinical	JJ	O	clinical	amod	26	SENT_48	[p6l540t2581r841b2660],
26	results	NNS	O	result	prep_of	22	SENT_48	[p6l868t2581r1170b2661],
27	.	.	O	.	_	0	SENT_48	[p6l868t2581r1170b2661],

1	This	DT	O	this	det	2	SENT_49	[p6l1200t2581r1385b2660],
2	Work	NN	O	work	nsubj	4	SENT_49	[p6l1411t2582r1633b2661],
3	Will	MD	O	will	aux	4	SENT_49	[p6l1652t2582r1808b2661],
4	require	VB	O	require	_	0	SENT_49	[p6l1835t2582r2135b2682],
5	substantially	RB	O	substantially	advmod	6	SENT_49	[p6l12t2709r550b2810],
6	more	JJR	O	more	amod	7	SENT_49	[p6l583t2735r802b2788],
7	effort	NN	O	effort	dobj	4	SENT_49	[p6l841t2709r1076b2788],
8	to	TO	O	to	aux	9	SENT_49	[p6l1108t2726r1187b2788],
9	develop	VB	O	develop	xcomp	4	SENT_49	[p6l1226t2709r1548b2810],
10	standardized	JJ	O	standardized	amod	12	SENT_49	[p6l1588t2709r2135b2788],
11	assay	NN	O	assay	nn	12	SENT_49	[p6l10t2864r234b2938],
12	procedures	NNS	O	procedure	dobj	9	SENT_49	[p6l261t2837r731b2938],
13	for	IN	O	for	_	0	SENT_49	[p6l765t2837r889b2916],
14	assessing	VBG	O	assess	prepc_for	9	SENT_49	[p6l918t2838r1323b2938],
15	and	CC	O	and	_	0	SENT_49	[p6l1351t2837r1507b2916],
16	predicting	VBG	O	predict	conj_and	14	SENT_49	[p6l1538t2838r1976b2938],
17	the	DT	O	the	det	18	SENT_49	[p6l2005t2838r2135b2916],
18	effects	NNS	O	effect	dobj	14	SENT_49	[p6l11t2965r281b3044],
19	of	IN	O	of	_	0	SENT_49	[p6l335t2965r435b3044],
20	whole	JJ	O	whole	amod	21	SENT_49	[p6l462t2966r721b3045],
21	classes	NNS	O	class	prep_of	18	SENT_49	[p6l772t2966r1060b3044],
22	of	IN	O	of	_	0	SENT_49	[p6l1113t2965r1214b3044],
23	molecularly	RB	O	molecularly	advmod	24	SENT_49	[p6l1246t2965r1744b3066],
24	targeted	VBN	O	target	amod	25	SENT_49	[p6l1790t2965r2135b3066],
25	agents	NNS	O	agent	prep_of	21	SENT_49	[p6l10t3110r289b3194],
26	and	CC	O	and	_	0	SENT_49	[p6l328t3093r486b3172],
27	highly	RB	O	highly	advmod	29	SENT_49	[p6l523t3093r796b3194],
28	standardized	JJ	O	standardized	amod	29	SENT_49	[p6l830t3093r1390b3172],
29	methods	NNS	O	method	prep_of	21	SENT_49	[p6l1428t3094r1802b3172],
30	for	IN	O	for	_	0	SENT_49	[p6l1842t3093r1967b3172],
31	the	DT	O	the	det	33	SENT_49	[p6l2003t3094r2134b3172],
32	prospective	JJ	O	prospective	amod	33	SENT_49	[p6l9t3222r502b3322],
33	collection	NN	O	collection	prep_for	29	SENT_49	[p6l530t3221r942b3300],
34	of	IN	O	of	_	0	SENT_49	[p6l967t3221r1068b3300],
35	human	JJ	O	human	amod	37	SENT_49	[p6l1074t3221r1374b3301],
36	tumor	NN	O	tumor	nn	37	SENT_49	[p6l1399t3238r1662b3301],
37	tissue	NN	O	tissue	prep_of	33	SENT_49	[p6l1684t3222r1949b3301],
38	.	.	O	.	_	0	SENT_49	[p6l1684t3222r1949b3301],

1	The	DT	O	the	det	2	SENT_50	[p6l136t3350r298b3428],
2	results	NNS	O	result	nsubj	17	SENT_50	[p6l339t3349r615b3429],
3	of	IN	O	of	_	0	SENT_50	[p6l660t3349r760b3428],
4	the	DT	O	the	det	6	SENT_50	[p6l782t3350r912b3428],
5	NCIC	NNP	ORGANIZATION	NCIC	nn	6	SENT_50	[p6l950t3355r1184b3428],
6	study	NN	O	study	prep_of	2	SENT_50	[p6l1229t3350r1455b3450],
7	of	IN	O	of	_	0	SENT_50	[p6l1491t3349r1592b3428],
8	erlotinib	NN	O	erlotinib	prep_of	6	SENT_50	[p6l1615t3350r1973b3428],
9	for	IN	O	for	_	0	SENT_50	[p6l2015t3349r2138b3428],
10	non	JJ	O	non	amod	16	SENT_50	[p6l11t3477r642b3556],
11	—	JJ	O	—	amod	16	SENT_50	[p6l11t3477r642b3556],
12	small	JJ	O	small	amod	16	SENT_50	[p6l11t3477r642b3556],
13	—	NN	O	—	nn	16	SENT_50	[p6l11t3477r642b3556],
14	cell	NN	O	cell	nn	16	SENT_50	[p6l11t3477r642b3556],
15	lung	NN	O	lung	nn	16	SENT_50	[p6l686t3478r880b3578],
16	cancer	NN	O	cancer	prep_for	8	SENT_50	[p6l922t3503r1198b3556],
17	support	VBP	O	support	_	0	SENT_50	[p6l1241t3494r1573b3578],
18	the	DT	O	the	det	19	SENT_50	[p6l1613t3478r1743b3556],
19	promise	NN	O	promise	dobj	17	SENT_50	[p6l1786t3478r2135b3578],
20	that	WDT	O	that	nsubj	21	SENT_50	[p6l11t3606r178b3684],
21	individualized	VBD	O	individualize	rcmod	19	SENT_50	[p6l204t3605r801b3685],
22	oncologic	JJ	O	oncologic	amod	23	SENT_50	[p6l833t3605r1249b3706],
23	therapies	NNS	O	therapy	nsubjpass	26	SENT_50	[p6l1281t3606r1665b3706],
24	can	MD	O	can	aux	26	SENT_50	[p6l1700t3631r1844b3684],
25	be	VB	O	be	auxpass	26	SENT_50	[p6l1877t3606r1972b3684],
26	developed	VBN	O	develop	ccomp	21	SENT_50	[p6l2005t3606r2134b3684, p7l6t20r334b121],

1	and	CC	O	and	cc	2	SENT_51	[p7l377t21r534b99],
2	applied	VBN	O	apply	_	0	SENT_51	[p7l577t20r889b121],
3	on	IN	O	on	_	0	SENT_51	[p7l934t46r1040b99],
4	the	DT	O	the	det	5	SENT_51	[p7l1085t21r1214b99],
5	basis	NN	O	basis	prep_on	2	SENT_51	[p7l1259t21r1468b99],
6	of	IN	O	of	_	0	SENT_51	[p7l1515t20r1616b99],
7	the	DT	O	the	det	10	SENT_51	[p7l1642t21r1771b99],
8	speciﬁc	JJ	O	speciﬁc	amod	10	SENT_51	[p7l1817t20r2136b121],
9	molecular	JJ	O	molecular	amod	10	SENT_51	[p7l11t149r436b228],
10	characteristics	NNS	O	characteristic	prep_of	5	SENT_51	[p7l469t149r1073b227],
11	of	IN	O	of	_	0	SENT_51	[p7l1111t148r1211b227],
12	a	DT	O	a	det	13	SENT_51	[p7l1227t175r1272b227],
13	patient	NN	O	patient	poss	16	SENT_51	[p7l1303t149r1665b249],
14	’s	POS	O	’s	_	0	SENT_51	[p7l1303t149r1665b249],
15	malignant	JJ	O	malignant	amod	16	SENT_51	[p7l1702t149r2140b249],
16	disease	NN	O	disease	prep_of	10	SENT_51	[p7l11t277r338b355],
17	.	.	O	.	_	0	SENT_51	[p7l11t277r338b355],

1	Only	RB	O	only	advmod	5	SENT_52	[p7l379t276r580b377],
2	the	DT	O	the	det	5	SENT_52	[p7l611t277r740b355],
3	most	RBS	O	most	advmod	4	SENT_52	[p7l775t293r992b355],
4	assiduous	JJ	O	assiduous	amod	5	SENT_52	[p7l1021t276r1439b356],
5	attention	NN	O	attention	nsubj	30	SENT_52	[p7l1475t277r1855b355],
6	to	TO	O	to	_	0	SENT_52	[p7l1890t293r1969b355],
7	the	DT	O	the	det	8	SENT_52	[p7l2006t277r2135b355],
8	development	NN	O	development	prep_to	5	SENT_52	[p7l11t405r553b505],
9	of	IN	O	of	_	0	SENT_52	[p7l571t404r671b483],
10	drug	NN	O	drug	nn	12	SENT_52	[p7l676t404r1220b505],
11	—	NN	O	—	nn	12	SENT_52	[p7l676t404r1220b505],
12	speciﬁc	NN	O	speciﬁc	nn	15	SENT_52	[p7l676t404r1220b505],
13	molecular	JJ	O	molecular	amod	15	SENT_52	[p7l1243t405r1661b484],
14	pharmacodynamic	JJ	O	pharmacodynamic	amod	15	SENT_52	[p7l1680t405r2135b505, p7l11t533r364b633],
15	tools	NNS	O	tool	prep_of	8	SENT_52	[p7l390t533r620b628],
16	,	,	O	,	_	0	SENT_52	[p7l390t533r620b628],
17	and	CC	O	and	_	0	SENT_52	[p7l652t533r808b611],
18	the	DT	O	the	det	19	SENT_52	[p7l836t533r965b611],
19	implementation	NN	O	implementation	conj_and	15	SENT_52	[p7l992t532r1676b633],
20	of	IN	O	of	_	0	SENT_52	[p7l1704t532r1804b611],
21	meticu	FW	O	meticu	nn	24	SENT_52	[p7l1813t533r2134b612],
22	—	FW	O	—	nn	24	SENT_52	[p7l1813t533r2134b612],
23	lous	JJ	O	lous	amod	24	SENT_52	[p7l10t661r184b740],
24	tumor	NN	O	tumor	prep_of	19	SENT_52	[p7l217t661r984b761],
25	—	NN	O	—	nn	27	SENT_52	[p7l217t661r984b761],
26	acquisition	NN	O	acquisition	nn	27	SENT_52	[p7l217t661r984b761],
27	techniques	NNS	O	technique	dep	24	SENT_52	[p7l1015t661r1498b761],
28	,	,	O	,	_	0	SENT_52	[p7l1015t661r1498b761],
29	will	MD	O	will	aux	30	SENT_52	[p7l1530t660r1687b740],
30	allow	VB	O	allow	_	0	SENT_52	[p7l1716t661r1946b740],
31	that	DT	O	that	det	32	SENT_52	[p7l1973t661r2140b739],
32	promise	NN	O	promise	dobj	30	SENT_52	[p7l9t789r357b889],
33	to	TO	O	to	aux	35	SENT_52	[p7l384t805r463b867],
34	be	VB	O	be	auxpass	35	SENT_52	[p7l490t788r585b867],
35	realized	VBN	O	realize	infmod	32	SENT_52	[p7l610t789r964b867],
36	.	.	O	.	_	0	SENT_52	[p7l610t789r964b867],

1	From	IN	O	from	dep	12	SENT_53	[p7l16t1016r177b1072],
2	the	DT	O	the	det	3	SENT_53	[p7l205t1011r308b1072],
3	Division	NN	O	division	pobj	1	SENT_53	[p7l340t1016r601b1072],
4	of	IN	O	of	_	0	SENT_53	[p7l631t1010r703b1072],
5	Cancer	NNP	O	Cancer	nn	6	SENT_53	[p7l718t1016r944b1072],
6	Treatment	NN	O	treatment	prep_of	3	SENT_53	[p7l965t1016r1302b1072],
7	and	CC	O	and	_	0	SENT_53	[p7l1328t1011r1444b1072],
8	Diagnosis	NN	O	diagnosis	prep_of	3	SENT_53	[p7l1479t1016r1821b1091],
9	,	,	O	,	_	0	SENT_53	[p7l1479t1016r1821b1091],
10	National	NNP	ORGANIZATION	National	nn	12	SENT_53	[p7l1856t1011r2131b1072],
11	Cancer	NNP	ORGANIZATION	Cancer	nn	12	SENT_53	[p7l11t1112r237b1168],
12	Institute	NNP	ORGANIZATION	Institute	_	0	SENT_53	[p7l264t1112r551b1178],
13	,	,	O	,	_	0	SENT_53	[p7l264t1112r551b1178],
14	Bethesda	NNP	LOCATION	Bethesda	appos	12	SENT_53	[p7l584t1107r899b1178],
15	,	,	O	,	_	0	SENT_53	[p7l584t1107r899b1178],
16	Md.	NNP	O	Md.	appos	12	SENT_53	[p7l932t1107r1053b1168],
17	1	CD	NUMBER	1	num	16	SENT_53	[p7l12t1219r60b1270],
18	.	.	O	.	_	0	SENT_53	[p7l12t1219r60b1270],

1	Kris	NNP	PERSON	Kris	nn	2	SENT_54	[p7l138t1212r266b1272],
2	MG	NN	PERSON	mg	_	0	SENT_54	[p7l282t1215r421b1282],
3	,	,	O	,	_	0	SENT_54	[p7l282t1215r421b1282],
4	Natale	NNP	PERSON	Natale	nn	5	SENT_54	[p7l440t1211r646b1270],
5	RB	NN	O	rb	appos	2	SENT_54	[p7l662t1216r772b1282],
6	,	,	O	,	_	0	SENT_54	[p7l662t1216r772b1282],
7	Herbst	NNP	ORGANIZATION	Herbst	nn	8	SENT_54	[p7l793t1211r1012b1270],
8	RS	NN	ORGANIZATION	r	appos	2	SENT_54	[p7l1024t1215r1127b1282],
9	,	,	O	,	_	0	SENT_54	[p7l1024t1215r1127b1282],
10	et	FW	O	et	nn	11	SENT_54	[p7l1149t1224r1207b1269],
11	al.	FW	O	al.	appos	2	SENT_54	[p7l1220t1211r1290b1270],
12	.	.	O	.	_	0	SENT_54	[p7l1220t1211r1290b1270],

1	Efficacy	NN	O	efficacy	_	0	SENT_55	[p7l1310t1210r1560b1286],
2	of	IN	O	of	_	0	SENT_55	[p7l1574t1210r1650b1270],
3	gefitinib	NN	O	gefitinib	prep_of	1	SENT_55	[p7l1652t1210r1937b1286],
4	,	,	O	,	_	0	SENT_55	[p7l1652t1210r1937b1286],
5	an	DT	O	a	det	6	SENT_55	[p7l1958t1230r2033b1269],
6	inhibitor	NN	O	inhibitor	appos	3	SENT_55	[p7l2049t1212r2135b1269, p7l10t1307r227b1366],
7	of	IN	O	of	_	0	SENT_55	[p7l251t1306r326b1366],
8	the	DT	O	the	det	14	SENT_55	[p7l337t1307r434b1365],
9	epidermal	JJ	O	epidermal	amod	14	SENT_55	[p7l460t1307r779b1382],
10	growth	NN	O	growth	nn	14	SENT_55	[p7l803t1307r1031b1382],
11	factor	NN	O	factor	nn	14	SENT_55	[p7l1056t1306r1241b1366],
12	receptor	NN	O	receptor	nn	14	SENT_55	[p7l1264t1320r1527b1382],
13	tyrosine	NN	O	tyrosine	nn	14	SENT_55	[p7l1550t1308r1802b1382],
14	kinase	NN	O	kinase	prep_of	6	SENT_55	[p7l1826t1307r2047b1378],
15	,	,	O	,	_	0	SENT_55	[p7l1826t1307r2047b1378],
16	in	IN	O	in	_	0	SENT_55	[p7l2075t1308r2137b1365],
17	symptomatic	JJ	O	symptomatic	amod	18	SENT_55	[p7l11t1403r422b1478],
18	patients	NNS	O	patient	prep_in	3	SENT_55	[p7l447t1403r699b1478],
19	With	IN	O	with	_	0	SENT_55	[p7l724t1403r866b1463],
20	non	JJ	O	non	amod	25	SENT_55	[p7l893t1403r1218b1462],
21	—	JJ	O	—	amod	25	SENT_55	[p7l893t1403r1218b1462],
22	small	JJ	O	small	amod	25	SENT_55	[p7l893t1403r1218b1462],
23	cell	NN	O	cell	nn	25	SENT_55	[p7l1245t1403r1352b1461],
24	lung	NN	O	lung	nn	25	SENT_55	[p7l1377t1403r1523b1478],
25	cancer	NN	O	cancer	prep_with	18	SENT_55	[p7l1548t1422r1771b1462],
26	:	:	O	:	_	0	SENT_55	[p7l1548t1422r1771b1462],
27	a	DT	O	a	det	29	SENT_55	[p7l1801t1422r1834b1461],
28	randomized	JJ	O	randomized	amod	29	SENT_55	[p7l1860t1403r2136b1462, p7l9t1499r139b1557],
29	trial	NN	O	trial	dep	1	SENT_55	[p7l158t1499r300b1557],
30	.	.	O	.	_	0	SENT_55	[p7l158t1499r300b1557],

1	JAMA	NNP	O	JAMA	_	0	SENT_56	[p7l315t1504r506b1567],
2	2003	CD	DATE	2003	num	1	SENT_56	[p7l522t1503r1123b1570],
3	;	:	O	;	_	0	SENT_56	[p7l522t1503r1123b1570],
4	290:2149	CD	NUMBER	290:2149	number	5	SENT_56	[p7l522t1503r1123b1570],
5	—	CD	NUMBER	—	dep	1	SENT_56	[p7l522t1503r1123b1570],
6	58	CD	NUMBER	58	dep	5	SENT_56	[p7l522t1503r1123b1570],
7	.	.	O	.	_	0	SENT_56	[p7l522t1503r1123b1570],

1	2	LS	NUMBER	2	_	0	SENT_57	[p7l8t1602r60b1653],
2	.	.	O	.	_	0	SENT_57	[p7l8t1602r60b1653],

1	Perez-Soler	NNP	O	Perez-Soler	nn	2	SENT_58	[p7l137t1595r500b1653],
2	R	NNP	O	R	_	0	SENT_58	[p7l518t1600r583b1666],
3	,	,	O	,	_	0	SENT_58	[p7l518t1600r583b1666],
4	Chachoua	NNP	O	Chachoua	nn	5	SENT_58	[p7l608t1595r927b1654],
5	A	NNP	O	A	appos	2	SENT_58	[p7l945t1600r1010b1666],
6	,	,	O	,	_	0	SENT_58	[p7l945t1600r1010b1666],
7	Hammond	NNP	ORGANIZATION	Hammond	nn	8	SENT_58	[p7l1034t1595r1381b1654],
8	LA	NNP	ORGANIZATION	LA	appos	2	SENT_58	[p7l1402t1600r1504b1666],
9	,	,	O	,	_	0	SENT_58	[p7l1402t1600r1504b1666],
10	et	FW	O	et	nn	11	SENT_58	[p7l1531t1607r1588b1653],
11	al.	FW	O	al.	appos	2	SENT_58	[p7l1605t1595r1676b1653],
12	.	.	O	.	_	0	SENT_58	[p7l1605t1595r1676b1653],

1	Determinants	NNS	O	determinant	_	0	SENT_59	[p7l1700t1595r2135b1653],
2	of	IN	O	of	_	0	SENT_59	[p7l10t1690r86b1750],
3	tumor	NN	O	tumor	nn	4	SENT_59	[p7l93t1703r290b1751],
4	response	NN	O	response	prep_of	1	SENT_59	[p7l308t1710r593b1766],
5	and	CC	O	and	_	0	SENT_59	[p7l613t1691r730b1750],
6	survival	NN	O	survival	prep_of	1	SENT_59	[p7l752t1691r991b1751],
7	with	IN	O	with	_	0	SENT_59	[p7l1007t1691r1149b1751],
8	erlotinib	NN	O	erlotinib	prep_with	1	SENT_59	[p7l1171t1691r1440b1750],
9	in	IN	O	in	_	0	SENT_59	[p7l1460t1692r1522b1749],
10	patients	NNS	O	patient	prep_in	1	SENT_59	[p7l1541t1692r1792b1766],
11	with	IN	O	with	_	0	SENT_59	[p7l1811t1691r1953b1751],
12	nonsmall	JJ	O	nonsmall	amod	16	SENT_59	[p7l1973t1710r2139b1750, p7l11t1787r318b1845],
13	—	NN	O	—	nn	16	SENT_59	[p7l1973t1710r2139b1750, p7l11t1787r318b1845],
14	cell	NN	O	cell	nn	16	SENT_59	[p7l1973t1710r2139b1750, p7l11t1787r318b1845],
15	lung	NN	O	lung	nn	16	SENT_59	[p7l335t1787r481b1862],
16	cancer	NN	O	cancer	prep_with	10	SENT_59	[p7l497t1806r716b1846],
17	.	.	O	.	_	0	SENT_59	[p7l497t1806r716b1846],

1	J	NNP	O	J	nn	3	SENT_60	[p7l731t1792r759b1855],
2	Clin	NNP	O	Clin	nn	3	SENT_60	[p7l776t1787r907b1846],
3	Oncol	NNP	O	Oncol	_	0	SENT_60	[p7l925t1787r1116b1846],
4	2004	CD	DATE	2004	num	3	SENT_60	[p7l1134t1791r1695b1858],
5	;	:	O	;	_	0	SENT_60	[p7l1134t1791r1695b1858],
6	22:3238	CD	NUMBER	22:3238	number	7	SENT_60	[p7l1134t1791r1695b1858],
7	—	CD	NUMBER	—	dep	3	SENT_60	[p7l1134t1791r1695b1858],
8	47	CD	NUMBER	47	dep	7	SENT_60	[p7l1134t1791r1695b1858],
9	.	.	O	.	_	0	SENT_60	[p7l1134t1791r1695b1858],

1	ENGLJ	NNP	O	ENGLJ	nn	4	SENT_61	[p7l556t1938r640b1960],
2	MED	NNP	O	MED	nn	4	SENT_61	[p7l655t1939r707b1954],
3	353:2	CD	NUMBER	353:2	num	4	SENT_61	[p7l720t1938r783b1960],
4	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	_	0	SENT_61	[p7l818t1938r1029b1960],
5	ULY	NNP	O	ULY	dep	4	SENT_61	[p7l1078t1939r1123b1954],
6	14	CD	NUMBER	14	num	5	SENT_61	[p7l1136t1938r1170b1960],
7	,	,	O	,	_	0	SENT_61	[p7l1136t1938r1170b1960],
8	2oo5	CD	NUMBER	2oo5	num	5	SENT_61	[p7l1183t1938r1246b1960],
9	201	CD	NUMBER	201	dep	4	SENT_61	[p7l1959t1937r2016b1958],

1	The	DT	O	the	det	5	SENT_62	[p7l702t1971r753b1994],
2	New	NNP	O	New	nn	5	SENT_62	[p7l762t1972r824b1994],
3	England	NNP	O	England	nn	5	SENT_62	[p7l833t1971r944b2001],
4	Journa	NNP	O	Journa	nn	5	SENT_62	[p7l952t1972r1041b1994],
5	o	NN	O	o	_	0	SENT_62	[p7l1060t1978r1075b1994],
6	Medicine	NN	O	medicine	dep	5	SENT_62	[p7l1095t1971r1220b1994],

1	Downloaded	VBN	O	download	_	0	SENT_63	[p7l144t2011r314b2034],
2	from	IN	O	from	_	0	SENT_63	[p7l323t2011r387b2034],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_63	[p7l396t2011r514b2041],
4	at	IN	O	at	_	0	SENT_63	[p7l524t2015r547b2034],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_63	[p7l556t2011r739b2034],
6	on	IN	O	on	_	0	SENT_63	[p7l748t2018r780b2034],
7	Janu	NNP	DATE	Janu	prep_on	1	SENT_63	[p7l789t2011r849b2034],
8	5	CD	DATE	5	num	7	SENT_63	[p7l902t2011r924b2038],
9	,	,	DATE	,	_	0	SENT_63	[p7l902t2011r924b2038],
10	2014	CD	DATE	2014	num	7	SENT_63	[p7l935t2011r1007b2034],
11	.	.	O	.	_	0	SENT_63	[p7l935t2011r1007b2034],

1	For	IN	O	for	_	0	SENT_64	[p7l1018t2011r1064b2034],
2	personal	JJ	O	personal	amod	3	SENT_64	[p7l1072t2011r1184b2041],
3	use	NN	O	use	pobj	1	SENT_64	[p7l1194t2018r1237b2034],
4	only	RB	O	only	advmod	3	SENT_64	[p7l1247t2011r1311b2041],
5	.	.	O	.	_	0	SENT_64	[p7l1247t2011r1311b2041],

1	No	DT	O	no	det	3	SENT_65	[p7l1322t2011r1362b2034],
2	other	JJ	O	other	amod	3	SENT_65	[p7l1372t2011r1440b2034],
3	uses	NNS	O	use	_	0	SENT_65	[p7l1448t2018r1504b2034],
4	without	IN	O	without	_	0	SENT_65	[p7l1514t2011r1615b2034],
5	permission	NN	O	permission	prep_without	3	SENT_65	[p7l1624t2011r1776b2041],
6	.	.	O	.	_	0	SENT_65	[p7l1624t2011r1776b2041],

1	Copyright	NN	O	copyright	nn	5	SENT_66	[p7l494t2052r629b2082],
2	©	CD	NUMBER	©	num	5	SENT_66	[p7l638t2052r661b2075],
3	2005	CD	DATE	2005	num	5	SENT_66	[p7l672t2052r735b2075],
4	Massac	NNP	LOCATION	Massac	nn	5	SENT_66	[p7l746t2053r844b2075],
5	usetts	NNP	O	usetts	_	0	SENT_66	[p7l863t2056r937b2075],
6	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_66	[p7l947t2052r1055b2075],
7	Society	NNP	ORGANIZATION	Society	dep	5	SENT_66	[p7l1065t2052r1170b2082],
8	.	.	O	.	_	0	SENT_66	[p7l1065t2052r1170b2082],

1	All	DT	O	all	det	2	SENT_67	[p7l1181t2052r1223b2075],
2	rights	NNS	O	rights	nsubj	3	SENT_67	[p7l1232t2052r1306b2082],
3	reserved	VBN	O	reserve	_	0	SENT_67	[p7l1316t2052r1435b2075],
4	.	.	O	.	_	0	SENT_67	[p7l1316t2052r1435b2075],

1	The	DT	O	the	det	4	SENT_68	[p7l715t2157r752b2178],
2	NEW	NNP	O	NEW	nn	4	SENT_68	[p7l764t2159r845b2178],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_68	[p7l859t2159r1034b2178],
4	IOURNAL	NNP	O	IOURNAL	_	0	SENT_68	[p7l1048t2159r1214b2185],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_68	[p7l1228t2157r1444b2184],

1	3	LS	NUMBER	3	_	0	SENT_69	[p7l9t2387r60b2438],
2	.	.	O	.	_	0	SENT_69	[p7l9t2387r60b2438],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_70	[p7l138t2379r361b2438],
2	RS	NN	ORGANIZATION	r	_	0	SENT_70	[p7l380t2384r485b2451],
3	,	,	O	,	_	0	SENT_70	[p7l380t2384r485b2451],
4	Giaccone	NNP	PERSON	Giaccone	nn	5	SENT_70	[p7l513t2380r814b2438],
5	G	NNP	PERSON	G	appos	2	SENT_70	[p7l838t2384r910b2451],
6	,	,	O	,	_	0	SENT_70	[p7l838t2384r910b2451],
7	Schiller	NNP	PERSON	Schiller	nn	8	SENT_70	[p7l940t2379r1185b2438],
8	JH	NNP	O	JH	appos	2	SENT_70	[p7l1199t2384r1302b2451],
9	,	,	O	,	_	0	SENT_70	[p7l1199t2384r1302b2451],
10	et	FW	O	et	nn	11	SENT_70	[p7l1331t2392r1389b2438],
11	al.	FW	O	al.	appos	2	SENT_70	[p7l1409t2379r1481b2438],
12	.	.	O	.	_	0	SENT_70	[p7l1409t2379r1481b2438],

1	Geﬁtinib	NNP	O	Geﬁtinib	_	0	SENT_71	[p7l1509t2379r1798b2438],
2	in	IN	O	in	_	0	SENT_71	[p7l1823t2380r1885b2437],
3	combination	NN	O	combination	prep_in	1	SENT_71	[p7l1909t2379r2136b2438, p7l9t2476r217b2534],
4	with	IN	O	with	_	0	SENT_71	[p7l234t2476r379b2535],
5	paclitaxel	NN	O	paclitaxel	prep_with	3	SENT_71	[p7l400t2475r710b2551],
6	and	CC	O	and	_	0	SENT_71	[p7l730t2475r849b2534],
7	carboplatin	NN	O	carboplatin	conj_and	5	SENT_71	[p7l871t2475r1240b2551],
8	in	IN	O	in	_	0	SENT_71	[p7l1261t2476r1323b2533],
9	advanced	JJ	O	advanced	amod	11	SENT_71	[p7l1344t2475r1644b2535],
10	non	JJ	O	non	amod	11	SENT_71	[p7l1665t2475r2137b2534],
11	—	NN	O	—	prep_in	1	SENT_71	[p7l1665t2475r2137b2534],
12	small	JJ	O	small	amod	16	SENT_71	[p7l1665t2475r2137b2534],
13	—	NN	O	—	nn	16	SENT_71	[p7l1665t2475r2137b2534],
14	cell	NN	O	cell	nn	16	SENT_71	[p7l1665t2475r2137b2534],
15	lung	NN	O	lung	nn	16	SENT_71	[p7l8t2571r157b2647],
16	cancer	NN	O	cancer	dep	1	SENT_71	[p7l180t2590r408b2630],
17	:	:	O	:	_	0	SENT_71	[p7l180t2590r408b2630],
18	a	DT	O	a	det	21	SENT_71	[p7l436t2591r469b2630],
19	phase	NN	O	phase	nn	21	SENT_71	[p7l492t2571r680b2647],
20	III	CD	NUMBER	iii	num	21	SENT_71	[p7l705t2577r779b2629],
21	trial	NN	O	trial	dep	1	SENT_71	[p7l804t2571r933b2630],
22	—	CD	NUMBER	—	num	23	SENT_71	[p7l955t2605r1035b2611],
23	INTACT	NN	O	intact	dep	21	SENT_71	[p7l1057t2576r1323b2630],
24	2	CD	NUMBER	2	dep	23	SENT_71	[p7l1346t2576r1401b2630],
25	.	.	O	.	_	0	SENT_71	[p7l1346t2576r1401b2630],

1	J	NNP	O	J	nn	3	SENT_72	[p7l1423t2577r1451b2640],
2	Clin	NNP	O	Clin	nn	3	SENT_72	[p7l1475t2571r1607b2630],
3	Oncol	NNP	O	Oncol	_	0	SENT_72	[p7l1633t2571r1827b2630],
4	2004	CD	DATE	2004	num	3	SENT_72	[p7l1852t2576r2134b2643],
5	;	:	O	;	_	0	SENT_72	[p7l1852t2576r2134b2643],
6	22	CD	NUMBER	22	num	8	SENT_72	[p7l1852t2576r2134b2643],
7	:	:	O	:	_	0	SENT_72	[p7l1852t2576r2134b2643],
8	785-94	CD	NUMBER	785-94	dep	3	SENT_72	[p7l10t2672r253b2726],
9	.	.	O	.	_	0	SENT_72	[p7l10t2672r253b2726],

1	4	LS	NUMBER	4	_	0	SENT_73	[p7l7t2770r60b2821],
2	.	.	O	.	_	0	SENT_73	[p7l7t2770r60b2821],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_74	[p7l138t2762r357b2821],
2	RS	NN	ORGANIZATION	r	_	0	SENT_74	[p7l372t2767r476b2834],
3	,	,	O	,	_	0	SENT_74	[p7l372t2767r476b2834],
4	Prager	NN	PERSON	prager	nn	5	SENT_74	[p7l499t2767r706b2838],
5	D	NN	PERSON	d	appos	2	SENT_74	[p7l722t2767r788b2834],
6	,	,	O	,	_	0	SENT_74	[p7l722t2767r788b2834],
7	Hermann	NNP	PERSON	Hermann	nn	8	SENT_74	[p7l812t2768r1118b2821],
8	R	NNP	PERSON	R	appos	2	SENT_74	[p7l1136t2767r1200b2834],
9	,	,	O	,	_	0	SENT_74	[p7l1136t2767r1200b2834],
10	et	FW	O	et	nn	11	SENT_74	[p7l1225t2775r1283b2821],
11	al.	FW	O	al.	appos	2	SENT_74	[p7l1298t2762r1369b2821],
12	.	.	O	.	_	0	SENT_74	[p7l1298t2762r1369b2821],

1	TRIBUTE	NN	O	tribute	nsubj	2	SENT_75	[p7l1391t2767r1695b2825],
2	—	VBD	O	—	_	0	SENT_75	[p7l1713t2796r1794b2802],
3	a	DT	O	a	det	6	SENT_75	[p7l1811t2782r1844b2821],
4	phase	NN	O	phase	nn	6	SENT_75	[p7l1862t2762r2046b2837],
5	III	CD	NUMBER	iii	num	6	SENT_75	[p7l2066t2768r2139b2820],
6	trial	NN	O	trial	nn	14	SENT_75	[p7l9t2858r135b2917],
7	of	IN	O	of	_	0	SENT_75	[p7l153t2858r228b2917],
8	erlotinib	NN	O	erlotinib	nn	9	SENT_75	[p7l234t2858r503b2917],
9	HCl	NN	O	hcl	prep_of	6	SENT_75	[p7l521t2858r647b2917],
10	(	CD	NUMBER	(	num	9	SENT_75	[p7l668t2863r974b2927],
11	OSI	NNP	O	OSI	amod	14	SENT_75	[p7l668t2863r974b2927],
12	—	CD	NUMBER	—	num	11	SENT_75	[p7l668t2863r974b2927],
13	774	CD	NUMBER	774	dep	11	SENT_75	[p7l668t2863r974b2927],
14	)	NN	O	)	dobj	2	SENT_75	[p7l668t2863r974b2927],
15	combined	VBN	O	combine	prep	2	SENT_75	[p7l997t2858r1315b2917],
16	with	IN	O	with	pcomp	15	SENT_75	[p7l1329t2858r1472b2918],
17	carboplatin	NN	O	carboplatin	pobj	16	SENT_75	[p7l1491t2858r1852b2934],
18	and	CC	O	and	_	0	SENT_75	[p7l1870t2858r1987b2917],
19	paclitaxel	NN	O	paclitaxel	conj_and	17	SENT_75	[p7l2004t2878r2138b2934, p7l8t2954r200b3013],
20	(	CD	NUMBER	(	num	23	SENT_75	[p7l229t2959r360b3023],
21	CP	NN	MISC	cp	nn	23	SENT_75	[p7l229t2959r360b3023],
22	)	NN	O	)	nn	23	SENT_75	[p7l229t2959r360b3023],
23	chemotherapy	NN	O	chemotherapy	dep	31	SENT_75	[p7l390t2955r847b3030],
24	in	IN	O	in	_	0	SENT_75	[p7l869t2955r931b3012],
25	advanced	JJ	O	advanced	amod	27	SENT_75	[p7l957t2954r1252b3014],
26	non	JJ	O	non	amod	27	SENT_75	[p7l1278t2954r1604b3013],
27	—	NN	O	—	prep_in	23	SENT_75	[p7l1278t2954r1604b3013],
28	small	JJ	O	small	amod	29	SENT_75	[p7l1278t2954r1604b3013],
29	cell	NN	O	cell	dep	31	SENT_75	[p7l1631t2954r1738b3013],
30	lung	NN	O	lung	nn	31	SENT_75	[p7l1763t2954r1909b3030],
31	cancer	NN	O	cancer	dep	34	SENT_75	[p7l1934t2973r2141b3013],
32	(	CD	NUMBER	(	num	33	SENT_75	[p7l13t3054r90b3117],
33	N	NN	O	n	dep	31	SENT_75	[p7l13t3054r90b3117],
34	SCLC	NN	O	sclc	dep	17	SENT_75	[p7l94t3054r309b3117],
35	)	CD	NUMBER	)	num	34	SENT_75	[p7l94t3054r309b3117],
36	.	.	O	.	_	0	SENT_75	[p7l94t3054r309b3117],

1	Proc	NNP	O	Proc	nn	5	SENT_76	[p7l331t3054r472b3108],
2	Am	NNP	O	Am	nn	5	SENT_76	[p7l487t3055r600b3107],
3	Soc	NNP	O	Soc	nn	5	SENT_76	[p7l620t3054r730b3108],
4	Clin	NNP	O	Clin	nn	5	SENT_76	[p7l748t3049r878b3108],
5	Oncol	NNP	O	Oncol	_	0	SENT_76	[p7l897t3050r1088b3108],
6	2004	CD	DATE	2004	num	5	SENT_76	[p7l1106t3054r1522b3121],
7	;	:	O	;	_	0	SENT_76	[p7l1106t3054r1522b3121],
8	23:617	CD	NUMBER	23:617	dep	5	SENT_76	[p7l1106t3054r1522b3121],
9	.	.	O	.	_	0	SENT_76	[p7l1106t3054r1522b3121],

1	abstract	JJ	O	abstract	_	0	SENT_77	[p7l1545t3050r1813b3108],
2	.	.	O	.	_	0	SENT_77	[p7l1545t3050r1813b3108],

1	5	CD	NUMBER	5	_	0	SENT_78	[p7l10t3153r60b3204],
2	.	.	O	.	_	0	SENT_78	[p7l10t3153r60b3204],

1	Shepherd	NNP	ORGANIZATION	Shepherd	nn	2	SENT_79	[p7l140t3145r441b3220],
2	FA	NNP	ORGANIZATION	FA	_	0	SENT_79	[p7l456t3151r554b3217],
3	,	,	O	,	_	0	SENT_79	[p7l456t3151r554b3217],
4	PereiraJR	NNP	O	PereiraJR	appos	2	SENT_79	[p7l572t3146r893b3218],
5	,	,	O	,	_	0	SENT_79	[p7l572t3146r893b3218],
6	Ciuleanu	NNP	ORGANIZATION	Ciuleanu	nn	7	SENT_79	[p7l913t3145r1197b3205],
7	T	NN	ORGANIZATION	t	appos	2	SENT_79	[p7l1209t3150r1264b3217],
8	,	,	O	,	_	0	SENT_79	[p7l1209t3150r1264b3217],
9	et	FW	O	et	nn	10	SENT_79	[p7l1284t3158r1342b3204],
10	al.	FW	O	al.	appos	2	SENT_79	[p7l1354t3145r1424b3205],
11	.	.	O	.	_	0	SENT_79	[p7l1354t3145r1424b3205],

1	Erlotinib	NNP	O	Erlotinib	nsubj	4	SENT_80	[p7l1443t3145r1722b3205],
2	in	IN	O	in	prep	1	SENT_80	[p7l1739t3146r1800b3203],
3	previously	RB	DATE	previously	pcomp	2	SENT_80	[p7l1814t3145r2140b3220],
4	treated	VBN	O	treat	_	0	SENT_80	[p7l9t3241r227b3300],
5	non	JJ	O	non	amod	8	SENT_80	[p7l245t3241r720b3300],
6	—	JJ	O	—	amod	8	SENT_80	[p7l245t3241r720b3300],
7	small	JJ	O	small	amod	8	SENT_80	[p7l245t3241r720b3300],
8	—	NN	O	—	tmod	4	SENT_80	[p7l245t3241r720b3300],
9	cell	NN	O	cell	nn	11	SENT_80	[p7l245t3241r720b3300],
10	lung	NN	O	lung	nn	11	SENT_80	[p7l737t3242r884b3317],
11	cancer	NN	O	cancer	dep	8	SENT_80	[p7l900t3261r1118b3300],
12	.	.	O	.	_	0	SENT_80	[p7l900t3261r1118b3300],

1	N	NN	O	n	nn	2	SENT_81	[p7l1139t3247r1195b3300],
2	EnglJ	NN	O	englj	nsubj	3	SENT_81	[p7l1212t3242r1397b3317],
3	Med	VBD	O	med	_	0	SENT_81	[p7l1412t3241r1552b3300],
4	2005	CD	DATE	2005	dobj	3	SENT_81	[p7l1571t3246r2132b3312],
5	;	:	O	;	_	0	SENT_81	[p7l1571t3246r2132b3312],
6	353:123	CD	NUMBER	353:123	number	7	SENT_81	[p7l1571t3246r2132b3312],
7	—	CD	NUMBER	—	dep	4	SENT_81	[p7l1571t3246r2132b3312],
8	32	CD	NUMBER	32	dep	7	SENT_81	[p7l1571t3246r2132b3312],
9	.	.	O	.	_	0	SENT_81	[p7l1571t3246r2132b3312],

1	6	CD	NUMBER	6	_	0	SENT_82	[p7l9t3344r60b3396],
2	.	.	O	.	_	0	SENT_82	[p7l9t3344r60b3396],

1	Tsao	NNP	PERSON	Tsao	nsubj	2	SENT_83	[p7l136t3342r285b3396],
2	M	NN	O	m	_	0	SENT_83	[p7l299t3342r446b3409],
3	.	.	O	.	_	0	SENT_83	[p7l299t3342r446b3409],

1	—	NN	O	—	_	0	SENT_84	[p7l299t3342r446b3409],
2	.	.	O	.	_	0	SENT_84	[p7l299t3342r446b3409],

1	S	NN	O	s	_	0	SENT_85	[p7l299t3342r446b3409],
2	,	,	O	,	_	0	SENT_85	[p7l299t3342r446b3409],
3	Sakurada	NNP	ORGANIZATION	Sakurada	nn	4	SENT_85	[p7l468t3337r760b3397],
4	A	NNP	ORGANIZATION	A	appos	1	SENT_85	[p7l773t3343r837b3409],
5	,	,	O	,	_	0	SENT_85	[p7l773t3343r837b3409],
6	Cutz	NNP	O	Cutz	nn	7	SENT_85	[p7l858t3342r1003b3396],
7	J	NNP	O	J	appos	4	SENT_85	[p7l1012t3342r1131b3409],
8	.	.	O	.	_	0	SENT_85	[p7l1012t3342r1131b3409],

1	—	NN	O	—	_	0	SENT_86	[p7l1012t3342r1131b3409],
2	.	.	O	.	_	0	SENT_86	[p7l1012t3342r1131b3409],

1	C	NN	O	c	_	0	SENT_87	[p7l1012t3342r1131b3409],
2	,	,	O	,	_	0	SENT_87	[p7l1012t3342r1131b3409],
3	et	FW	O	et	nn	4	SENT_87	[p7l1151t3350r1209b3396],
4	al.	FW	O	al.	appos	1	SENT_87	[p7l1221t3337r1291b3396],
5	.	.	O	.	_	0	SENT_87	[p7l1221t3337r1291b3396],

1	Erlotinib	NNP	O	Erlotinib	_	0	SENT_88	[p7l1311t3337r1590b3396],
2	in	IN	O	in	_	0	SENT_88	[p7l1607t3338r1668b3395],
3	lung	NN	O	lung	nn	4	SENT_88	[p7l1683t3337r1829b3413],
4	cancer	NN	O	cancer	prep_in	1	SENT_88	[p7l1842t3356r2049b3396],
5	—	CD	NUMBER	—	number	6	SENT_88	[p7l2060t3371r2141b3377],
6	molecular	JJ	O	molecular	dep	1	SENT_88	[p7l9t3433r329b3493],
7	and	CC	O	and	_	0	SENT_88	[p7l352t3433r468b3492],
8	clinical	JJ	O	clinical	amod	9	SENT_88	[p7l495t3433r720b3492],
9	predictors	NNS	O	predictor	dep	1	SENT_88	[p7l744t3433r1066b3509],
10	of	IN	O	of	_	0	SENT_88	[p7l1093t3433r1169b3492],
11	outcome	NN	O	outcome	prep_of	6	SENT_88	[p7l1181t3446r1475b3493],
12	.	.	O	.	_	0	SENT_88	[p7l1181t3446r1475b3493],

1	N	NN	O	n	nn	2	SENT_89	[p7l1502t3439r1559b3492],
2	EnglJ	NN	O	englj	nsubj	3	SENT_89	[p7l1582t3433r1774b3509],
3	Med	VBD	O	med	_	0	SENT_89	[p7l1795t3433r1935b3492],
4	2005	CD	DATE	2005	dobj	3	SENT_89	[p7l1961t3438r2135b3504],
5	;	:	O	;	_	0	SENT_89	[p7l1961t3438r2135b3504],
6	353:133	CD	NUMBER	353:133	number	7	SENT_89	[p7l10t3534r389b3588],
7	—	CD	NUMBER	—	dep	4	SENT_89	[p7l10t3534r389b3588],
8	44	CD	NUMBER	44	dep	7	SENT_89	[p7l10t3534r389b3588],
9	.	.	O	.	_	0	SENT_89	[p7l10t3534r389b3588],

1	7	CD	NUMBER	7	_	0	SENT_90	[p8l11t33r60b84],
2	.	.	O	.	_	0	SENT_90	[p8l11t33r60b84],

1	Lynch	NNP	PERSON	Lynch	nn	2	SENT_91	[p8l137t25r327b100],
2	TJ	NNP	PERSON	TJ	_	0	SENT_91	[p8l344t30r428b97],
3	,	,	O	,	_	0	SENT_91	[p8l344t30r428b97],
4	Bell	NNP	ORGANIZATION	Bell	nn	5	SENT_91	[p8l451t25r571b84],
5	DW	NNP	ORGANIZATION	DW	appos	2	SENT_91	[p8l589t30r719b97],
6	,	,	O	,	_	0	SENT_91	[p8l589t30r719b97],
7	Sordella	NNP	PERSON	Sordella	nn	8	SENT_91	[p8l745t25r1002b84],
8	R	NNP	PERSON	R	appos	2	SENT_91	[p8l1019t30r1084b97],
9	,	,	O	,	_	0	SENT_91	[p8l1019t30r1084b97],
10	et	FW	O	et	nn	11	SENT_91	[p8l1108t38r1167b84],
11	al.	FW	O	al.	appos	2	SENT_91	[p8l1182t25r1252b84],
12	.	.	O	.	_	0	SENT_91	[p8l1182t25r1252b84],

1	Activating	VBG	O	activate	amod	2	SENT_92	[p8l1274t26r1598b101],
2	mutations	NNS	O	mutation	_	0	SENT_92	[p8l1615t26r1938b84],
3	in	IN	O	in	_	0	SENT_92	[p8l1958t26r2019b83],
4	the	DT	O	the	det	7	SENT_92	[p8l2039t25r2137b84],
5	epidermal	JJ	O	epidermal	amod	7	SENT_92	[p8l10t121r330b197],
6	growth	NN	O	growth	nn	7	SENT_92	[p8l371t121r599b197],
7	factor	NN	O	factor	prep_in	2	SENT_92	[p8l640t121r825b180],
8	receptor	NN	O	receptor	nn	10	SENT_92	[p8l864t134r1129b197],
9	underlying	VBG	O	underlie	amod	10	SENT_92	[p8l1168t121r1514b197],
10	responsiveness	NN	O	responsiveness	dep	2	SENT_92	[p8l1553t122r2032b197],
11	of	IN	O	of	_	0	SENT_92	[p8l2076t121r2152b180],
12	non	JJ	O	non	amod	18	SENT_92	[p8l9t217r484b276],
13	—	JJ	O	—	amod	18	SENT_92	[p8l9t217r484b276],
14	small	JJ	O	small	amod	18	SENT_92	[p8l9t217r484b276],
15	—	NN	O	—	nn	18	SENT_92	[p8l9t217r484b276],
16	cell	NN	O	cell	nn	18	SENT_92	[p8l9t217r484b276],
17	lung	NN	O	lung	nn	18	SENT_92	[p8l514t218r660b293],
18	cancer	NN	O	cancer	prep_of	10	SENT_92	[p8l690t236r896b276],
19	to	TO	O	to	_	0	SENT_92	[p8l926t230r986b276],
20	geﬁtinib	NN	O	geﬁtinib	prep_to	10	SENT_92	[p8l1018t217r1302b293],
21	.	.	O	.	_	0	SENT_92	[p8l1018t217r1302b293],

1	N	NN	O	n	nn	3	SENT_93	[p8l1337t223r1393b276],
2	Engl	NNP	O	Engl	nn	3	SENT_93	[p8l1422t218r1568b293],
3	J	NNP	O	J	nsubj	4	SENT_93	[p8l1591t223r1620b286],
4	Med	VBD	O	med	_	0	SENT_93	[p8l1648t217r1788b276],
5	2004	CD	DATE	2004	dobj	4	SENT_93	[p8l1820t222r2135b289],
6	;	:	O	;	_	0	SENT_93	[p8l1820t222r2135b289],
7	350	CD	NUMBER	350	num	9	SENT_93	[p8l1820t222r2135b289],
8	:	:	O	:	_	0	SENT_93	[p8l1820t222r2135b289],
9	2129-39	CD	NUMBER	2129-39	dep	5	SENT_93	[p8l9t318r288b372],
10	.	.	O	.	_	0	SENT_93	[p8l9t318r288b372],

1	8	CD	NUMBER	8	_	0	SENT_94	[p8l6t415r58b469],
2	.	.	O	.	_	0	SENT_94	[p8l6t415r58b469],

1	Paez	NNP	PERSON	Paez	nn	2	SENT_95	[p8l136t414r280b469],
2	JG	NNP	O	JG	_	0	SENT_95	[p8l291t414r393b482],
3	,	,	O	,	_	0	SENT_95	[p8l291t414r393b482],
4	Janne	NNP	PERSON	Janne	nn	5	SENT_95	[p8l408t415r591b478],
5	PA	NN	PERSON	pa	appos	2	SENT_95	[p8l609t414r710b482],
6	,	,	O	,	_	0	SENT_95	[p8l609t414r710b482],
7	Lee	NNP	PERSON	Lee	nn	8	SENT_95	[p8l731t415r838b469],
8	JC	NNP	PERSON	JC	appos	2	SENT_95	[p8l848t414r942b482],
9	,	,	O	,	_	0	SENT_95	[p8l848t414r942b482],
10	et	FW	O	et	nn	11	SENT_95	[p8l965t422r1023b469],
11	al.	FW	O	al.	appos	2	SENT_95	[p8l1037t409r1108b469],
12	.	.	O	.	_	0	SENT_95	[p8l1037t409r1108b469],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_96	[p8l1129t414r1325b473],
2	mutations	NNS	O	mutation	_	0	SENT_96	[p8l1336t410r1660b469],
3	in	IN	O	in	_	0	SENT_96	[p8l1679t410r1741b468],
4	lung	NN	O	lung	nn	5	SENT_96	[p8l1758t409r1905b486],
5	cancer	NN	O	cancer	prep_in	2	SENT_96	[p8l1921t428r2146b469],
6	:	:	O	:	_	0	SENT_96	[p8l1921t428r2146b469],
7	correlation	NN	O	correlation	dep	2	SENT_96	[p8l7t506r356b566],
8	with	IN	O	with	_	0	SENT_96	[p8l370t507r513b566],
9	clinical	JJ	O	clinical	amod	10	SENT_96	[p8l531t506r759b566],
10	response	NN	O	response	prep_with	7	SENT_96	[p8l776t526r1062b583],
11	to	TO	O	to	_	0	SENT_96	[p8l1080t519r1140b566],
12	geﬁtinib	NN	O	geﬁtinib	nn	13	SENT_96	[p8l1159t506r1427b583],
13	therapy	NN	O	therapy	prep_to	10	SENT_96	[p8l1446t507r1693b583],
14	.	.	O	.	_	0	SENT_96	[p8l1446t507r1693b583],

1	Science	NNP	O	Science	_	0	SENT_97	[p8l1716t507r1953b566],
2	2004	CD	DATE	2004	num	1	SENT_97	[p8l1970t511r2146b579],
3	;	:	O	;	_	0	SENT_97	[p8l1970t511r2146b579],
4	304:1497	CD	NUMBER	304:1497	number	5	SENT_97	[p8l7t608r470b663],
5	—	CD	NUMBER	—	dep	1	SENT_97	[p8l7t608r470b663],
6	500	CD	NUMBER	500	dep	5	SENT_97	[p8l7t608r470b663],
7	.	.	O	.	_	0	SENT_97	[p8l7t608r470b663],

1	9	CD	NUMBER	9	_	0	SENT_98	[p8l6t707r58b760],
2	.	.	O	.	_	0	SENT_98	[p8l6t707r58b760],

1	Pao	NNP	O	Pao	nn	2	SENT_99	[p8l136t705r249b760],
2	W	NNP	O	W	_	0	SENT_99	[p8l268t706r348b773],
3	,	,	O	,	_	0	SENT_99	[p8l268t706r348b773],
4	Miller	NNP	PERSON	Miller	nn	5	SENT_99	[p8l371t700r564b760],
5	VA.	NNP	O	VA.	appos	2	SENT_99	[p8l579t706r685b760],
6	.	.	O	.	_	0	SENT_99	[p8l579t706r685b760],

1	Epidermal	JJ	O	epidermal	amod	5	SENT_100	[p8l709t700r1041b776],
2	growth	NN	O	growth	nn	5	SENT_100	[p8l1062t700r1291b777],
3	factor	NN	O	factor	nn	5	SENT_100	[p8l1311t700r1498b760],
4	receptor	NN	O	receptor	nn	5	SENT_100	[p8l1516t713r1782b776],
5	mutations	NNS	O	mutation	_	0	SENT_100	[p8l1800t701r2145b773],
6	,	,	O	,	_	0	SENT_100	[p8l1800t701r2145b773],
7	small	JJ	O	small	amod	11	SENT_100	[p8l8t797r500b857],
8	—	NN	O	—	nn	11	SENT_100	[p8l8t797r500b857],
9	molecule	NN	O	molecule	nn	11	SENT_100	[p8l8t797r500b857],
10	kinase	NN	O	kinase	nn	11	SENT_100	[p8l526t798r730b857],
11	inhibitors	NNS	O	inhibitor	conj_and	5	SENT_100	[p8l756t798r1089b870],
12	,	,	O	,	_	0	SENT_100	[p8l756t798r1089b870],
13	and	CC	O	and	_	0	SENT_100	[p8l1119t797r1236b857],
14	non	JJ	O	non	amod	20	SENT_100	[p8l1262t797r1726b857],
15	—	JJ	O	—	amod	20	SENT_100	[p8l1262t797r1726b857],
16	small	JJ	O	small	amod	20	SENT_100	[p8l1262t797r1726b857],
17	—	NN	O	—	nn	20	SENT_100	[p8l1262t797r1726b857],
18	cell	NN	O	cell	nn	20	SENT_100	[p8l1262t797r1726b857],
19	lung	NN	O	lung	nn	20	SENT_100	[p8l1752t797r1898b874],
20	cancer	NN	O	cancer	conj_and	5	SENT_100	[p8l1922t817r2147b857],
21	:	:	O	:	_	0	SENT_100	[p8l1922t817r2147b857],
22	current	JJ	DATE	current	amod	23	SENT_100	[p8l7t907r240b954],
23	knowledge	NN	O	knowledge	dep	5	SENT_100	[p8l273t894r624b971],
24	and	CC	O	and	_	0	SENT_100	[p8l660t894r777b954],
25	future	JJ	DATE	future	amod	26	SENT_100	[p8l814t894r1005b954],
26	directions	NNS	O	direction	dep	5	SENT_100	[p8l1042t894r1378b954],
27	.	.	O	.	_	0	SENT_100	[p8l1042t894r1378b954],

1	J	NNP	O	J	nn	3	SENT_101	[p8l1410t900r1439b963],
2	Clin	NNP	O	Clin	nn	3	SENT_101	[p8l1474t894r1604b954],
3	Oncol	NNP	O	Oncol	_	0	SENT_101	[p8l1641t895r1833b954],
4	2005	CD	DATE	2005	num	3	SENT_101	[p8l1869t899r2147b967],
5	;	:	O	;	_	0	SENT_101	[p8l1869t899r2147b967],
6	23	CD	NUMBER	23	num	8	SENT_101	[p8l1869t899r2147b967],
7	:	:	O	:	_	0	SENT_101	[p8l1869t899r2147b967],
8	2556-68	CD	NUMBER	2556-68	dep	3	SENT_101	[p8l7t996r287b1051],
9	.	.	O	.	_	0	SENT_101	[p8l7t996r287b1051],

1	10	CD	NUMBER	10	_	0	SENT_102	[p8l10t1094r96b1148],
2	.	.	O	.	_	0	SENT_102	[p8l10t1094r96b1148],

1	Cappuzzo	NNP	PERSON	Cappuzzo	nn	2	SENT_103	[p8l137t1093r457b1164],
2	F	NN	O	f	_	0	SENT_103	[p8l478t1094r525b1161],
3	,	,	O	,	_	0	SENT_103	[p8l478t1094r525b1161],
4	Hirsch	NNP	PERSON	Hirsch	nn	5	SENT_103	[p8l550t1088r765b1148],
5	FR	NN	O	fr	appos	2	SENT_103	[p8l785t1093r890b1161],
6	,	,	O	,	_	0	SENT_103	[p8l785t1093r890b1161],
7	Rossi	NNP	PERSON	Rossi	nn	8	SENT_103	[p8l914t1089r1089b1152],
8	E	NNP	O	E	appos	2	SENT_103	[p8l1109t1094r1167b1161],
9	,	,	O	,	_	0	SENT_103	[p8l1109t1094r1167b1161],
10	et	FW	O	et	nn	11	SENT_103	[p8l1193t1101r1251b1148],
11	al.	FW	O	al.	appos	2	SENT_103	[p8l1268t1088r1339b1148],
12	.	.	O	.	_	0	SENT_103	[p8l1268t1088r1339b1148],

1	Epidermal	JJ	O	epidermal	amod	3	SENT_104	[p8l1363t1088r1695b1164],
2	growth	NN	O	growth	nn	3	SENT_104	[p8l1716t1088r1945b1165],
3	factor	NN	O	factor	_	0	SENT_104	[p8l1966t1088r2153b1148],
4	receptor	NN	O	receptor	nn	5	SENT_104	[p8l7t1198r273b1262],
5	gene	NN	O	gene	dep	3	SENT_104	[p8l289t1205r440b1262],
6	and	CC	O	and	_	0	SENT_104	[p8l459t1185r577b1245],
7	protein	NN	O	protein	nn	10	SENT_104	[p8l595t1186r827b1262],
8	and	CC	O	and	_	0	SENT_104	[p8l846t1186r963b1245],
9	geﬁtinib	NN	O	geﬁtinib	nn	10	SENT_104	[p8l982t1185r1251b1262],
10	sensitivity	NN	O	sensitivity	dep	3	SENT_104	[p8l1272t1186r1590b1262],
11	in	IN	O	in	_	0	SENT_104	[p8l1605t1186r1667b1244],
12	non	JJ	O	non	amod	18	SENT_104	[p8l1686t1185r2150b1245],
13	—	JJ	O	—	amod	18	SENT_104	[p8l1686t1185r2150b1245],
14	small	JJ	O	small	amod	18	SENT_104	[p8l1686t1185r2150b1245],
15	—	NN	O	—	nn	18	SENT_104	[p8l1686t1185r2150b1245],
16	cell	NN	O	cell	nn	18	SENT_104	[p8l1686t1185r2150b1245],
17	lung	NN	O	lung	nn	18	SENT_104	[p8l6t1282r153b1359],
18	cancer	NN	O	cancer	prep_in	3	SENT_104	[p8l170t1302r390b1342],
19	.	.	O	.	_	0	SENT_104	[p8l170t1302r390b1342],

1	J	NNP	O	J	nn	4	SENT_105	[p8l405t1288r434b1351],
2	Natl	NNP	O	Natl	nn	4	SENT_105	[p8l449t1282r585b1342],
3	Cancer	NNP	O	Cancer	nn	4	SENT_105	[p8l604t1287r828b1342],
4	Inst	NNP	O	Inst	_	0	SENT_105	[p8l843t1288r970b1342],
5	2005	CD	DATE	2005	num	4	SENT_105	[p8l985t1287r1139b1342],
6	;	:	O	;	_	0	SENT_105	[p8l1149t1287r1449b1355],
7	97:643	CD	NUMBER	97:643	number	8	SENT_105	[p8l1149t1287r1449b1355],
8	-5	CD	NUMBER	-5	dep	4	SENT_105	[p8l1149t1287r1449b1355],
9	5	CD	NUMBER	5	dep	8	SENT_105	[p8l1457t1288r1509b1342],
10	.	.	O	.	_	0	SENT_105	[p8l1457t1288r1509b1342],

1	11	CD	NUMBER	11	_	0	SENT_106	[p8l10t1387r96b1439],
2	.	.	O	.	_	0	SENT_106	[p8l10t1387r96b1439],

1	Engelman	NNP	PERSON	Engelman	nn	2	SENT_107	[p8l136t1379r462b1456],
2	JA	NNP	O	JA	_	0	SENT_107	[p8l473t1385r565b1452],
3	,	,	O	,	_	0	SENT_107	[p8l473t1385r565b1452],
4	Janne	NNP	PERSON	Janne	nn	5	SENT_107	[p8l581t1385r764b1448],
5	PA	NN	PERSON	pa	appos	2	SENT_107	[p8l782t1384r882b1452],
6	,	,	O	,	_	0	SENT_107	[p8l782t1384r882b1452],
7	Mermel	NNP	PERSON	Mermel	nn	8	SENT_107	[p8l903t1379r1152b1439],
8	C	NNP	O	C	appos	2	SENT_107	[p8l1170t1384r1233b1452],
9	,	,	O	,	_	0	SENT_107	[p8l1170t1384r1233b1452],
10	et	FW	O	et	nn	11	SENT_107	[p8l1257t1392r1314b1439],
11	al.	FW	O	al.	appos	2	SENT_107	[p8l1328t1379r1400b1439],
12	.	.	O	.	_	0	SENT_107	[p8l1328t1379r1400b1439],

1	ErbB-3	NN	O	erbb-3	nsubj	2	SENT_108	[p8l1421t1379r1642b1439],
2	mediates	VBZ	O	mediate	_	0	SENT_108	[p8l1662t1379r1948b1439],
3	phosphoinositide	JJ	O	phosphoinositide	acomp	2	SENT_108	[p8l1967t1379r2149b1455, p8l6t1476r411b1553],
4	3	CD	NUMBER	3	num	7	SENT_108	[p8l442t1477r712b1537],
5	—	NN	O	—	nn	7	SENT_108	[p8l442t1477r712b1537],
6	kinase	NN	O	kinase	nn	7	SENT_108	[p8l442t1477r712b1537],
7	activity	NN	O	activity	dep	3	SENT_108	[p8l742t1477r966b1553],
8	in	IN	O	in	_	0	SENT_108	[p8l992t1477r1054b1535],
9	gefitinib-sensitive	JJ	O	gefitinib-sensitive	amod	15	SENT_108	[p8l1084t1476r1655b1553],
10	non-small	JJ	O	non-small	amod	15	SENT_108	[p8l1686t1476r2014b1536],
11	cell	NN	O	cell	nn	15	SENT_108	[p8l2043t1476r2151b1536],
12	lung	NN	O	lung	nn	15	SENT_108	[p8l6t1573r153b1650],
13	cancer	NN	O	cancer	nn	15	SENT_108	[p8l170t1593r378b1633],
14	cell	NN	O	cell	nn	15	SENT_108	[p8l395t1573r502b1633],
15	lines	NNS	O	line	prep_in	7	SENT_108	[p8l520t1573r688b1633],
16	.	.	O	.	_	0	SENT_108	[p8l520t1573r688b1633],

1	Proc	NNP	ORGANIZATION	Proc	nn	7	SENT_109	[p8l710t1578r852b1633],
2	Natl	NNP	ORGANIZATION	Natl	nn	7	SENT_109	[p8l868t1573r1005b1633],
3	Acad	NNP	ORGANIZATION	Acad	nn	7	SENT_109	[p8l1020t1573r1180b1633],
4	Sci	NNP	ORGANIZATION	Sci	nn	7	SENT_109	[p8l1200t1574r1290b1633],
5	U	NNP	ORGANIZATION	U	nn	7	SENT_109	[p8l1307t1579r1360b1633],
6	S	NNP	ORGANIZATION	S	nn	7	SENT_109	[p8l1379t1578r1412b1633],
7	A	NNP	O	A	_	0	SENT_109	[p8l1430t1579r1479b1632],
8	2005	CD	DATE	2005	num	7	SENT_109	[p8l1496t1578r2101b1646],
9	;	:	O	;	_	0	SENT_109	[p8l1496t1578r2101b1646],
10	102:3788	CD	NUMBER	102:3788	number	11	SENT_109	[p8l1496t1578r2101b1646],
11	—	CD	NUMBER	—	dep	7	SENT_109	[p8l1496t1578r2101b1646],
12	93	CD	NUMBER	93	dep	11	SENT_109	[p8l1496t1578r2101b1646],
13	.	.	O	.	_	0	SENT_109	[p8l1496t1578r2101b1646],

1	12	CD	NUMBER	12	_	0	SENT_110	[p8l10t1677r96b1729],
2	.	.	O	.	_	0	SENT_110	[p8l10t1677r96b1729],

1	Slamon	NNP	PERSON	Slamon	nn	2	SENT_111	[p8l139t1669r380b1729],
2	DJ	NNP	O	DJ	_	0	SENT_111	[p8l397t1674r490b1741],
3	,	,	O	,	_	0	SENT_111	[p8l397t1674r490b1741],
4	Leyland	NNP	PERSON	Leyland	appos	2	SENT_111	[p8l512t1669r958b1744],
5	.	.	O	.	_	0	SENT_111	[p8l512t1669r958b1744],

1	—	NN	O	—	_	0	SENT_112	[p8l512t1669r958b1744],
2	.	.	O	.	_	0	SENT_112	[p8l512t1669r958b1744],

1	Jones	NNP	PERSON	Jones	nn	2	SENT_113	[p8l512t1669r958b1744],
2	B	NNP	O	B	_	0	SENT_113	[p8l976t1674r1038b1741],
3	,	,	O	,	_	0	SENT_113	[p8l976t1674r1038b1741],
4	Shak	NNP	PERSON	Shak	nn	5	SENT_113	[p8l1062t1669r1219b1729],
5	S	NNP	O	S	appos	2	SENT_113	[p8l1236t1674r1288b1741],
6	,	,	O	,	_	0	SENT_113	[p8l1236t1674r1288b1741],
7	et	FW	O	et	nn	8	SENT_113	[p8l1311t1682r1369b1728],
8	al.	FW	O	al.	appos	5	SENT_113	[p8l1383t1669r1454b1729],
9	.	.	O	.	_	0	SENT_113	[p8l1383t1669r1454b1729],

1	Use	NN	O	use	_	0	SENT_114	[p8l1476t1675r1595b1729],
2	of	IN	O	of	_	0	SENT_114	[p8l1614t1669r1690b1729],
3	chemotherapy	NN	O	chemotherapy	prep_of	1	SENT_114	[p8l1695t1669r2154b1744],
4	plus	CC	O	plus	prep	1	SENT_114	[p8l6t1767r139b1843],
5	a	DT	O	a	det	7	SENT_114	[p8l157t1787r191b1826],
6	monoclonal	JJ	O	monoclonal	amod	7	SENT_114	[p8l206t1767r591b1826],
7	antibody	NN	O	antibody	dep	4	SENT_114	[p8l606t1766r887b1843],
8	against	IN	O	against	_	0	SENT_114	[p8l899t1767r1134b1843],
9	HER2	NN	O	her2	prep_against	1	SENT_114	[p8l1146t1771r1334b1830],
10	for	IN	O	for	_	0	SENT_114	[p8l1351t1766r1444b1826],
11	metastatic	JJ	O	metastatic	amod	13	SENT_114	[p8l1458t1767r1789b1826],
12	breast	NN	O	breast	nn	13	SENT_114	[p8l1804t1767r2001b1826],
13	cancer	NN	O	cancer	prep_for	1	SENT_114	[p8l2014t1786r2148b1826, p8l7t1884r102b1923],
14	that	WDT	O	that	nsubj	15	SENT_114	[p8l119t1864r245b1923],
15	overexpresses	VBZ	O	overexpress	rcmod	13	SENT_114	[p8l261t1883r701b1940],
16	HER2	NN	O	her2	dobj	15	SENT_114	[p8l721t1868r927b1927],
17	.	.	O	.	_	0	SENT_114	[p8l721t1868r927b1927],

1	N	NN	O	n	nn	2	SENT_115	[p8l949t1869r1006b1923],
2	EnglJ	NN	O	englj	nsubj	3	SENT_115	[p8l1022t1863r1208b1940],
3	Med	VBD	O	med	_	0	SENT_115	[p8l1223t1863r1365b1923],
4	2001	CD	DATE	2001	dobj	3	SENT_115	[p8l1383t1868r1948b1936],
5	;	:	O	;	_	0	SENT_115	[p8l1383t1868r1948b1936],
6	344:783	CD	NUMBER	344:783	number	7	SENT_115	[p8l1383t1868r1948b1936],
7	—	CD	NUMBER	—	dep	4	SENT_115	[p8l1383t1868r1948b1936],
8	92	CD	NUMBER	92	dep	7	SENT_115	[p8l1383t1868r1948b1936],
9	.	.	O	.	_	0	SENT_115	[p8l1383t1868r1948b1936],

1	Copyright	NN	O	copyright	_	0	SENT_116	[p8l9t1950r249b2015],
2	©	CD	NUMBER	©	num	6	SENT_116	[p8l271t1955r325b2009],
3	2005	CD	DATE	2005	num	6	SENT_116	[p8l349t1953r476b1999],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_116	[p8l496t1950r860b1999],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_116	[p8l881t1950r1082b1999],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_116	[p8l1099t1952r1283b2014],
7	.	.	O	.	_	0	SENT_116	[p8l1099t1952r1283b2014],

1	Pacemaker	NN	O	pacemaker	nn	2	SENT_117	[p8l435t2091r722b2139],
2	Selection	NN	O	selection	_	0	SENT_117	[p8l738t2091r976b2139],
3	—	CD	NUMBER	—	nsubj	6	SENT_117	[p8l995t2120r1060b2126],
4	The	DT	O	the	det	6	SENT_117	[p8l1075t2091r1174b2139],
5	Changing	VBG	O	change	amod	6	SENT_117	[p8l1191t2091r1447b2154],
6	Deﬁnition	NN	O	deﬁnition	rcmod	2	SENT_117	[p8l1467t2090r1724b2139],
7	of	IN	O	of	_	0	SENT_117	[p8l797t2160r857b2209],
8	Physiologic	JJ	O	physiologic	amod	9	SENT_117	[p8l868t2161r1165b2224],
9	Pacing	NN	O	pacing	prep_of	6	SENT_117	[p8l1186t2162r1360b2224],

1	Kenneth	NNP	PERSON	Kenneth	nn	3	SENT_118	[p8l610t2240r745b2271],
2	A.	NNP	PERSON	A.	nn	3	SENT_118	[p8l759t2242r791b2271],
3	Ellenbogen	NNP	PERSON	Ellenbogen	_	0	SENT_118	[p8l808t2240r1003b2281],
4	,	,	O	,	_	0	SENT_118	[p8l808t2240r1003b2281],
5	M.D.	NNP	O	M.D.	conj_and	3	SENT_118	[p8l1020t2243r1110b2276],
6	,	,	O	,	_	0	SENT_118	[p8l1020t2243r1110b2276],
7	and	CC	O	and	_	0	SENT_118	[p8l1125t2240r1185b2271],
8	Mark	NNP	PERSON	Mark	nn	12	SENT_118	[p8l1202t2240r1286b2271],
9	A.	NNP	PERSON	A.	nn	12	SENT_118	[p8l1297t2242r1329b2271],
10	Wood	NNP	PERSON	Wood	nn	12	SENT_118	[p8l1342t2240r1449b2276],
11	,	,	O	,	_	0	SENT_118	[p8l1342t2240r1449b2276],
12	M.D.	NNP	O	M.D.	conj_and	3	SENT_118	[p8l1467t2243r1546b2271],

1	Almost	RB	O	almost	advmod	3	SENT_119	[p8l7t2408r319b2486],
2	50	CD	DURATION	50	num	3	SENT_119	[p8l349t2413r446b2486],
3	years	NNS	NUMBER	year	npadvmod	22	SENT_119	[p8l476t2434r690b2508],
4	after	IN	O	after	_	0	SENT_119	[p8l725t2407r918b2486],
5	the	DT	O	the	det	7	SENT_119	[p8l948t2408r1077b2486],
6	first	JJ	ORDINAL	first	amod	7	SENT_119	[p8l1110t2407r1283b2486],
7	report	NN	O	report	prep_after	22	SENT_119	[p8l1311t2424r1574b2508],
8	of	IN	O	of	_	0	SENT_119	[p8l1602t2407r1703b2486],
9	the	DT	O	the	det	10	SENT_119	[p8l1718t2408r1846b2486],
10	use	NN	O	use	prep_of	7	SENT_119	[p8l1880t2434r2019b2487],
11	of	IN	O	of	_	0	SENT_119	[p8l2053t2407r2153b2486],
12	cardiac	JJ	O	cardiac	amod	13	SENT_119	[p8l11t2536r311b2614],
13	pacing	NN	O	pacing	prep_of	10	SENT_119	[p8l334t2536r642b2636],
14	,	,	O	,	_	0	SENT_119	[p8l334t2536r642b2636],
15	in	IN	O	in	_	0	SENT_119	[p8l673t2536r753b2613],
16	the	DT	O	the	det	17	SENT_119	[p8l780t2535r1275b2636],
17	]	NN	O	]	prep_in	22	SENT_119	[p8l780t2535r1275b2636],
18	ournal	JJ	O	ournal	amod	20	SENT_119	[p8l780t2535r1275b2636],
19	,1	NN	O	,1	nn	20	SENT_119	[p8l780t2535r1275b2636],
20	pacing	NN	O	pacing	nsubj	22	SENT_119	[p8l1299t2536r1587b2636],
21	is	VBZ	O	be	aux	22	SENT_119	[p8l1608t2536r1673b2614],
22	playing	VBG	O	play	_	0	SENT_119	[p8l1699t2535r2012b2636],
23	an	DT	O	a	det	26	SENT_119	[p8l2034t2561r2134b2614],
24	increasingly	RB	O	increasingly	advmod	25	SENT_119	[p8l10t2664r524b2764],
25	important	JJ	O	important	amod	26	SENT_119	[p8l549t2664r982b2764],
26	role	NN	O	role	dobj	22	SENT_119	[p8l1006t2663r1167b2742],
27	in	IN	O	in	_	0	SENT_119	[p8l1196t2664r1277b2741],
28	the	DT	O	the	det	29	SENT_119	[p8l1308t2663r1436b2742],
29	management	NN	O	management	prep_in	26	SENT_119	[p8l1466t2680r2028b2764],
30	of	IN	O	of	_	0	SENT_119	[p8l2053t2663r2153b2742],
31	cardiac	JJ	O	cardiac	amod	32	SENT_119	[p8l11t2792r317b2870],
32	disease	NN	O	disease	prep_of	29	SENT_119	[p8l346t2792r681b2870],
33	.	.	O	.	_	0	SENT_119	[p8l346t2792r681b2870],

1	Cardiologists	NNS	MISC	cardiologist	nsubj	3	SENT_120	[p8l715t2791r1290b2892],
2	have	VBP	O	have	aux	3	SENT_120	[p8l1321t2792r1513b2871],
3	evaluated	VBN	O	evaluate	_	0	SENT_120	[p8l1543t2791r1944b2871],
4	single	JJ	O	single	amod	6	SENT_120	[p8l1974t2792r2132b2870, p8l10t2919r574b3020],
5	—	NN	O	—	nn	6	SENT_120	[p8l1974t2792r2132b2870, p8l10t2919r574b3020],
6	chamber	NN	O	chamber	dobj	3	SENT_120	[p8l1974t2792r2132b2870, p8l10t2919r574b3020],
7	,	,	O	,	_	0	SENT_120	[p8l1974t2792r2132b2870, p8l10t2919r574b3020],
8	dual	JJ	O	dual	amod	10	SENT_120	[p8l622t2920r1243b3015],
9	—	NN	O	—	nn	10	SENT_120	[p8l622t2920r1243b3015],
10	chamber	NN	O	chamber	dobj	3	SENT_120	[p8l622t2920r1243b3015],
11	,	,	O	,	_	0	SENT_120	[p8l622t2920r1243b3015],
12	and	CC	O	and	_	0	SENT_120	[p8l1290t2920r1447b2998],
13	triple	JJ	O	triple	amod	16	SENT_120	[p8l1489t2919r2136b3020],
14	—	NN	O	—	nn	16	SENT_120	[p8l1489t2919r2136b3020],
15	chamber	NN	O	chamber	nn	16	SENT_120	[p8l1489t2919r2136b3020],
16	pacemakers	NNS	O	pacemaker	conj_and	6	SENT_120	[p8l9t3048r521b3148],
17	in	IN	O	in	_	0	SENT_120	[p8l548t3048r628b3125],
18	patients	NNS	O	patient	prep_in	3	SENT_120	[p8l651t3048r985b3148],
19	with	IN	O	with	_	0	SENT_120	[p8l1006t3048r1196b3127],
20	different	JJ	O	different	amod	21	SENT_120	[p8l1220t3047r1587b3126],
21	types	NNS	O	type	prep_with	3	SENT_120	[p8l1605t3064r1817b3148],
22	of	IN	O	of	_	0	SENT_120	[p8l1843t3047r1944b3126],
23	conduction	NN	O	conduction	nn	26	SENT_120	[p8l1949t3073r2134b3126, p8l11t3176r674b3276],
24	—	NN	O	—	nn	26	SENT_120	[p8l1949t3073r2134b3126, p8l11t3176r674b3276],
25	system	NN	O	system	nn	26	SENT_120	[p8l1949t3073r2134b3126, p8l11t3176r674b3276],
26	disease	NN	O	disease	prep_of	21	SENT_120	[p8l730t3175r1039b3254],
27	and	CC	O	and	_	0	SENT_120	[p8l1094t3176r1251b3254],
28	underlying	VBG	O	underlie	amod	30	SENT_120	[p8l1306t3176r1776b3276],
29	cardiac	JJ	O	cardiac	amod	30	SENT_120	[p8l1828t3175r2134b3254],
30	function	NN	O	function	prep_of	21	SENT_120	[p8l10t3303r391b3383],
31	.	.	O	.	_	0	SENT_120	[p8l10t3303r391b3383],

1	The	DT	O	the	det	2	SENT_121	[p8l431t3304r593b3382],
2	goal	NN	O	goal	nsubj	9	SENT_121	[p8l631t3303r811b3404],
3	of	IN	O	of	_	0	SENT_121	[p8l850t3303r950b3382],
4	these	DT	O	these	det	8	SENT_121	[p8l971t3304r1189b3382],
5	increasingly	RB	O	increasingly	advmod	6	SENT_121	[p8l1228t3304r1742b3404],
6	complex	JJ	O	complex	amod	8	SENT_121	[p8l1777t3303r2138b3404],
7	pacing	NN	O	pacing	nn	8	SENT_121	[p8l9t3432r296b3532],
8	systems	NNS	O	system	prep_of	2	SENT_121	[p8l324t3448r653b3532],
9	is	VBZ	O	be	_	0	SENT_121	[p8l684t3432r749b3510],
10	to	TO	O	to	aux	11	SENT_121	[p8l781t3448r860b3510],
11	reproduce	VB	O	reproduce	xcomp	9	SENT_121	[p8l891t3431r1318b3532],
12	the	DT	O	the	det	15	SENT_121	[p8l1349t3432r1478b3510],
13	normal	JJ	O	normal	amod	15	SENT_121	[p8l1508t3431r1815b3510],
14	electrical	JJ	O	electrical	amod	15	SENT_121	[p8l1845t3432r2134b3510, p8l11t3559r126b3638],
15	activation	NN	O	activation	dobj	11	SENT_121	[p8l149t3560r557b3639],
16	of	IN	O	of	_	0	SENT_121	[p8l583t3559r684b3638],
17	the	DT	O	the	det	18	SENT_121	[p8l691t3560r819b3638],
18	heart	NN	O	heart	prep_of	15	SENT_121	[p8l845t3560r1082b3638],
19	.	.	O	.	_	0	SENT_121	[p8l845t3560r1082b3638],

1	Dual	JJ	O	dual	amod	4	SENT_122	[p8l138t3687r749b3767],
2	—	NN	O	—	nn	4	SENT_122	[p8l138t3687r749b3767],
3	chamber	NN	O	chamber	nn	4	SENT_122	[p8l138t3687r749b3767],
4	pacing	NN	O	pacing	nsubj	5	SENT_122	[p8l796t3688r1084b3788],
5	confers	VBZ	O	confer	_	0	SENT_122	[p8l1132t3687r1441b3766],
6	potentially	RB	O	potentially	advmod	7	SENT_122	[p8l1493t3687r1944b3788],
7	important	JJ	O	important	acomp	5	SENT_122	[p8l1990t3688r2134b3765, p9l9t37r328b121],

1	hemodynamic	JJ	O	hemodynamic	amod	2	SENT_123	[p9l352t21r955b121],
2	advantages	NNS	O	advantage	_	0	SENT_123	[p9l982t20r1450b121],
3	over	IN	O	over	_	0	SENT_123	[p9l1482t46r1659b100],
4	ventricular	JJ	O	ventricular	amod	5	SENT_123	[p9l1681t20r2138b100],
5	pacing	NN	O	pacing	prep_over	2	SENT_123	[p9l9t149r292b249],
6	by	IN	O	by	_	0	SENT_123	[p9l310t149r406b249],
7	linking	VBG	O	link	prepc_by	5	SENT_123	[p9l422t149r722b249],
8	the	DT	O	the	det	9	SENT_123	[p9l740t149r868b227],
9	timing	NN	O	timing	dobj	7	SENT_123	[p9l890t149r1169b249],
10	of	IN	O	of	_	0	SENT_123	[p9l1188t148r1287b227],
11	atrial	JJ	O	atrial	amod	14	SENT_123	[p9l1290t148r1500b227],
12	and	CC	O	and	_	0	SENT_123	[p9l1519t148r1673b227],
13	ventricular	JJ	O	ventricular	conj_and	11	SENT_123	[p9l1690t148r2139b228],
14	contraction	NN	O	contraction	prep_of	2	SENT_123	[p9l11t277r517b372],
15	,	,	O	,	_	0	SENT_123	[p9l11t277r517b372],
16	a	DT	O	a	det	17	SENT_123	[p9l549t303r593b355],
17	phenomenon	NN	O	phenomenon	appos	14	SENT_123	[p9l618t277r1189b377],
18	called	VBN	O	call	partmod	2	SENT_123	[p9l1217t277r1460b355],
19	atrioventricular	JJ	O	atrioventricular	amod	20	SENT_123	[p9l1487t276r2138b356],
20	synchrony	NN	O	synchrony	dobj	18	SENT_123	[p9l12t404r506b505],
21	?	.	O	?	_	0	SENT_123	[p9l12t404r506b505],

1	In	IN	O	in	_	0	SENT_124	[p9l540t412r628b482],
2	short	JJ	O	short	amod	4	SENT_124	[p9l665t405r1119b483],
3	—	JJ	O	—	amod	4	SENT_124	[p9l665t405r1119b483],
4	term	NN	O	term	prep_in	13	SENT_124	[p9l665t405r1119b483],
5	and	CC	O	and	_	0	SENT_124	[p9l1155t404r1311b483],
6	long	JJ	O	long	amod	9	SENT_124	[p9l1345t405r1772b505],
7	—	NN	O	—	nn	9	SENT_124	[p9l1345t405r1772b505],
8	term	NN	O	term	nn	9	SENT_124	[p9l1345t405r1772b505],
9	studies	NNS	O	study	conj_and	4	SENT_124	[p9l1810t404r2129b500],
10	,	,	O	,	_	0	SENT_124	[p9l1810t404r2129b500],
11	atrioventricular	JJ	O	atrioventricular	amod	12	SENT_124	[p9l10t533r648b612],
12	synchrony	NN	O	synchrony	nsubj	17	SENT_124	[p9l669t532r1099b633],
13	improves	VBZ	O	improve	_	0	SENT_124	[p9l1117t533r1499b633],
14	stroke	NN	O	stroke	nn	15	SENT_124	[p9l1526t533r1780b612],
15	volume	NN	O	volume	dobj	13	SENT_124	[p9l1799t533r2130b628],
16	,	,	O	,	_	0	SENT_124	[p9l1799t533r2130b628],
17	raises	VBZ	O	raise	conj_and	13	SENT_124	[p9l10t661r248b739],
18	systolic	JJ	O	systolic	amod	20	SENT_124	[p9l286t661r596b761],
19	blood	NN	O	blood	nn	20	SENT_124	[p9l630t660r872b739],
20	pressure	NN	O	pressure	dobj	17	SENT_124	[p9l904t687r1289b761],
21	,	,	O	,	_	0	SENT_124	[p9l904t687r1289b761],
22	reduces	VBZ	O	reduce	conj_and	13	SENT_124	[p9l1327t661r1649b740],
23	right	JJ	O	right	amod	25	SENT_124	[p9l1684t660r1893b761],
24	atrial	JJ	O	atrial	amod	25	SENT_124	[p9l1921t661r2135b739],
25	pressure	NN	O	pressure	iobj	22	SENT_124	[p9l9t815r370b889],
26	and	CC	O	and	_	0	SENT_124	[p9l394t789r549b867],
27	pulmonary	JJ	O	pulmonary	amod	28	SENT_124	[p9l572t788r1432b889],
28	—	NN	O	—	conj_and	25	SENT_124	[p9l572t788r1432b889],
29	capillary	JJ	O	capillary	amod	31	SENT_124	[p9l572t788r1432b889],
30	Wedge	NN	O	wedge	nn	31	SENT_124	[p9l1447t789r1721b889],
31	pressure	NN	O	pressure	dobj	22	SENT_124	[p9l1745t815r2129b889],
32	,	,	O	,	_	0	SENT_124	[p9l1745t815r2129b889],
33	and	CC	O	and	_	0	SENT_124	[p9l10t916r165b995],
34	is	VBZ	O	be	cop	36	SENT_124	[p9l199t917r264b995],
35	less	RBR	O	less	advmod	36	SENT_124	[p9l300t917r454b995],
36	likely	JJ	O	likely	conj_and	13	SENT_124	[p9l490t917r716b1017],
37	to	TO	O	to	aux	38	SENT_124	[p9l747t933r826b995],
38	elicit	VB	O	elicit	xcomp	36	SENT_124	[p9l863t916r1068b995],
39	cardioinhibitory	NN	O	cardioinhibitory	nn	40	SENT_124	[p9l1098t916r1783b1017],
40	reﬂexes	NNS	O	reﬂexes	dobj	38	SENT_124	[p9l1813t916r2133b995],
41	than	IN	O	than	mark	44	SENT_124	[p9l11t1045r199b1123],
42	is	VBZ	O	be	cop	44	SENT_124	[p9l234t1045r299b1123],
43	ventricular	JJ	O	ventricular	amod	44	SENT_124	[p9l332t1044r789b1124],
44	pacing	NN	O	pacing	ccomp	36	SENT_124	[p9l820t1045r1128b1145],
45	.	.	O	.	_	0	SENT_124	[p9l820t1045r1128b1145],

1	The	DT	O	the	det	2	SENT_125	[p9l1166t1045r1327b1123],
2	importance	NN	O	importance	nsubjpass	12	SENT_125	[p9l1363t1045r1850b1145],
3	of	IN	O	of	_	0	SENT_125	[p9l1887t1044r1988b1123],
4	the	DT	O	the	det	6	SENT_125	[p9l2006t1044r2135b1123],
5	atrial	JJ	O	atrial	amod	6	SENT_125	[p9l10t1172r224b1251],
6	contribution	NN	O	contribution	prep_of	2	SENT_125	[p9l248t1173r776b1252],
7	to	TO	O	to	_	0	SENT_125	[p9l800t1189r879b1251],
8	cardiac	JJ	O	cardiac	amod	9	SENT_125	[p9l904t1173r1204b1251],
9	output	NN	O	output	prep_to	6	SENT_125	[p9l1228t1189r1509b1273],
10	has	VBZ	O	have	aux	12	SENT_125	[p9l1527t1173r1668b1251],
11	been	VBN	O	be	auxpass	12	SENT_125	[p9l1695t1173r1894b1251],
12	demonstrated	VBN	O	demonstrate	_	0	SENT_125	[p9l1918t1173r2134b1251, p9l11t1300r409b1379],
13	in	IN	O	in	_	0	SENT_125	[p9l433t1301r514b1378],
14	a	DT	O	a	det	15	SENT_125	[p9l539t1327r583b1379],
15	variety	NN	O	variety	prep_in	12	SENT_125	[p9l602t1301r881b1401],
16	of	IN	O	of	_	0	SENT_125	[p9l901t1300r1002b1379],
17	patient	NN	O	patient	nn	18	SENT_125	[p9l1007t1301r1305b1401],
18	groups	NNS	O	group	prep_of	15	SENT_125	[p9l1325t1326r1619b1401],
19	as	IN	O	as	_	0	SENT_125	[p9l1646t1327r1729b1379],
20	Well	NNP	O	Well	prep_as	12	SENT_125	[p9l1752t1300r1927b1380],
21	as	IN	O	as	prep	12	SENT_125	[p9l1950t1327r2034b1379],
22	at	IN	O	at	pcomp	21	SENT_125	[p9l2061t1317r2140b1379],
23	different	JJ	O	different	amod	25	SENT_125	[p9l11t1428r374b1507],
24	heart	NN	O	heart	nn	25	SENT_125	[p9l389t1429r606b1507],
25	rates	NNS	O	rate	pobj	22	SENT_125	[p9l621t1445r842b1507],
26	.	.	O	.	_	0	SENT_125	[p9l621t1445r842b1507],

1	The	DT	O	the	det	2	SENT_126	[p9l865t1428r1025b1507],
2	restoration	NN	O	restoration	_	0	SENT_126	[p9l1046t1429r1504b1507],
3	of	IN	O	of	_	0	SENT_126	[p9l1525t1428r1625b1507],
4	atrioventric	JJ	O	atrioventric	amod	5	SENT_126	[p9l1626t1429r2134b1508],
5	—	NN	O	—	prep_of	2	SENT_126	[p9l1626t1429r2134b1508],

1	ular	JJ	O	ular	amod	2	SENT_127	[p9l10t1557r175b1636],
2	synchrony	NN	O	synchrony	nsubjpass	6	SENT_127	[p9l205t1557r640b1657],
3	by	IN	O	by	_	0	SENT_127	[p9l669t1557r765b1657],
4	pacing	NN	O	pacing	prep_by	2	SENT_127	[p9l792t1557r1080b1657],
5	was	VBD	O	be	auxpass	6	SENT_127	[p9l1104t1583r1265b1636],
6	branded	VBN	O	brand	_	0	SENT_127	[p9l1300t1556r1649b1635],
7	early	RB	O	early	advmod	6	SENT_127	[p9l1682t1557r1881b1657],
8	on	IN	O	on	dep	6	SENT_127	[p9l1910t1582r2017b1635],
9	as	IN	O	as	_	0	SENT_127	[p9l2048t1583r2133b1635],
10	“	CD	NUMBER	“	num	13	SENT_127	[p9l14t1685r539b1785],
11	physiologic	JJ	O	physiologic	amod	13	SENT_127	[p9l14t1685r539b1785],
12	pacing	NN	O	pacing	nn	13	SENT_127	[p9l561t1685r884b1785],
13	”	NN	O	”	prep_as	6	SENT_127	[p9l561t1685r884b1785],
14	because	IN	O	because	mark	16	SENT_127	[p9l913t1684r1242b1764],
15	it	PRP	O	it	nsubj	16	SENT_127	[p9l1265t1685r1325b1763],
16	mimics	VBZ	O	mimic	dep	13	SENT_127	[p9l1344t1685r1653b1763],
17	the	DT	O	the	det	19	SENT_127	[p9l1679t1685r1807b1763],
18	normal	JJ	O	normal	amod	19	SENT_127	[p9l1832t1684r2136b1763],
19	sequence	NN	O	sequence	dobj	16	SENT_127	[p9l12t1838r400b1913],
20	of	IN	O	of	_	0	SENT_127	[p9l428t1812r529b1891],
21	atrioventricular	JJ	O	atrioventricular	amod	22	SENT_127	[p9l538t1812r1189b1892],
22	activation	NN	O	activation	prep_of	19	SENT_127	[p9l1214t1813r1645b1892],
23	.	.	O	.	_	0	SENT_127	[p9l1214t1813r1645b1892],

1	The	DT	O	the	det	2	SENT_128	[p9l1675t1812r1837b1891],
2	expectation	NN	O	expectation	nsubj	3	SENT_128	[p9l1866t1839r2134b1913, p9l11t1941r258b2019],
3	Was	VBD	O	be	_	0	SENT_128	[p9l278t1967r440b2020],
4	that	IN	O	that	complm	14	SENT_128	[p9l468t1940r634b2019],
5	the	DT	O	the	det	7	SENT_128	[p9l655t1941r784b2019],
6	hemodynamic	JJ	O	hemodynamic	amod	7	SENT_128	[p9l810t1941r1414b2041],
7	beneﬁts	NNS	O	beneﬁts	nsubj	14	SENT_128	[p9l1439t1940r1771b2019],
8	of	IN	O	of	_	0	SENT_128	[p9l1800t1940r1900b2019],
9	atrio	NN	O	atrio	npadvmod	11	SENT_128	[p9l1907t1941r2134b2019],
10	—	CD	NUMBER	—	num	9	SENT_128	[p9l1907t1941r2134b2019],
11	ventricular	JJ	O	ventricular	amod	12	SENT_128	[p9l6t2069r463b2148],
12	synchrony	NN	O	synchrony	prep_of	7	SENT_128	[p9l498t2069r934b2169],
13	would	MD	O	would	aux	14	SENT_128	[p9l962t2068r1227b2148],
14	translate	VB	O	translate	ccomp	3	SENT_128	[p9l1264t2068r1627b2147],
15	into	IN	O	into	_	0	SENT_128	[p9l1664t2069r1829b2147],
16	reductions	NNS	O	reduction	prep_into	14	SENT_128	[p9l1866t2069r2134b2148, p9l11t2197r222b2275],
17	in	IN	O	in	_	0	SENT_128	[p9l256t2197r338b2274],
18	cardiac	JJ	O	cardiac	amod	19	SENT_128	[p9l371t2196r677b2275],
19	mortality	NN	O	mortality	prep_in	16	SENT_128	[p9l709t2196r1120b2297],
20	,	,	O	,	_	0	SENT_128	[p9l709t2196r1120b2297],
21	a	DT	O	a	det	23	SENT_128	[p9l1157t2223r1201b2275],
22	reduced	VBN	O	reduce	amod	23	SENT_128	[p9l1232t2197r1574b2276],
23	risk	NN	O	risk	appos	19	SENT_128	[p9l1606t2197r1771b2276],
24	of	IN	O	of	_	0	SENT_128	[p9l1800t2196r1902b2275],
25	heart	NN	O	heart	nn	26	SENT_128	[p9l1915t2197r2139b2275],
26	failure	NN	O	failure	prep_of	23	SENT_128	[p9l10t2324r311b2420],
27	,	,	O	,	_	0	SENT_128	[p9l10t2324r311b2420],
28	and	CC	O	and	_	0	SENT_128	[p9l343t2325r496b2403],
29	a	DT	O	a	det	31	SENT_128	[p9l518t2351r562b2403],
30	better	JJR	O	better	amod	31	SENT_128	[p9l585t2325r824b2403],
31	quality	NN	O	quality	conj_and	23	SENT_128	[p9l844t2325r1124b2425],
32	of	IN	O	of	_	0	SENT_128	[p9l1143t2324r1242b2403],
33	life	NN	O	life	prep_of	31	SENT_128	[p9l1246t2324r1396b2403],
34	.	.	O	.	_	0	SENT_128	[p9l1246t2324r1396b2403],

1	These	DT	O	these	det	2	SENT_129	[p9l136t2452r387b2531],
2	expectations	NNS	O	expectation	nsubjpass	5	SENT_129	[p9l419t2453r947b2553],
3	have	VBP	O	have	aux	5	SENT_129	[p9l979t2453r1167b2532],
4	been	VBN	O	be	auxpass	5	SENT_129	[p9l1199t2453r1398b2531],
5	examined	VBN	O	examine	_	0	SENT_129	[p9l1430t2453r1839b2531],
6	in	IN	O	in	_	0	SENT_129	[p9l1869t2453r1950b2530],
7	two	CD	NUMBER	two	num	13	SENT_129	[p9l1981t2469r2134b2532],
8	previous	JJ	O	previous	amod	13	SENT_129	[p9l9t2581r366b2681],
9	large	JJ	O	large	amod	13	SENT_129	[p9l398t2581r629b2681],
10	,	,	O	,	_	0	SENT_129	[p9l398t2581r629b2681],
11	randomized	JJ	O	randomized	amod	13	SENT_129	[p9l666t2580r1177b2659],
12	clinical	JJ	O	clinical	amod	13	SENT_129	[p9l1208t2581r1509b2659],
13	trials	NNS	O	trial	prep_in	5	SENT_129	[p9l1540t2581r1747b2659],
14	comparing	VBG	O	compare	partmod	13	SENT_129	[p9l1780t2606r2135b2681, p9l10t2709r146b2809],
15	dual	JJ	O	dual	amod	18	SENT_129	[p9l170t2709r751b2788],
16	—	NN	O	—	nn	18	SENT_129	[p9l170t2709r751b2788],
17	chamber	NN	O	chamber	nn	18	SENT_129	[p9l170t2709r751b2788],
18	pacing	NN	O	pacing	dobj	14	SENT_129	[p9l773t2709r1055b2809],
19	with	IN	O	with	_	0	SENT_129	[p9l1074t2709r1260b2788],
20	single	JJ	O	single	amod	23	SENT_129	[p9l1288t2708r1937b2809],
21	—	NN	O	—	nn	23	SENT_129	[p9l1288t2708r1937b2809],
22	chamber	NN	O	chamber	nn	23	SENT_129	[p9l1288t2708r1937b2809],
23	pacing	NN	O	pacing	prep_with	18	SENT_129	[p9l1960t2735r2135b2809, p9l10t2837r165b2937],
24	.	.	O	.	_	0	SENT_129	[p9l1960t2735r2135b2809, p9l10t2837r165b2937],

1	These	DT	O	these	det	2	SENT_130	[p9l192t2836r441b2915],
2	trials	NNS	O	trial	nsubj	23	SENT_130	[p9l469t2837r702b2932],
3	,	,	O	,	_	0	SENT_130	[p9l469t2837r702b2932],
4	predominantly	RB	O	predominantly	advmod	5	SENT_130	[p9l733t2837r1362b2937],
5	involving	VBG	O	involve	dep	2	SENT_130	[p9l1384t2837r1776b2937],
6	patients	NNS	O	patient	dobj	5	SENT_130	[p9l1798t2837r2132b2937],
7	With	IN	O	with	_	0	SENT_130	[p9l6t2965r198b3044],
8	the	DT	O	the	det	11	SENT_130	[p9l233t2965r365b3043],
9	sick	JJ	O	sick	amod	11	SENT_130	[p9l401t2965r571b3044],
10	sinus	NN	O	sinus	nn	11	SENT_130	[p9l603t2965r826b3044],
11	syndrome	NN	O	syndrome	prep_with	6	SENT_130	[p9l864t2965r1289b3065],
12	and	CC	O	and	_	0	SENT_130	[p9l1323t2964r1481b3043],
13	having	VBG	O	have	dep	2	SENT_130	[p9l1515t2965r1806b3065],
14	a	DT	O	a	det	16	SENT_130	[p9l1837t2991r1881b3043],
15	combined	JJ	O	combined	amod	16	SENT_130	[p9l1915t2990r2132b3043, p9l11t3092r252b3171],
16	enrollment	NN	O	enrollment	dobj	13	SENT_130	[p9l306t3093r788b3171],
17	of	IN	O	of	_	0	SENT_130	[p9l838t3092r939b3171],
18	more	JJR	O	more	mwe	19	SENT_130	[p9l974t3118r1197b3171],
19	than	IN	O	than	quantmod	20	SENT_130	[p9l1252t3093r1443b3171],
20	4500	CD	NUMBER	4500	num	21	SENT_130	[p9l1495t3098r1706b3171],
21	patients	NNS	O	patient	prep_of	16	SENT_130	[p9l1759t3093r2128b3193],
22	,	,	O	,	_	0	SENT_130	[p9l1759t3093r2128b3193],
23	showed	VBD	O	show	_	0	SENT_130	[p9l12t3221r340b3300],
24	a	DT	O	a	det	26	SENT_130	[p9l363t3247r408b3299],
25	relative	JJ	O	relative	amod	26	SENT_130	[p9l425t3221r719b3300],
26	reduction	NN	O	reduction	dobj	23	SENT_130	[p9l739t3220r1135b3300],
27	in	IN	O	in	_	0	SENT_130	[p9l1154t3221r1234b3298],
28	the	DT	O	the	det	29	SENT_130	[p9l1254t3220r1381b3299],
29	risk	NN	O	risk	prep_in	23	SENT_130	[p9l1401t3221r1559b3300],
30	of	IN	O	of	_	0	SENT_130	[p9l1575t3220r1674b3299],
31	atrial	JJ	O	atrial	amod	32	SENT_130	[p9l1675t3221r1884b3299],
32	fibrillation	NN	O	fibrillation	prep_of	29	SENT_130	[p9l1903t3220r2134b3299, p9l9t3349r246b3427],

1	that	DT	O	that	nsubj	2	SENT_131	[p9l270t3349r433b3427],
2	ranged	VBD	O	range	_	0	SENT_131	[p9l452t3349r745b3449],
3	from	IN	O	from	_	0	SENT_131	[p9l771t3348r978b3427],
4	18	CD	NUMBER	18	number	6	SENT_131	[p9l1007t3354r1103b3427],
5	to	TO	O	to	dep	6	SENT_131	[p9l1131t3365r1210b3427],
6	23	CD	PERCENT	23	num	8	SENT_131	[p9l1237t3354r1335b3427],
7	percent	NN	PERCENT	percent	nn	8	SENT_131	[p9l1363t3354r1812b3449],
8	.3	NN	NUMBER	.3	prep_from	2	SENT_131	[p9l1363t3354r1812b3449],
9	»	CD	NUMBER	»	number	10	SENT_131	[p9l1363t3354r1812b3449],
10	4	CD	NUMBER	4	num	12	SENT_131	[p9l1363t3354r1812b3449],
11	No	DT	O	no	det	12	SENT_131	[p9l1835t3356r1961b3427],
12	difference	NN	O	difference	dobj	2	SENT_131	[p9l1989t3348r2132b3427, p9l10t3476r313b3555],
13	in	IN	O	in	_	0	SENT_131	[p9l336t3477r417b3554],
14	total	JJ	O	total	amod	15	SENT_131	[p9l441t3477r628b3555],
15	mortality	NN	O	mortality	prep_in	12	SENT_131	[p9l652t3477r1047b3577],
16	,	,	O	,	_	0	SENT_131	[p9l652t3477r1047b3577],
17	mortality	NN	O	mortality	conj_or	12	SENT_131	[p9l1077t3476r1461b3577],
18	from	IN	O	from	_	0	SENT_131	[p9l1481t3476r1687b3555],
19	cardiovascular	JJ	O	cardiovascular	amod	20	SENT_131	[p9l1711t3477r2134b3556, p9l11t3604r219b3683],
20	causes	NNS	O	cause	prep_from	17	SENT_131	[p9l242t3630r539b3698],
21	,	,	O	,	_	0	SENT_131	[p9l242t3630r539b3698],
22	or	CC	O	or	_	0	SENT_131	[p9l570t3629r659b3682],
23	stroke	NN	O	stroke	dobj	2	SENT_131	[p9l682t3604r941b3683],
24	was	VBD	O	be	auxpass	25	SENT_131	[p9l962t3630r1123b3683],
25	observed	VBN	O	observe	rcmod	23	SENT_131	[p9l1151t3603r1549b3683],
26	.	.	O	.	_	0	SENT_131	[p9l1151t3603r1549b3683],

1	It	PRP	O	it	nsubj	4	SENT_132	[p10l138t31r202b102],
2	was	VBD	O	be	cop	4	SENT_132	[p10l212t50r370b103],
3	only	RB	O	only	advmod	4	SENT_132	[p10l393t24r570b124],
4	natural	JJ	O	natural	_	0	SENT_132	[p10l585t23r877b103],
5	that	IN	O	that	complm	11	SENT_132	[p10l896t23r1059b102],
6	a	DT	O	a	det	8	SENT_132	[p10l1072t50r1117b102],
7	similar	JJ	O	similar	amod	8	SENT_132	[p10l1136t24r1424b102],
8	evaluation	NN	O	evaluation	nsubjpass	11	SENT_132	[p10l1440t24r1861b103],
9	would	MD	O	would	aux	11	SENT_132	[p10l1875t24r2136b103],
10	be	VB	O	be	auxpass	11	SENT_132	[p10l11t152r107b230],
11	conducted	VBN	O	conduct	ccomp	4	SENT_132	[p10l132t152r571b231],
12	in	IN	O	in	_	0	SENT_132	[p10l595t152r676b229],
13	patients	NNS	O	patient	prep_in	11	SENT_132	[p10l699t152r1034b252],
14	with	IN	O	with	_	0	SENT_132	[p10l1056t152r1245b231],
15	high	JJ	O	high	amod	19	SENT_132	[p10l1270t151r1736b252],
16	—	NN	O	—	nn	19	SENT_132	[p10l1270t151r1736b252],
17	grade	NN	O	grade	nn	19	SENT_132	[p10l1270t151r1736b252],
18	atrioventricular	JJ	O	atrioventricular	amod	19	SENT_132	[p10l1760t152r2133b231, p10l11t280r313b359],
19	block	NN	O	block	prep_with	11	SENT_132	[p10l331t279r582b375],
20	,	,	O	,	_	0	SENT_132	[p10l331t279r582b375],
21	Who	WP	O	who	nsubj	22	SENT_132	[p10l603t280r785b359],
22	make	VB	O	make	rcmod	19	SENT_132	[p10l807t280r1034b359],
23	up	RP	O	up	prt	22	SENT_132	[p10l1055t306r1158b380],
24	a	DT	O	a	det	26	SENT_132	[p10l1180t306r1224b358],
25	substantial	JJ	O	substantial	amod	26	SENT_132	[p10l1244t280r1703b359],
26	portion	NN	O	portion	dobj	22	SENT_132	[p10l1721t280r2033b380],
27	of	IN	O	of	_	0	SENT_132	[p10l2054t279r2154b358],
28	patients	NNS	O	patient	prep_of	26	SENT_132	[p10l9t408r351b507],
29	now	RB	DATE	now	advmod	30	SENT_132	[p10l388t432r574b486],
30	receiving	VBG	O	receive	partmod	28	SENT_132	[p10l604t408r996b507],
31	pacemakers	NNS	O	pacemaker	dobj	30	SENT_132	[p10l1025t408r1565b507],
32	.	.	O	.	_	0	SENT_132	[p10l1025t408r1565b507],

1	In	IN	O	in	_	0	SENT_133	[p10l1603t414r1691b484],
2	this	DT	O	this	det	3	SENT_133	[p10l1726t408r1882b485],
3	issue	NN	O	issue	nsubj	10	SENT_133	[p10l1918t408r2133b486],
4	of	IN	O	of	_	0	SENT_133	[p10l11t535r112b614],
5	thejoumal	JJ	O	thejoumal	prep_of	3	SENT_133	[p10l118t535r541b636],
6	,	,	O	,	_	0	SENT_133	[p10l551t602r565b631],
7	Toff	NNP	PERSON	Toff	prep_of	3	SENT_133	[p10l588t535r779b614],
8	and	CC	O	and	_	0	SENT_133	[p10l782t535r938b614],
9	colleagues	NNS	O	colleague	prep_of	3	SENT_133	[p10l961t536r1399b636],
10	report	VBP	O	report	prepc_in	63	SENT_133	[p10l1424t552r1686b636],
11	the	DT	O	the	det	12	SENT_133	[p10l1704t536r1833b614],
12	results	NNS	O	result	dobj	10	SENT_133	[p10l1855t536r2132b615],
13	of	IN	O	of	_	0	SENT_133	[p10l11t663r112b742],
14	the	DT	O	the	det	17	SENT_133	[p10l130t664r260b742],
15	United	NNP	LOCATION	United	nn	17	SENT_133	[p10l295t664r585b742],
16	Kingdom	NNP	LOCATION	Kingdom	nn	17	SENT_133	[p10l619t663r1025b764],
17	Pacing	NN	LOCATION	pacing	prep_of	12	SENT_133	[p10l1059t664r1349b764],
18	and	CC	O	and	_	0	SENT_133	[p10l1380t663r1538b742],
19	Cardiovascular	NNP	ORGANIZATION	Cardiovascular	nn	20	SENT_133	[p10l1572t663r2132b743, p10l9t792r120b870],
20	Events	NNS	ORGANIZATION	event	nsubj	21	SENT_133	[p10l145t799r415b871],
21	(	VBP	O	(	conj_and	10	SENT_133	[p10l453t797r877b883],
22	UKPACE	NNP	O	UKPACE	nn	24	SENT_133	[p10l453t797r877b883],
23	)	CD	NUMBER	)	num	24	SENT_133	[p10l453t797r877b883],
24	trial	NN	O	trial	dobj	21	SENT_133	[p10l913t792r1100b887],
25	,	,	O	,	_	0	SENT_133	[p10l913t792r1100b887],
26	a	DT	O	a	det	27	SENT_133	[p10l1135t818r1180b870],
27	comparison	NN	O	comparison	appos	24	SENT_133	[p10l1209t792r1709b892],
28	of	IN	O	of	_	0	SENT_133	[p10l1740t791r1840b870],
29	singlechamber	NN	O	singlechamber	nn	30	SENT_133	[p10l1853t792r2134b892, p10l11t920r379b998],
30	pacing	NN	O	pacing	prep_of	27	SENT_133	[p10l394t920r678b1020],
31	with	IN	O	with	_	0	SENT_133	[p10l691t920r877b999],
32	dual	JJ	O	dual	amod	35	SENT_133	[p10l899t919r1481b999],
33	—	NN	O	—	nn	35	SENT_133	[p10l899t919r1481b999],
34	chamber	NN	O	chamber	nn	35	SENT_133	[p10l899t919r1481b999],
35	pacing	NN	O	pacing	prep_with	21	SENT_133	[p10l1497t920r1780b1020],
36	in	IN	O	in	_	0	SENT_133	[p10l1797t920r1877b997],
37	elderly	JJ	O	elderly	amod	38	SENT_133	[p10l1898t919r2134b998, p10l9t1048r80b1148],
38	patients	NNS	O	patient	prep_in	35	SENT_133	[p10l97t1048r432b1148],
39	with	IN	O	with	_	0	SENT_133	[p10l455t1047r644b1127],
40	high	JJ	O	high	amod	42	SENT_133	[p10l669t1048r1135b1148],
41	—	NN	O	—	nn	42	SENT_133	[p10l669t1048r1135b1148],
42	grade	NN	O	grade	prep_with	21	SENT_133	[p10l669t1048r1135b1148],
43	atrioventricular	JJ	O	atrioventricular	amod	44	SENT_133	[p10l1160t1048r1811b1127],
44	block	NN	O	block	dobj	21	SENT_133	[p10l1834t1047r2131b1127],
45	.5	CD	NUMBER	.5	num	44	SENT_133	[p10l1834t1047r2131b1127],
46	The	DT	O	the	det	48	SENT_133	[p10l7t1176r167b1254],
47	patient	NN	O	patient	nn	48	SENT_133	[p10l190t1176r485b1276],
48	population	NN	O	population	nsubj	50	SENT_133	[p10l503t1176r962b1276],
49	studied	VBN	O	study	partmod	48	SENT_133	[p10l988t1175r1292b1255],
50	differs	VBZ	O	differ	rcmod	44	SENT_133	[p10l1317t1175r1581b1254],
51	in	IN	O	in	_	0	SENT_133	[p10l1607t1176r1688b1253],
52	important	JJ	O	important	amod	53	SENT_133	[p10l1711t1176r2140b1276],
53	Ways	NNPS	O	Ways	prep_in	50	SENT_133	[p10l6t1330r210b1404],
54	from	IN	O	from	_	0	SENT_133	[p10l243t1303r450b1382],
55	that	DT	O	that	prep_from	50	SENT_133	[p10l483t1304r649b1382],
56	in	IN	O	in	_	0	SENT_133	[p10l675t1304r757b1381],
57	other	JJ	O	other	amod	59	SENT_133	[p10l789t1304r1013b1382],
58	clinical	JJ	O	clinical	amod	59	SENT_133	[p10l1042t1304r1343b1382],
59	trials	NNS	O	trial	prep_in	55	SENT_133	[p10l1375t1303r1582b1382],
60	in	IN	O	in	_	0	SENT_133	[p10l1615t1304r1696b1381],
61	that	DT	O	that	prep_in	59	SENT_133	[p10l1728t1304r1895b1382],
62	there	EX	O	there	expl	63	SENT_133	[p10l1922t1304r2135b1382],
63	was	VBD	O	be	_	0	SENT_133	[p10l6t1458r166b1511],
64	a	DT	O	a	det	67	SENT_133	[p10l189t1458r233b1510],
65	higher	JJR	O	higher	amod	67	SENT_133	[p10l252t1432r528b1532],
66	mean	NN	O	mean	nn	67	SENT_133	[p10l546t1457r778b1510],
67	age	NN	O	age	nsubj	63	SENT_133	[p10l798t1458r940b1532],
68	(	CD	NUMBER	(	number	69	SENT_133	[p10l966t1437r1095b1523],
69	80	CD	DURATION	80	num	70	SENT_133	[p10l966t1437r1095b1523],
70	years	NNS	NUMBER	year	tmod	71	SENT_133	[p10l1113t1439r1355b1532],
71	)	RB	O	)	amod	67	SENT_133	[p10l1113t1439r1355b1532],
72	and	CC	O	and	_	0	SENT_133	[p10l1381t1431r1536b1510],
73	higher	JJR	O	higher	amod	75	SENT_133	[p10l1557t1432r1833b1532],
74	annual	JJ	SET	annual	amod	75	SENT_133	[p10l1850t1431r2136b1511],
75	mortality	NN	O	mortality	conj_and	67	SENT_133	[p10l10t1559r400b1660],
76	(	CD	NUMBER	(	number	77	SENT_133	[p10l433t1565r592b1651],
77	7.2	CD	NUMBER	7.2	dep	75	SENT_133	[p10l433t1565r592b1651],
78	to	TO	O	to	_	0	SENT_133	[p10l627t1576r706b1638],
79	7.4	CD	PERCENT	7.4	num	81	SENT_133	[p10l742t1566r872b1638],
80	percent	NN	PERCENT	percent	nn	81	SENT_133	[p10l904t1566r1277b1660],
81	)	NN	O	)	prep_to	63	SENT_133	[p10l904t1566r1277b1660],
82	.	.	O	.	_	0	SENT_133	[p10l904t1566r1277b1660],

1	Dual	JJ	O	dual	amod	4	SENT_134	[p10l1315t1559r1926b1639],
2	—	NN	O	—	nn	4	SENT_134	[p10l1315t1559r1926b1639],
3	chamber	NN	O	chamber	nn	4	SENT_134	[p10l1315t1559r1926b1639],
4	pacing	NN	O	pacing	nsubj	7	SENT_134	[p10l1955t1586r2133b1660, p10l10t1688r148b1788],
5	did	VBD	O	do	aux	7	SENT_134	[p10l171t1688r304b1766],
6	not	RB	O	not	neg	7	SENT_134	[p10l330t1704r473b1766],
7	reduce	VB	O	reduce	_	0	SENT_134	[p10l494t1688r773b1767],
8	the	DT	O	the	det	9	SENT_134	[p10l799t1688r929b1766],
9	rate	NN	O	rate	dobj	7	SENT_134	[p10l954t1704r1111b1766],
10	of	IN	O	of	_	0	SENT_134	[p10l1137t1687r1238b1766],
11	death	NN	O	death	prep_of	9	SENT_134	[p10l1246t1688r1477b1766],
12	from	IN	O	from	_	0	SENT_134	[p10l1503t1687r1710b1766],
13	all	DT	O	all	det	14	SENT_134	[p10l1736t1687r1834b1766],
14	causes	NNS	O	cause	prep_from	7	SENT_134	[p10l1861t1714r2132b1767],
15	or	CC	O	or	_	0	SENT_134	[p10l11t1840r100b1893],
16	from	IN	O	from	_	0	SENT_134	[p10l129t1814r337b1893],
17	cardiovascular	JJ	O	cardiovascular	amod	18	SENT_134	[p10l370t1815r979b1893],
18	causes	NNS	O	cause	conj_or	14	SENT_134	[p10l1009t1841r1307b1909],
19	,	,	O	,	_	0	SENT_134	[p10l1009t1841r1307b1909],
20	nor	CC	O	nor	_	0	SENT_134	[p10l1345t1840r1492b1893],
21	did	VBD	O	do	aux	23	SENT_134	[p10l1522t1814r1655b1893],
22	it	PRP	O	it	nsubj	23	SENT_134	[p10l1687t1815r1746b1892],
23	decrease	VB	O	decrease	conj_nor	7	SENT_134	[p10l1774t1815r2134b1893],
24	the	DT	O	the	det	25	SENT_134	[p10l11t1942r138b2021],
25	incidence	NN	O	incidence	dobj	23	SENT_134	[p10l157t1943r552b2021],
26	of	IN	O	of	_	0	SENT_134	[p10l573t1942r672b2021],
27	atrial	JJ	O	atrial	amod	28	SENT_134	[p10l673t1942r882b2021],
28	ﬁbrillation	NN	O	ﬁbrillation	prep_of	25	SENT_134	[p10l901t1942r1362b2038],
29	,	,	O	,	_	0	SENT_134	[p10l901t1942r1362b2038],
30	myocardial	JJ	O	myocardial	amod	31	SENT_134	[p10l1388t1942r1846b2043],
31	infarction	NN	O	infarction	conj_or	28	SENT_134	[p10l1865t1942r2134b2021, p10l11t2071r196b2166],
32	,	,	O	,	_	0	SENT_134	[p10l1865t1942r2134b2021, p10l11t2071r196b2166],
33	congestive	JJ	O	congestive	amod	35	SENT_134	[p10l223t2071r665b2171],
34	heart	NN	O	heart	nn	35	SENT_134	[p10l688t2070r907b2149],
35	failure	NN	O	failure	conj_or	28	SENT_134	[p10l924t2070r1193b2150],
36	or	CC	O	or	_	0	SENT_134	[p10l1217t2096r1306b2149],
37	stroke	NN	O	stroke	conj_or	35	SENT_134	[p10l1327t2071r1610b2166],
38	,	,	O	,	_	0	SENT_134	[p10l1327t2071r1610b2166],
39	transient	JJ	O	transient	amod	41	SENT_134	[p10l1638t2071r2017b2149],
40	ischemic	JJ	O	ischemic	amod	41	SENT_134	[p10l2034t2071r2133b2149, p10l11t2198r312b2275],
41	attack	NN	O	attack	prep_of	25	SENT_134	[p10l332t2197r606b2292],
42	,	,	O	,	_	0	SENT_134	[p10l332t2197r606b2292],
43	or	CC	O	or	_	0	SENT_134	[p10l633t2223r722b2276],
44	other	JJ	O	other	amod	45	SENT_134	[p10l741t2198r963b2276],
45	thromboembolism	NN	O	thromboembolism	prep_of	25	SENT_134	[p10l982t2197r1799b2276],
46	.	.	O	.	_	0	SENT_134	[p10l982t2197r1799b2276],

1	The	DT	O	the	det	2	SENT_135	[p10l1822t2197r1983b2275],
2	authors	NNS	O	author	nsubj	3	SENT_135	[p10l2004t2224r2134b2276, p10l11t2326r224b2404],
3	conclude	VBP	O	conclude	_	0	SENT_135	[p10l246t2325r620b2405],
4	that	IN	O	that	complm	12	SENT_135	[p10l640t2326r822b2421],
5	,	,	O	,	_	0	SENT_135	[p10l640t2326r822b2421],
6	in	IN	O	in	_	0	SENT_135	[p10l846t2326r926b2403],
7	this	DT	O	this	det	9	SENT_135	[p10l946t2326r1096b2404],
8	patient	NN	O	patient	nn	9	SENT_135	[p10l1116t2326r1409b2426],
9	population	NN	O	population	prep_in	12	SENT_135	[p10l1422t2325r1901b2426],
10	,	,	O	,	_	0	SENT_135	[p10l1422t2325r1901b2426],
11	there	EX	O	there	expl	12	SENT_135	[p10l1927t2326r2135b2404],
12	is	VBZ	O	be	ccomp	3	SENT_135	[p10l10t2454r75b2532],
13	no	DT	O	no	det	15	SENT_135	[p10l104t2479r210b2532],
14	additional	JJ	O	additional	amod	15	SENT_135	[p10l238t2454r666b2532],
15	beneﬁt	NN	O	beneﬁt	nsubj	12	SENT_135	[p10l694t2453r990b2532],
16	to	TO	O	to	_	0	SENT_135	[p10l1013t2470r1092b2532],
17	dual	JJ	O	dual	amod	20	SENT_135	[p10l1122t2453r1714b2533],
18	—	NN	O	—	nn	20	SENT_135	[p10l1122t2453r1714b2533],
19	chamber	NN	O	chamber	nn	20	SENT_135	[p10l1122t2453r1714b2533],
20	pacing	NN	O	pacing	prep_to	15	SENT_135	[p10l1737t2454r2025b2554],
21	as	IN	O	as	mark	31	SENT_135	[p10l2048t2480r2132b2532],
22	compared	VBN	O	compare	csubj	31	SENT_135	[p10l11t2582r433b2682],
23	with	IN	O	with	_	0	SENT_135	[p10l465t2582r654b2661],
24	the	DT	O	the	det	25	SENT_135	[p10l691t2582r819b2660],
25	simpler	JJR	O	simpler	prep_with	22	SENT_135	[p10l857t2582r1179b2682],
26	and	CC	O	and	_	0	SENT_135	[p10l1211t2582r1367b2660],
27	easier	JJR	O	easier	prep_with	22	SENT_135	[p10l1403t2582r2140b2682],
28	—	CD	NUMBER	—	number	30	SENT_135	[p10l1403t2582r2140b2682],
29	to	TO	O	to	dep	30	SENT_135	[p10l1403t2582r2140b2682],
30	—	CD	NUMBER	—	num	25	SENT_135	[p10l1403t2582r2140b2682],
31	implant	VBP	O	implant	advcl	12	SENT_135	[p10l1403t2582r2140b2682],
32	single	JJ	O	single	amod	36	SENT_135	[p10l12t2709r675b2810],
33	—	NN	O	—	nn	36	SENT_135	[p10l12t2709r675b2810],
34	chamber	NN	O	chamber	nn	36	SENT_135	[p10l12t2709r675b2810],
35	ventricular	JJ	O	ventricular	amod	36	SENT_135	[p10l692t2710r1149b2789],
36	pacemaker	NN	O	pacemaker	dobj	31	SENT_135	[p10l1171t2709r1651b2810],
37	.	.	O	.	_	0	SENT_135	[p10l1171t2709r1651b2810],

1	The	DT	O	the	det	3	SENT_136	[p10l136t2838r296b2916],
2	UKPACE	JJ	O	ukpace	amod	3	SENT_136	[p10l317t2843r682b2919],
3	trial	NN	O	trial	nsubj	6	SENT_136	[p10l705t2838r869b2916],
4	did	VBD	O	do	aux	6	SENT_136	[p10l891t2837r1023b2916],
5	not	RB	O	not	neg	6	SENT_136	[p10l1044t2854r1187b2916],
6	examine	VB	O	examine	_	0	SENT_136	[p10l1203t2838r1553b2916],
7	quality	NN	O	quality	dobj	6	SENT_136	[p10l1576t2837r1858b2938],
8	of	IN	O	of	_	0	SENT_136	[p10l1876t2837r1976b2916],
9	life	NN	O	life	prep_of	7	SENT_136	[p10l1977t2837r2130b2933],
10	,	,	O	,	_	0	SENT_136	[p10l1977t2837r2130b2933],
11	but	CC	O	but	_	0	SENT_136	[p10l11t2966r152b3045],
12	this	DT	O	this	nsubj	16	SENT_136	[p10l174t2966r326b3044],
13	is	VBZ	O	be	cop	16	SENT_136	[p10l354t2966r419b3044],
14	an	DT	O	a	det	16	SENT_136	[p10l447t2991r548b3044],
15	important	JJ	O	important	amod	16	SENT_136	[p10l574t2966r1007b3066],
16	issue	NN	O	issue	conj_but	6	SENT_136	[p10l1028t2966r1263b3045],
17	.	.	O	.	_	0	SENT_136	[p10l1028t2966r1263b3045],

1	The	DT	O	the	det	2	SENT_137	[p10l1292t2965r1453b3044],
2	quality	NN	O	quality	_	0	SENT_137	[p10l1480t2966r1766b3066],
3	of	IN	O	of	dep	2	SENT_137	[p10l1789t2965r1890b3044],
4	life	NN	O	life	pobj	3	SENT_137	[p10l1897t2965r2028b3044],
5	in	IN	O	in	dep	2	SENT_137	[p10l2053t2966r2135b3043],

1	202	CD	NUMBER	202	num	3	SENT_138	[p10l149t3141r206b3162],
2	N	NN	O	n	nn	3	SENT_138	[p10l919t3143r933b3158],
3	ENGLJ	NN	O	englj	nsubj	4	SENT_138	[p10l948t3142r1032b3164],
4	MED	VBD	O	med	_	0	SENT_138	[p10l1048t3143r1100b3158],
5	35	CD	NUMBER	35	number	6	SENT_138	[p10l1112t3142r1137b3164],
6	:2	CD	NUMBER	:2	dobj	4	SENT_138	[p10l1156t3142r1176b3162],
7	WWW.NEjM.ORG	NNP	O	WWW.NEjM.ORG	nn	8	SENT_138	[p10l1211t3142r1422b3164],
8	JULY	NNP	DATE	JULY	dep	6	SENT_138	[p10l1456t3143r1516b3164],
9	14	CD	DATE	14	num	8	SENT_138	[p10l1528t3142r1563b3164],
10	,	,	DATE	,	_	0	SENT_138	[p10l1528t3142r1563b3164],
11	2005	CD	DATE	2005	num	8	SENT_138	[p10l1576t3142r1639b3164],

1	The	DT	O	the	det	4	SENT_139	[p10l936t3175r987b3199],
2	New	NNP	O	New	nn	4	SENT_139	[p10l996t3176r1058b3199],
3	Englan	NNP	O	Englan	nn	4	SENT_139	[p10l1067t3175r1161b3206],
4	oumal	NN	O	oumal	_	0	SENT_139	[p10l1201t3175r1284b3199],
5	of	IN	O	of	_	0	SENT_139	[p10l1294t3175r1323b3199],
6	Medicine	NN	MISC	medicine	prep_of	4	SENT_139	[p10l1330t3175r1455b3199],

1	Downloaded	VBN	O	download	_	0	SENT_140	[p10l378t3216r548b3239],
2	from	IN	O	from	_	0	SENT_140	[p10l557t3216r621b3239],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_140	[p10l630t3216r748b3246],
4	at	IN	O	at	_	0	SENT_140	[p10l759t3220r782b3239],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_140	[p10l790t3216r973b3239],
6	on	IN	O	on	_	0	SENT_140	[p10l982t3223r1015b3239],
7	January	NNP	DATE	January	prep_on	1	SENT_140	[p10l1023t3216r1126b3246],
8	5	CD	DATE	5	num	7	SENT_140	[p10l1136t3216r1159b3243],
9	,	,	DATE	,	_	0	SENT_140	[p10l1136t3216r1159b3243],
10	2014	CD	DATE	2014	num	7	SENT_140	[p10l1169t3216r1242b3239],
11	.	.	O	.	_	0	SENT_140	[p10l1169t3216r1242b3239],

1	For	IN	O	for	_	0	SENT_141	[p10l1252t3216r1299b3239],
2	personal	JJ	O	personal	amod	3	SENT_141	[p10l1307t3216r1419b3246],
3	use	NN	O	use	pobj	1	SENT_141	[p10l1428t3223r1472b3239],
4	only	RB	O	only	advmod	3	SENT_141	[p10l1482t3216r1546b3246],
5	.	.	O	.	_	0	SENT_141	[p10l1482t3216r1546b3246],

1	No	DT	O	no	det	3	SENT_142	[p10l1557t3216r1597b3239],
2	other	JJ	O	other	amod	3	SENT_142	[p10l1607t3216r1675b3239],
3	uses	NNS	O	use	_	0	SENT_142	[p10l1683t3223r1739b3239],
4	without	IN	O	without	_	0	SENT_142	[p10l1749t3216r1850b3239],
5	permission	NN	O	permission	prep_without	3	SENT_142	[p10l1859t3216r2011b3246],
6	.	.	O	.	_	0	SENT_142	[p10l1859t3216r2011b3246],

1	Copyright	NN	O	copyright	_	0	SENT_143	[p10l728t3257r863b3288],
2	©	CD	NUMBER	©	num	6	SENT_143	[p10l872t3257r896b3281],
3	2005	CD	DATE	2005	num	6	SENT_143	[p10l906t3257r970b3281],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_143	[p10l980t3257r1171b3281],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_143	[p10l1181t3257r1289b3281],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_143	[p10l1300t3257r1405b3288],
7	.	.	O	.	_	0	SENT_143	[p10l1300t3257r1405b3288],

1	All	DT	O	all	det	2	SENT_144	[p10l1416t3257r1457b3281],
2	rights	NNS	O	rights	nsubj	3	SENT_144	[p10l1466t3257r1541b3288],
3	reserved	VBN	O	reserve	_	0	SENT_144	[p10l1551t3257r1670b3281],
4	.	.	O	.	_	0	SENT_144	[p10l1551t3257r1670b3281],

